<!DOCTYPE html><html lang="en" prefix="og: https://ogp.me/ns#"><head><meta charset="utf-8"><title data-static-tag-from="prerender">Vical Incorporated. Q2 2010 Earnings Call Transcript | Seeking Alpha</title><script>!function(e,t,o){e&&e.documentElement&&"object"==typeof e.documentElement.dataset&&t&&"function"==typeof t.getItem&&t.getItem(o)&&(e.documentElement.dataset.colorScheme=t.getItem(o))}(document,localStorage,"COLOR_SCHEME")</script><link rel="preconnect" href="https://static.seekingalpha.com"><link rel="preconnect" href="https://static1.seekingalpha.com"><link rel="preconnect" href="https://static2.seekingalpha.com"><link rel="preconnect" href="https://static3.seekingalpha.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="anonymous"><meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover,maximum-scale=1"><meta content="ie=edge" http-equiv="X-UA-Compatible"><meta name="application-name" content="Seeking Alpha"><meta name="HandheldFriendly" content="True"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-title" content="SeekingAlpha"><meta name="apple-mobile-web-app-status-bar-style" content="black"><meta name="apple-itunes-app" content="app-id=552799694"><meta name="format-detection" content="telephone=yes"><meta name="theme-color" content="#333333"><meta property="fb:app_id" content="159723149420031"><meta property="fb:pages" content="224867310939090"><meta content="SeekingAlpha" property="al:ios:app_name"><meta content="552799694" property="al:ios:app_store_id"><meta content="SeekingAlpha" property="al:android:app_name"><meta content="com.seekingalpha.webwrapper" property="al:android:package"><meta name="google-site-verification" content="8arRaWMkVniCnxJWf9hbm-0PYkb_LhjaXAk7rGd97iw"><meta name="msvalidate.01" content="0FEA0055AC330065CFA87CA3045E9860"><meta property="og:locale" content="en_US"><meta property="og:site_name" content="Seeking Alpha"><link rel="mask-icon" href="/samw/static/images/favicon.svg" color="#ff7200"><link rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon.png"><link sizes="57x57" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-57x57.png"><link sizes="60x60" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-60x60.png"><link sizes="72x72" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-72x72.png"><link sizes="76x76" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-76x76.png"><link sizes="114x114" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-114x114.png"><link sizes="120x120" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-120x120.png"><link sizes="144x144" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-144x144.png"><link sizes="152x152" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-152x152.png"><link sizes="180x180" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-180x180.png"><link sizes="16x16" rel="icon" type="image/png" href="/samw/static/images/favicon-16x16.png"><link sizes="32x32" rel="icon" type="image/png" href="/samw/static/images/favicon-32x32.png"><link sizes="32x32" rel="icon" type="image/png" href="/samw/static/images/favicon-96x96.png"><link sizes="192x192" rel="icon" type="image/png" href="/samw/static/images/favicon-192x192.png"><link href="https://seekingalpha.com/javascripts/seeking.xml" title="Seeking Alpha&#x27;s Symbol search" type="application/opensearchdescription+xml"><script>performance&&"function"==typeof performance.mark&&performance.mark("SA_booted")</script><script id="sa_build_number">window.SA_PR_NUMBER = "null";
    window.SA_RUN_NUMBER = "12356";
    window.SA_BUILD_DATE = 1696602425426;</script><link href="/samw/favicon.ico" rel="icon"><style data-href="/samw/static/styles/app.217b4ccc.css">@keyframes au_eN{to{transform:rotate(1turn)}}.au_gs{animation:au_eN 1s linear infinite;color:var(--sa-spinner-color,currentColor);height:1em;width:1em}@media screen and (prefers-reduced-motion:reduce){.au_gs{animation:none}}.s_as{padding:0}.s_at{margin:0}.s_au{padding-top:0}.s_av{padding-top:2px}.s_aw{padding-top:4px}.s_ax{padding-top:6px}.s_ay{padding-top:8px}.s_az{padding-top:10px}.s_aA{padding-top:12px}.s_aB{padding-top:14px}.s_aC{padding-top:16px}.s_aE{padding-top:18px}.s_aF{padding-top:20px}.s_aG{padding-top:24px}.s_aH{padding-top:28px}.s_aI{padding-top:30px}.s_aJ{padding-top:32px}.s_aK{padding-top:36px}.s_aL{padding-top:40px}.s_aM{padding-top:42px}.s_aN{padding-top:48px}.s_aO{padding-top:64px}.s_aP{padding-top:72px}.s_aQ{padding-left:0}.s_aR{padding-left:2px}.s_aS{padding-left:4px}.s_aT{padding-left:6px}.s_aU{padding-left:8px}.s_aV{padding-left:10px}.s_aW{padding-left:12px}.s_aX{padding-left:14px}.s_aY{padding-left:16px}.s_aZ{padding-left:18px}.s_a0{padding-left:20px}.s_a1{padding-left:24px}.s_a2{padding-left:28px}.s_a3{padding-left:30px}.s_a4{padding-left:32px}.s_a5{padding-left:36px}.s_a6{padding-left:40px}.s_a7{padding-left:44px}.s_a8{padding-left:48px}.s_a9{padding-left:50px}.s_ba{padding-left:54px}.s_bb{padding-left:64px}.s_bc{padding-left:72px}.s_bd{padding-right:0}.s_be{padding-right:2px}.s_bf{padding-right:4px}.s_bg{padding-right:6px}.s_bh{padding-right:8px}.s_bi{padding-right:10px}.s_bj{padding-right:12px}.s_bk{padding-right:14px}.s_bl{padding-right:16px}.s_bm{padding-right:18px}.s_bn{padding-right:20px}.s_bo{padding-right:24px}.s_bp{padding-right:26px}.s_bq{padding-right:28px}.s_br{padding-right:30px}.s_bs{padding-right:32px}.s_bt{padding-right:36px}.s_bu{padding-right:40px}.s_bv{padding-right:48px}.s_bw{padding-right:64px}.s_bx{padding-right:72px}.s_by{padding-bottom:0}.s_bz{padding-bottom:2px}.s_bA{padding-bottom:4px}.s_bB{padding-bottom:6px}.s_bC{padding-bottom:8px}.s_bD{padding-bottom:10px}.s_bE{padding-bottom:12px}.s_bF{padding-bottom:14px}.s_bG{padding-bottom:16px}.s_bH{padding-bottom:18px}.s_bI{padding-bottom:20px}.s_bJ{padding-bottom:24px}.s_bK{padding-bottom:28px}.s_bL{padding-bottom:30px}.s_bM{padding-bottom:32px}.s_bN{padding-bottom:36px}.s_bO{padding-bottom:40px}.s_bP{padding-bottom:42px}.s_bQ{padding-bottom:44px}.s_bR{padding-bottom:48px}.s_bS{padding-bottom:64px}.s_bT{padding-bottom:72px}.s_bU,.s_bV{margin-top:0}.s_bW{margin-top:2px}.s_bX{margin-top:-2px}.s_bY{margin-top:4px}.s_bZ{margin-top:-4px}.s_b0{margin-top:6px}.s_b1{margin-top:-6px}.s_b2{margin-top:8px}.s_b3{margin-top:-8px}.s_b4{margin-top:10px}.s_b5{margin-top:-10px}.s_b6{margin-top:12px}.s_b7{margin-top:-12px}.s_b8{margin-top:14px}.s_b9{margin-top:-14px}.s_ca{margin-top:16px}.s_cb{margin-top:-16px}.s_cc{margin-top:18px}.s_cd{margin-top:-18px}.s_ce{margin-top:20px}.s_cf{margin-top:-20px}.s_cg{margin-top:24px}.s_ch{margin-top:-24px}.s_ci{margin-top:28px}.s_cj{margin-top:-28px}.s_ck{margin-top:30px}.s_cl{margin-top:-30px}.s_cm{margin-top:32px}.s_cn{margin-top:-32px}.s_co{margin-top:36px}.s_cp{margin-top:-36px}.s_cq{margin-top:40px}.s_cr{margin-top:-40px}.s_cs{margin-top:48px}.s_ct{margin-top:-48px}.s_cu{margin-top:64px}.s_cv{margin-top:-64px}.s_cw{margin-top:72px}.s_cx{margin-top:-72px}.s_cy{margin-left:auto}.s_cA,.s_cz{margin-left:0}.s_cB{margin-left:2px}.s_cC{margin-left:-2px}.s_cD{margin-left:4px}.s_cE{margin-left:-4px}.s_cF{margin-left:6px}.s_cG{margin-left:-6px}.s_cH{margin-left:8px}.s_cI{margin-left:-8px}.s_cJ{margin-left:10px}.s_cK{margin-left:-10px}.s_cL{margin-left:12px}.s_cM{margin-left:-12px}.s_cN{margin-left:14px}.s_cO{margin-left:-14px}.s_cP{margin-left:16px}.s_cQ{margin-left:-16px}.s_cR{margin-left:18px}.s_cS{margin-left:-18px}.s_cT{margin-left:20px}.s_cU{margin-left:-20px}.s_cV{margin-left:24px}.s_cW{margin-left:-24px}.s_cX{margin-left:28px}.s_cY{margin-left:-28px}.s_cZ{margin-left:30px}.s_c0{margin-left:-30px}.s_c1{margin-left:32px}.s_c2{margin-left:-32px}.s_c3{margin-left:36px}.s_c4{margin-left:-36px}.s_c5{margin-left:40px}.s_c6{margin-left:-40px}.s_c7{margin-left:48px}.s_c8{margin-left:-48px}.s_c9{margin-left:64px}.s_da{margin-left:-64px}.s_db{margin-left:72px}.s_dc{margin-left:-72px}.s_dd{margin-right:auto}.s_de,.s_df{margin-right:0}.s_dg{margin-right:2px}.s_dh{margin-right:-2px}.s_di{margin-right:4px}.s_dj{margin-right:-4px}.s_dk{margin-right:6px}.s_dl{margin-right:-6px}.s_dm{margin-right:8px}.s_dn{margin-right:-8px}.s_do{margin-right:10px}.s_dp{margin-right:-10px}.s_dq{margin-right:12px}.s_dr{margin-right:-12px}.s_ds{margin-right:14px}.s_dt{margin-right:-14px}.s_du{margin-right:16px}.s_dv{margin-right:-16px}.s_dw{margin-right:18px}.s_dx{margin-right:-18px}.s_dy{margin-right:20px}.s_dz{margin-right:-20px}.s_dA{margin-right:24px}.s_dB{margin-right:-24px}.s_dC{margin-right:28px}.s_dD{margin-right:-28px}.s_dE{margin-right:30px}.s_dF{margin-right:-30px}.s_dG{margin-right:32px}.s_dH{margin-right:-32px}.s_dI{margin-right:36px}.s_dJ{margin-right:-36px}.s_dK{margin-right:40px}.s_dL{margin-right:-40px}.s_dM{margin-right:48px}.s_dN{margin-right:-48px}.s_dO{margin-right:64px}.s_dP{margin-right:-64px}.s_dQ{margin-right:72px}.s_dR{margin-right:-72px}.s_dS{margin-bottom:auto}.s_dT,.s_dU{margin-bottom:0}.s_dV{margin-bottom:2px}.s_dW{margin-bottom:-2px}.s_dX{margin-bottom:4px}.s_dY{margin-bottom:-4px}.s_dZ{margin-bottom:6px}.s_d0{margin-bottom:-6px}.s_d1{margin-bottom:8px}.s_d2{margin-bottom:-8px}.s_d3{margin-bottom:10px}.s_d4{margin-bottom:-10px}.s_d5{margin-bottom:12px}.s_d6{margin-bottom:-12px}.s_d7{margin-bottom:14px}.s_d8{margin-bottom:-14px}.s_d9{margin-bottom:16px}.s_ea{margin-bottom:-16px}.s_eb{margin-bottom:18px}.s_ec{margin-bottom:-18px}.s_ed{margin-bottom:20px}.s_ee{margin-bottom:-20px}.s_ef{margin-bottom:22px}.s_eg{margin-bottom:24px}.s_eh{margin-bottom:26px}.s_ei{margin-bottom:-24px}.s_ej{margin-bottom:28px}.s_ek{margin-bottom:-28px}.s_el{margin-bottom:30px}.s_em{margin-bottom:-30px}.s_en{margin-bottom:32px}.s_eo{margin-bottom:-32px}.s_ep{margin-bottom:36px}.s_eq{margin-bottom:-36px}.s_er{margin-bottom:40px}.s_es{margin-bottom:42px}.s_et{margin-bottom:-40px}.s_eu{margin-bottom:48px}.s_ev{margin-bottom:-48px}.s_ew{margin-bottom:64px}.s_ex{margin-bottom:-64px}.s_ey{margin-bottom:72px}.s_ez{margin-bottom:-72px}.s_eA{margin-top:auto}.r_4{display:flex}.r_5{display:inline-flex}.r_6{align-items:center}.r_7{align-items:flex-start}.r_8{align-items:flex-end}.r_9{align-items:baseline}.r_aa{align-items:stretch}.r_ab{justify-content:center}.r_ac{justify-content:flex-end}.r_ae{justify-content:flex-start}.r_af{justify-content:space-between}.r_ag{justify-content:space-around}.r_ah{flex-flow:row wrap}.r_ai{flex-flow:column wrap}.r_aj{flex-flow:row}.r_ak{flex-flow:row-reverse}.r_al{flex-flow:row nowrap}.r_am{flex-flow:column}.r_an{flex-flow:column-reverse}.r_ao{flex-flow:column nowrap}.r_ap{flex-grow:1}.r_aq{flex-grow:9999}.r_ar{flex-shrink:0}.U_gW{--modal-padding:36px;max-width:420px;width:calc(100vw - var(--modal-padding))}@media(min-width:768px){.U_gW{flex-grow:0;max-width:none;min-height:566px;width:408px}}.U_gs{font-size:2.5rem}.ax_g{position:relative;text-align:center}@media(min-width:768px){.ax_g{padding:0 54px 28px}}.ax_H{justify-content:center}.ax_iE{background-color:var(--black-5)}@media(min-width:768px){.ax_iE{padding:36px}}[data-color-scheme=dark] .ax_iE:not([data-skip-color-scheme]){background-color:var(--black-95)}.ax_G{border:0;color:var(--sa-link-color);font-weight:500;vertical-align:initial}@media(min-width:768px){.ax_I{left:54px;margin-bottom:0;position:absolute;right:54px}}p+.aR_jh{margin-top:12px}p+.aR_ji{margin-top:18px}p+.aR_jj{margin-top:20px}p+.aR_jk{margin-top:24px}.aS_jl{font-size:.625rem}.aS_jm{font-size:.6875rem}.aS_jn{font-size:.75rem}.aS_jo{font-size:.875rem}.aS_jp{font-size:1rem}.aS_jq{font-size:1.125rem}.aS_jr{font-size:1.25rem}.aS_js{font-size:1.375rem}.aS_jt{font-size:1.5rem}.aS_ju{font-size:1.75rem}.aS_jv{font-size:2rem}.aS_jw{font-size:2.25rem}.aS_jx{font-size:2.375rem}.aS_jy{font-size:3.125rem}.aS_jz{font-size:4.25rem}.aS_jA{line-height:.75rem}.aS_jB{line-height:.8125rem}.aS_jC{line-height:.875rem}.aS_jD{line-height:1.25rem}.aS_jE{line-height:1rem}.aS_jF{line-height:1.75rem}.aS_jG{line-height:1.5rem}.aS_jH{line-height:1.375rem}.aS_jI{line-height:1.625rem}.aS_jJ{line-height:1.875rem}.aS_jK{line-height:2rem}.aS_jL{line-height:2.25rem}.aS_jM{line-height:2.125rem}.aS_jN{line-height:2.375rem}.aS_jO{line-height:2.75rem}.aS_jP{line-height:2.875rem}.aS_jQ{line-height:3.75rem}.aS_jR{line-height:5.125rem}.aS_jS{font-weight:400}.aS_jT{font-weight:700}.aS_jU{font-style:italic}@media(min-width:768px){.aS_jV{font-size:.625rem}.aS_jW{font-size:.6875rem}.aS_jX{font-size:.75rem}.aS_jY{font-size:.875rem}.aS_jZ{font-size:1rem}.aS_j0{font-size:1.125rem}.aS_j1{font-size:1.25rem}.aS_j2{font-size:1.375rem}.aS_j3{font-size:1.5rem}.aS_j4{font-size:1.75rem}.aS_j5{font-size:2rem}.aS_j6{font-size:2.25rem}.aS_j7{font-size:2.375rem}.aS_j8{font-size:3.125rem}.aS_j9{font-size:4.25rem}.aS_ka{line-height:.75rem}.aS_kb{line-height:.8125rem}.aS_kc{line-height:.875rem}.aS_kd{line-height:1.25rem}.aS_ke{line-height:1rem}.aS_kf{line-height:1.75rem}.aS_kg{line-height:1.5rem}.aS_kh{line-height:1.375rem}.aS_ki{line-height:1.625rem}.aS_kj{line-height:1.875rem}.aS_kk{line-height:2rem}.aS_kl{line-height:2.25rem}.aS_km{line-height:2.125rem}.aS_kn{line-height:2.375rem}.aS_ko{line-height:2.75rem}.aS_kp{line-height:2.875rem}.aS_kq{line-height:3.75rem}.aS_kr{line-height:5.125rem}.aS_ks{font-weight:400}.aS_kt{font-weight:700}.aS_ku{font-style:italic}}@media(min-width:1024px){.aS_kv{font-size:.625rem}.aS_kw{font-size:.6875rem}.aS_kx{font-size:.75rem}.aS_ky{font-size:.875rem}.aS_kz{font-size:1rem}.aS_kA{font-size:1.125rem}.aS_kB{font-size:1.25rem}.aS_kC{font-size:1.375rem}.aS_kD{font-size:1.5rem}.aS_kE{font-size:1.75rem}.aS_kF{font-size:2rem}.aS_kG{font-size:2.25rem}.aS_kH{font-size:2.375rem}.aS_kI{font-size:3.125rem}.aS_kJ{font-size:4.25rem}.aS_kK{line-height:.75rem}.aS_kL{line-height:.8125rem}.aS_kM{line-height:.875rem}.aS_kN{line-height:1.25rem}.aS_kO{line-height:1rem}.aS_kP{line-height:1.75rem}.aS_kQ{line-height:1.5rem}.aS_kR{line-height:1.375rem}.aS_kS{line-height:1.625rem}.aS_kT{line-height:1.875rem}.aS_kU{line-height:2rem}.aS_kV{line-height:2.25rem}.aS_kW{line-height:2.125rem}.aS_kX{line-height:2.375rem}.aS_kY{line-height:2.75rem}.aS_kZ{line-height:2.875rem}.aS_k0{line-height:3.75rem}.aS_k1{line-height:5.125rem}.aS_k2{font-weight:400}.aS_k3{font-weight:700}.aS_k4{font-style:italic}}@media(min-width:1200px){.aS_k5{font-size:.625rem}.aS_k6{font-size:.6875rem}.aS_k7{font-size:.75rem}.aS_k8{font-size:.875rem}.aS_k9{font-size:1rem}.aS_la{font-size:1.125rem}.aS_lb{font-size:1.25rem}.aS_lc{font-size:1.375rem}.aS_ld{font-size:1.5rem}.aS_le{font-size:1.75rem}.aS_lf{font-size:2rem}.aS_lg{font-size:2.25rem}.aS_lh{font-size:2.375rem}.aS_li{font-size:3.125rem}.aS_lj{font-size:4.25rem}.aS_lk{line-height:.75rem}.aS_ll{line-height:.8125rem}.aS_lm{line-height:.875rem}.aS_ln{line-height:1.25rem}.aS_lo{line-height:1rem}.aS_lp{line-height:1.75rem}.aS_lq{line-height:1.5rem}.aS_lr{line-height:1.375rem}.aS_ls{line-height:1.625rem}.aS_lt{line-height:1.875rem}.aS_lu{line-height:2rem}.aS_lv{line-height:2.25rem}.aS_lw{line-height:2.125rem}.aS_lx{line-height:2.375rem}.aS_ly{line-height:2.75rem}.aS_lz{line-height:2.875rem}.aS_lA{line-height:3.75rem}.aS_lB{line-height:5.125rem}.aS_lC{font-weight:400}.aS_lD{font-weight:700}.aS_lE{font-style:italic}}.k_g{color:var(--sa-text-color-1);text-align:center}@media(min-width:768px){.k_g{width:590px}}.k_D{max-width:420px}.k_E{word-break:break-all}.k_H{text-align:center}@media(min-width:768px){.k_I{margin-top:36px}}.E_fc{padding:0!important}[data-color-scheme=dark] .E_fc:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--white-100)}.E_fc>header{pointer-events:none;position:absolute;width:100%}.E_fd{fill:var(--black-35)}.E_fd:hover{fill:var(--black-50)}.d_m{background-color:var(--red-100);border-radius:50%;bottom:20px;flex-shrink:0;height:30px;position:fixed;right:20px;width:30px;z-index:1070}.t_eB{display:none}.t_eC{display:inline}.t_eD{display:block}.t_eE{display:inline-block}.g_p{align-items:center;background:var(--black-100-alpha-80);justify-content:center;left:0;overflow:hidden;position:fixed;top:0;z-index:1060}.g_g,.g_p{height:100%;width:100%}.g_g{--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background:var(--white-100);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.g_g{padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.g_g:before{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.g_g:before{height:var(--env-safe-area-inset-top,0)}}@media(min-width:768px){.g_g{height:500px;width:400px}}.g_f{min-height:424px}.px-captcha-visible{display:flex}.c_g{bottom:-56px;height:56px;left:0;opacity:0;position:fixed;right:0;z-index:1070}.c_h{background-color:var(--black-100);border:1px solid var(--black-10);border-radius:28px;color:var(--white-100);font-size:.875rem;font-weight:700;min-width:252px;text-align:center}@media(min-width:1024px){.c_h{min-width:172px}}[data-color-scheme=dark] .c_h:not([data-skip-color-scheme]){background-color:var(--black-10);border-color:var(--black-10);color:var(--black-100)}.c_i{background:var(--red-100-alpha-75)}.c_j{background:var(--teal-100-alpha-75)}@keyframes c_l{0%{bottom:-56px;opacity:0}10%{bottom:26px;opacity:1}90%{bottom:26px;opacity:1}to{bottom:-56px;opacity:0}}.c_k{animation-name:c_l;animation-timing-function:linear}@media screen and (prefers-reduced-motion:reduce){.c_k{animation:none}}.bh_l4{overflow:hidden;text-overflow:ellipsis}.p_g{background-color:var(--orange-60)}.p_a{height:44px}@media(min-width:1024px){.p_a{height:30px}}.p_G{font-size:.875rem;font-weight:700;white-space:nowrap}.p_G,.p_G:focus,.p_G:hover,.p_G:visited{color:var(--white-100);text-decoration:none}.p_G:focus,.p_G:hover{text-decoration:underline}.p_U{height:25px;opacity:.7;position:relative;width:25px}.p_U:focus,.p_U:hover{cursor:pointer;opacity:1}.p_U:after,.p_U:before{background-color:var(--white-100);content:" ";height:25px;left:12.5px;position:absolute;top:0;width:1px}.p_U:before{transform:rotate(45deg)}.p_U:after{transform:rotate(-45deg)}.m_h{min-height:30px;position:relative}.m_N{height:100%;position:absolute;right:0;top:0}.m_O{height:-webkit-fit-content;height:-moz-fit-content;height:fit-content}.m_O:active,.m_O:focus,.m_O:hover{background-color:var(--black-100-alpha-10)}.m_O:active,.m_O:focus{background-color:#0000}.I_fw{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fw.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}.I_fy{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fy.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}.I_fz{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fz.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}.I_fA{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fA.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}.I_fB{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fB.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}@media(min-width:768px){.I_fC{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fC.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}}@media(min-width:768px){.I_fD{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fD.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}}@media(min-width:768px){.I_fE{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fE.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}}@media(min-width:768px){.I_fF{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fF.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}}@media(min-width:768px){.I_fG{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fG.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}@media(min-width:1024px){.I_fH{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fH.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}}@media(min-width:1024px){.I_fI{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fI.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}}@media(min-width:1024px){.I_fJ{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fJ.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}}@media(min-width:1024px){.I_fK{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fK.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}}@media(min-width:1024px){.I_fL{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fL.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}@media(min-width:1200px){.I_fM{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fM.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}.I_fN{--sa-button-size:3rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.625rem;--sa-button-x-padding:1.375rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color,#0000)}.I_fN.I_fx{--sa-btn-icon-margin:0rem;--sa-button-x-padding:0.625rem}.I_fN:active{--sa-button-border-color:#0000}.I_fO{--sa-button-size:2.25rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color)}.I_fO.I_fx{--sa-btn-icon-margin:0rem}.I_fO:active{--sa-button-border-color:#0000}.I_fP{--sa-button-background-color:var(--black-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fP:active,.I_fP:hover{--sa-button-background-color:var(--black-70)}.I_fP.I_fQ,.I_fP:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-70)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):active{--sa-button-background-color:var(--black-10);--sa-button-border-color:var(--black-10)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]).I_fQ,[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fR{--sa-button-background-color:#0000;--sa-button-color:var(--black-100);--sa-button-border-color:var(--black-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fR:active,.I_fR:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--black-100)}.I_fR.I_fQ,.I_fR:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-100);opacity:.6}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]){--sa-button-color:var(--black-10);--sa-button-border-color:var(--black-10)}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]):hover{--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-30)}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]):active{--sa-button-border-color:var(--black-30);--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-100)}.I_fS{--sa-button-background-color:var(--teal-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fS:active,.I_fS:hover{--sa-button-background-color:var(--green-90)}.I_fS .I_fQ,.I_fS:disabled{--sa-button-background-color:var(--teal-100);opacity:.6}.I_fT{--sa-button-background-color:var(--red-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fT:active,.I_fT:hover{--sa-button-background-color:var(--orange-100)}.I_fT .I_fQ,.I_fT:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]){--sa-button-background-color:var(--red-80);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--orange-100)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fU{--sa-button-background-color:#0000;--sa-button-color:var(--red-100);--sa-button-border-color:var(--red-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fU:active,.I_fU:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--red-100)}.I_fU .I_fQ,.I_fU:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--red-100);opacity:.6}.I_fV{--sa-button-background-color:var(--orange-60);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fV:active,.I_fV:hover{--sa-button-background-color:var(--orange-70)}.I_fV .I_fQ,.I_fV:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]){--sa-button-background-color:var(--orange-60);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--orange-70)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fW{--sa-button-background-color:#0000;--sa-button-color:var(--orange-60);--sa-button-border-color:var(--orange-60);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fW:active,.I_fW:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--orange-70);--sa-button-border-color:var(--orange-70)}.I_fW .I_fQ,.I_fW:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--orange-60);--sa-button-border-color:var(--orange-60);opacity:.6}.I_fX{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-70);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fX:active,.I_fX:hover{--sa-button-background-color:var(--black-10)}.I_fX .I_fQ,.I_fX:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-95);--sa-button-border-color:var(--black-80);--sa-button-color:var(--black-30)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-80)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fY{--sa-button-background-color:#0000;--sa-button-color:var(--black-50);--sa-button-border-color:var(--black-10);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fY:active,.I_fY:hover{--sa-button-background-color:var(--black-5)}.I_fY .I_fQ,.I_fY:disabled{--sa-button-background-color:#0000;opacity:.6}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-95);--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80)}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-80)}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-95);opacity:.6}.I_fZ{--sa-button-background-color:var(--black-5);--sa-button-color:var(--sa-link-color);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fZ:active,.I_fZ:hover{--sa-button-background-color:var(--black-10)}.I_fZ .I_fQ,.I_fZ:disabled{--sa-button-background-color:var(--black-5);opacity:.6}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-30-alpha-20);--sa-button-color:var(--blue-70)}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30-alpha-30)}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f0{--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f0:active,.I_f0:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--black-70)}.I_f0 .I_fQ,.I_f0:disabled{--sa-button-color:var(--black-20);--sa-button-background-color:var(--black-10)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-90);--sa-button-color:var(--black-10)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30-alpha-20)}.I_f1{--sa-button-background-color:#0000;--sa-button-color:var(--black-50);--sa-button-border-color:var(--black-10);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f1:active,.I_f1:hover{--sa-button-background-color:var(--black-70);--sa-button-border-color:var(--black-70);--sa-button-color:var(--white-100)}.I_f1 .I_fQ,.I_f1:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-95);--sa-button-border-color:var(--black-10);opacity:.6}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]){--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80)}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80);opacity:.6}.I_f2{--sa-button-background-color:var(--blue-75);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f2:active,.I_f2:hover{--sa-button-background-color:var(--blue-80)}.I_f2 .I_fQ,.I_f2:disabled{--sa-button-background-color:var(--blue-75);opacity:.6}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]){--sa-button-background-color:var(--blue-75);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--blue-80)}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f3{--sa-button-background-color:#0000;--sa-button-color:var(--blue-75);--sa-button-border-color:var(--blue-75);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f3:active,.I_f3:hover{--sa-button-background-color:var(--blue-75);--sa-button-color:var(--white-100)}.I_f3 .I_fQ,.I_f3:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--blue-75);opacity:.6}.I_f4{--sa-button-background-color:var(--yellow-85);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f4:active,.I_f4:hover{--sa-button-background-color:var(--yellow-100)}.I_f4 .I_fQ,.I_f4:disabled{--sa-button-background-color:var(--yellow-85);opacity:.6}[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]){--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f5{--sa-button-background-color:var(--blue-80);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f5:active,.I_f5:hover{--sa-button-background-color:var(--blue-100);--sa-button-border-color:var(--blue-80)}.I_f5 .I_fQ,.I_f5:disabled{--sa-button-background-color:var(--blue-80);opacity:.6}.I_f6{--sa-button-background-color:#0000;--sa-button-color:var(--blue-80);--sa-button-border-color:var(--blue-80);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f6:active,.I_f6:hover{--sa-button-background-color:var(--blue-100);--sa-button-color:var(--white-100)}.I_f6 .I_fQ,.I_f6:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--blue-80);opacity:.6}.I_f7{--sa-button-background-color:var(--black-35);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f7:active,.I_f7:hover{--sa-button-background-color:var(--black-50)}.I_f7 .I_fQ,.I_f7:disabled{--sa-button-background-color:var(--black-35);opacity:.6}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-10)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):active{--sa-button-border-color:var(--black-50)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f8{--sa-button-background-color:#0000;--sa-button-color:var(--black-35);--sa-button-border-color:var(--black-35);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f8:active,.I_f8:hover{--sa-button-background-color:var(--black-50);--sa-button-border-color:var(--black-50);--sa-button-color:var(--white-100)}.I_f8 .I_fQ,.I_f8:disabled{--sa-button-background-color:#0000;--sa-button-border-color:var(--black-35);--sa-button-color:var(--black-35);opacity:.6}.I_f9{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f9:active,.I_f9:hover{--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-70)}.I_f9 .I_fQ,.I_f9:disabled{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-50);opacity:.6}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-80);--sa-button-color:var(--black-30)}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-90);--sa-button-color:var(--black-10)}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-30)}.I_ga{--sa-button-background-color:#0000;--sa-button-color:var(--black-70);--sa-button-border-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_ga:active,.I_ga:hover{--sa-button-background-color:var(--black-50);--sa-button-color:var(--white-100)}.I_ga .I_fQ,.I_ga:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-70);opacity:.6}.I_G{--sa-button-color:var(--sa-link-color);display:inline}.I_G:active,.I_G:focus,.I_G:hover{text-decoration:underline}.I_gb{--sa-button-background-color:var(--orange-60);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gb:active,.I_gb:hover{--sa-button-background-color:var(--orange-70)}.I_gb:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gb .I_fQ,.I_gb:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}.I_gc{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gc:active,.I_gc:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gc:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gc .I_fQ,.I_gc:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gd{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gd:active,.I_gd:hover{--sa-button-background-color:var(--navy-95-v2)}.I_gd:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gd .I_fQ,.I_gd:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_ge{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--navy-80-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_ge:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_ge:active,.I_ge:hover{--sa-button-background-color:var(--black-15-v2);--sa-button-color:var(--navy-80-v2)}.I_ge .I_fQ,.I_ge:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gf{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gf:active,.I_gf:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gf:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gf .I_fQ,.I_gf:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gg{--sa-button-background-color:var(--black-60-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gg:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gg:active,.I_gg:hover{--sa-button-background-color:var(--black-55-v2)}.I_gg .I_fQ,.I_gg:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}.I_gh{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gh:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gh:active,.I_gh:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gh .I_fQ,.I_gh:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gi{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gi:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gi:active,.I_gi:hover{--sa-button-background-color:var(--black-5-v2)}.I_gi .I_fQ,.I_gi:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gj{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gj:active,.I_gj:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gj:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gj .I_fQ,.I_gj:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_0{background-clip:padding-box;background-color:var(--sa-button-background-color);border-radius:var(--sa-button-border-radius);color:var(--sa-button-color);cursor:pointer;min-height:var(--sa-button-height);padding:var(--sa-button-y-padding) var(--sa-button-x-padding);position:relative;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;-webkit-user-select:none;user-select:none;white-space:nowrap;word-break:break-word}@media screen and (prefers-reduced-motion:reduce){.I_0{transition:none}}.I_0 svg{transition:fill .15s ease-in-out}@media screen and (prefers-reduced-motion:reduce){.I_0 svg{transition:none}}.I_gk{height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.I_gk svg{fill:var(--sa-btn-icon-color,currentColor);color:var(--sa-btn-icon-color,inherit);display:block;height:100%;width:100%}.I_gl{margin-right:var(--sa-btn-icon-margin)}.I_gm{margin-left:var(--sa-btn-icon-margin)}.I_fx{--sa-btn-icon-margin:0}.I_gn{clip:rect(0,0,0,0);border:0!important;height:1px!important;left:0!important;overflow:hidden;padding:0!important;position:absolute!important;top:0!important;white-space:nowrap;width:1px!important}.I_go{width:100%}.I_gp{white-space:normal}.I_gq{pointer-events:none;position:relative}.I_gr{opacity:0}.I_gs{left:50%;position:absolute;top:50%;transform:translate(-50%,-50%)}.I_gt{color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}@keyframes I_eN{0%{transform:rotate(0)}to{transform:rotate(1turn)}}.L_G,.L_G:hover{text-decoration:none}.L_gv,.L_gv:visited{--sa-button-color:var(--sa-link-color)}[data-color-scheme=dark] .n_f:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--black-98)}@media(min-width:768px){[data-color-scheme=dark] .n_f:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--black-80)}}.H_ft{width:130px}.H_e9{max-height:30px;max-width:130px}.H_e9,[data-color-scheme=dark] .H_e9:not([data-skip-color-scheme]){background:0 0}.u_h{padding-top:0}@media(min-width:1024px){.u_h{height:30px;padding-bottom:0;padding-top:0}}.u_eG{width:768px}@media(min-width:1024px){.u_eG .u_h{height:auto}}.u_eH{max-width:576px;width:100%}@media(min-width:1024px){.u_eH .u_h{height:auto}}.u_eI{background:var(--background)}@media(min-width:576px){.u_eI{text-align:center}}.u_O{color:var(--closeColor);position:relative}.u_O:after{background-color:var(--closeColor);content:"";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s ease-in-out;width:100%}.u_O:focus,.u_O:hover{background-color:#0000}.u_O:focus:after,.u_O:hover:after{opacity:.4}[data-color-scheme=dark] .u_O:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .u_O:hover:not([data-skip-color-scheme]){background-color:#0000}.u_eJ{height:100%;opacity:0;position:absolute;width:100%}@media(min-width:768px){.u_eK{margin-left:18px;margin-right:18px}}.u_eK p{color:var(--black-100);margin-bottom:0}@media(min-width:768px){.u_eK p{text-overflow:ellipsis;white-space:nowrap}}.u_eK a,.u_eK a:focus,.u_eK a:hover,.u_eK a:visited{color:currentColor;text-decoration:inherit}.u_eK a:before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.i_r{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-bottom:0}@supports(padding:max(0px)){.i_r{padding-bottom:var(--env-safe-area-inset-bottom,0)}}.bE_a{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px;width:100%}@supports(padding:max(0px)){.bE_a{padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.O_gA{color:var(--sa-text-color-2);font-size:.875rem;line-height:1.75}.bP_mY{list-style:none;margin:0;padding-left:0}.bP_G,.bP_G:focus,.bP_G:hover,.bP_G:visited{color:var(--white-100);text-decoration:none}.bP_G:focus,.bP_G:hover{text-decoration:underline}.T_gQ{background-image:url(/samw/static/images/stock-exchange.6df9b8a9.jpg);background-size:cover;height:100%}.T_gR{background-image:linear-gradient(180deg,#0000,#0000001a 0,#0000001c 0,#000 55%)}.T_f{color:var(--white-100);padding-top:170px}.T_gS{font-size:3rem;line-height:1}.T_gT{font-size:.875rem}.T_gU{color:var(--sa-text-color-3);font-weight:400}.T_gV{height:0;visibility:hidden;width:0}@keyframes a_c{0%{transform:translateY(100%)}to{transform:translateY(0)}}.a_a{bottom:0;left:var(--sa-aside-width,0);position:fixed;right:0;z-index:1030}.a_b{animation:a_c .4s ease-out;height:100%}@media screen and (prefers-reduced-motion:reduce){.a_b{animation:none}}.o_P{background-color:var(--sa-modal-container-bg-color);position:relative;text-align:center;width:320px}@media(min-width:576px){.o_P{padding:32px 36px;width:544px}}@media(min-width:768px){.o_P{width:736px}}@media(min-width:1024px){.o_P{width:800px}}.o_f{white-space:break-spaces}@media(min-width:576px){.o_S{padding:32px 0}}.o_T{border-radius:.25rem;height:44px;width:100%}@media(min-width:576px){.o_T{height:35px;width:160px}}.v_g{color:var(--white-100);text-align:center;width:320px}.v_eM{fill:currentColor;animation:v_eN 1.4s linear infinite;height:62px;width:62px}@media screen and (prefers-reduced-motion:reduce){.v_eM{animation:none}}@keyframes v_eN{to{transform:rotate(1turn)}}.f_g{height:100vh;left:0;min-width:100%;position:fixed;top:0;z-index:1040}.f_f{position:relative;z-index:1050}.f_f,.f_n{height:100%;width:100%}.f_n{background:var(--black-100);left:0;opacity:.6;position:fixed;top:0;z-index:1040}.f_o{overflow:hidden}.hf_fd{flex-shrink:0;height:1.125rem;width:1.125rem}.cT_P{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background-color:var(--white-100);box-shadow:0 4px 8px 0 #00000040;color:var(--black-100);pointer-events:auto;position:relative;width:100%}.cT_P:before{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.cT_P:before{height:var(--env-safe-area-inset-top,0)}}.cT_o8{height:100%;max-height:none;max-width:none;width:100%}@media(min-width:768px){.cT_o9{border-radius:10px;height:608px;max-width:360px;padding-bottom:44px}}.av_n{opacity:0!important}.ex_eM{fill:var(--black-10);animation:ex_eN 1.4s linear infinite;height:54px;width:55px}@media screen and (prefers-reduced-motion:reduce){.ex_eM{animation:none}}@keyframes ex_eN{to{transform:rotate(1turn)}}.scrollLocked .aB_iS{padding-right:var(--scrollbar-width)}@media print{.aQ_jg{display:none!important}}.bodyNavOpened .j_n{background:var(--black-100);height:100%;left:0;opacity:.6;position:fixed;top:0;width:100%;z-index:1040}.scrollLocked{overflow:hidden!important}.j_a{min-width:0}.j_s a:focus,.j_s a:hover{text-decoration:none}.j_t{padding-top:var(--headerFullHeight)}@media print{.j_t{padding-top:0!important}}.j_u{padding-bottom:var(--sa-mobile-bottom-navigation-height)}@media(min-width:768px){.j_v .j_a{display:flex}}.j_v .tp-backdrop,.j_v .tp-modal{display:none!important}.j_v.tp-modal-open{height:auto}.j_w{--env-safe-area-inset-top:env(safe-area-inset-top);--sa-header-bar-height:calc(50px + var(--env-safe-area-inset-top));--sa-drawer-top-offset:0;min-height:100vh;position:relative}@media(min-width:1024px){.j_w{--sa-header-bar-height:calc(90px + var(--env-safe-area-inset-top));z-index:0}}.j_x{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);min-height:calc(100vh - var(--sa-header-bar-height));padding-top:var(--headerHeight);position:relative}.j_x:after{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.j_x:after{height:var(--env-safe-area-inset-bottom,0)}}@media print{.j_x *{font-family:sans-serif!important}}@media(min-width:1024px){.j_y{padding-top:0}}@media(min-width:768px){.j_z{min-height:18px}}@media(min-width:1024px){.j_z{min-height:40px}}.j_A+.j_z{display:none}.J_gu{min-height:1.875rem}.h_f{box-shadow:0 4px 8px 0 #00000040}@media(min-width:768px){.h_f{max-width:500px;width:100%}}.bi_fu{text-align:left}.bi_l5{text-align:center}.bi_fv{text-align:right}.q_g{background:var(--black-100-alpha-50);height:100%;min-height:100vh;position:fixed;top:0;width:100%;z-index:1050}[data-color-scheme=dark] .q_g:not([data-skip-color-scheme]){background:var(--white-100-alpha-50)}.q_V{border-top:1px solid var(--sa-section-separator-thin-color);font-size:.875rem}.q_W{background:var(--sa-card-bg-color);border-radius:10px;box-sizing:border-box;position:relative;width:330px}.q_Y,.q_Z{text-align:center}.q_Z{word-wrap:break-word;font-size:.875rem}.q_0{border-top:1px solid var(--sa-section-separator-thin-color);bottom:0;color:var(--sa-link-color);font-weight:400}.q_1{width:100%}.q_2{left:0;width:50%}.q_3{border-left:1px solid var(--sa-section-separator-thin-color);right:0;width:50%}.aj_e2,.aj_e2:focus,.aj_e2:hover,.aj_e2:visited{color:inherit;text-decoration:none}.aj_gy{height:26px;width:142px}@media(min-width:375px){.aj_gy{height:30px;width:150px}}.aj_hl{color:var(--orange-60)}.aj_hL{fill:var(--orange-60);color:var(--white-100)}.aj_hM{fill:var(--teal-50)}.aj_hN{fill:var(--yellow-85)}.aj_hO{display:none;width:35px}@media(min-width:768px){.aj_hO{display:block}}.aj_hP{height:26px}@media(min-width:1024px){.aj_hP{height:32px;margin-bottom:2px}}.aj_gi{color:var(--white-100)}.aj_fP{color:var(--sa-text-color-1)}.aj_hQ{clip:rect(0,0,0,0);border:0!important;height:1px!important;left:0!important;overflow:hidden;padding:0!important;position:absolute!important;top:0!important;white-space:nowrap;width:1px!important}.aa_g0{display:none}@media(min-width:375px){.aa_g0{display:block}.aa_g1{display:none}}.aa_g2{display:none}@media(min-width:576px){.aa_g2{display:block}.aa_g3{display:none}}.aa_g4{display:none}@media(min-width:768px){.aa_g4{display:block}.aa_g5{display:none}}.aa_g6{display:none}@media(min-width:1024px){.aa_g6{display:block}.aa_g7{display:none}}.aa_g8{display:none}@media(min-width:1200px){.aa_g8{display:block}.aa_g9{display:none}}.aa_ha{display:none}@media(min-width:1540px){.aa_ha{display:block}.aa_hb{display:none}}.R_gL{height:20px;position:relative;width:18px}.R_gM{background-color:var(--white-100);height:2px;position:absolute;top:calc(50% - 1px);transition:background-color .05s ease-in-out .05s;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM{transition:none}}.R_gM:before{background-color:var(--white-100);content:"";display:block;height:2px;position:absolute;transform:translateY(-5px);transition:transform .1s ease-in-out;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM:before{transition:none}}.R_gM:after{background-color:var(--white-100);content:"";display:block;height:2px;position:absolute;transform:translateY(calc(100% + 3px));transition:transform .1s ease-in-out;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM:after{transition:none}}.R_gN{background-color:var(--white-100-alpha-0);transition:background-color .05s ease-in-out}.R_gN:before{transform:rotate(45deg) translateY(0)}.R_gN:after{transform:rotate(-45deg) translateY(0)}.ah_hI{transform:rotate(90deg)}.dz_nE{background-color:var(--orange-60);border:2px solid var(--sa-notification-badge-border-color,var(--black-70));border-radius:4px;color:var(--sa-notification-badge-color,var(--black-100));font-weight:700;min-width:1.25rem;padding:var(--sa-notification-badge-padding,2px);position:absolute;right:0;top:0;transform:translateX(var(--sa-notification-badge-translateX,50%)) translateY(var(--sa-notification-badge-translateY,-25%))}.dG_fd{height:25px;width:31px}.br_mj{--sa-header-sub-menu-bg:var(--white-100);background-color:var(--sa-header-sub-menu-bg);box-shadow:0 0 5px 2px #00000021;z-index:1060}[data-color-scheme=dark] .br_mj:not([data-skip-color-scheme]){--sa-header-sub-menu-bg:var(--black-80)}.br_mk:hover .br_mj{display:block}.br_ml{background-color:var(--sa-header-sub-menu-bg)}.br_ml,.br_ml:focus,.br_ml:hover,.br_ml:visited{color:var(--sa-header-sub-menu-color);text-decoration:none}.br_ml:focus,.br_ml:hover{--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--white-100);text-decoration:underline;text-decoration:none}[data-color-scheme=dark] .br_ml:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .br_ml:hover:not([data-skip-color-scheme]){--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--black-100)}.ce_nE{background-color:var(--orange-100-v2);border:1px solid var(--sa-notification-badge-border-color,var(--white-100));color:var(--sa-notification-badge-color,var(--white-100));font-size:8px;font-weight:600;left:50%;line-height:8px;min-height:.375rem;min-width:.375rem;padding:var(--sa-notification-badge-padding,1px);position:absolute;top:0}.al_a{height:var(--sa-btn-icon-size,24px);line-height:0;width:var(--sa-btn-icon-size,24px)}.ak_a,.al_a{--sa-notification-badge-color:var(--white-100);--sa-notification-badge-border-color:var(--sa-button-background-color,var(--black-90-v2));position:relative}.bz_gd{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gd:active,.bz_gd:hover{--sa-button-background-color:var(--navy-95-v2)}.bz_gd:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gd .bz_fQ,.bz_gd:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_gi{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gi:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gi:active,.bz_gi:hover{--sa-button-background-color:var(--black-5-v2)}.bz_gi .bz_fQ,.bz_gi:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_gj{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gj:active,.bz_gj:hover{--sa-button-background-color:var(--navy-75-v2)}.bz_gj:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gj .bz_fQ,.bz_gj:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0{--sa-button-size:2.25rem;--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;min-height:var(--sa-button-size);min-width:var(--sa-button-size)}@media(min-width:768px){.bz_0{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;--sa-button-size:2.25rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color);text-transform:uppercase}.bz_0:active,.bz_0:hover{--sa-button-background-color:var(--navy-95-v2)}.bz_0:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_0 .bz_fQ,.bz_0:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0.bz_fx{--sa-btn-icon-margin:0rem}.bz_0:active{--sa-button-border-color:#0000}}@media(min-width:1024px){.bz_0{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;--sa-button-size:3rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.625rem;--sa-button-x-padding:1.375rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color,#0000);text-transform:uppercase}.bz_0:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_0:active,.bz_0:hover{--sa-button-background-color:var(--black-5-v2)}.bz_0 .bz_fQ,.bz_0:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0.bz_fx{--sa-btn-icon-margin:0rem;--sa-button-x-padding:0.625rem}.bz_0:active{--sa-button-border-color:#0000}}.bz_f{display:none}@media(min-width:768px){.bz_f{display:flex}}.bz_fd{display:inline-flex}@media(min-width:768px){.bz_fd{display:none}}.Q_gE{margin-left:auto;margin-right:-12px}.Q_0{color:var(--white-100);min-width:36px}.Q_0:empty{display:none}@media(min-width:1024px){.Q_gF{margin-right:20px}}.Q_gG{--sa-notification-badge-padding:1px 2px;--sa-notification-badge-translateX:20%;--sa-notification-badge-translateY:-33%}.Q_gH{--sa-notification-badge-border-color:var(--black-100);--sa-notification-badge-color:var(--black-100)}.Q_gI{--sa-notification-badge-border-color:var(--black-5);--sa-notification-badge-color:var(--white-100)}[data-color-scheme=dark] .Q_gI:not([data-skip-color-scheme]){--sa-notification-badge-border-color:var(--black-98);--sa-notification-badge-color:var(--black-98)}.Q_gJ{width:24px}.Q_gK{fill:var(--sa-text-color-2);color:var(--sa-text-color-2)}.B_B{z-index:1030}.B_eY{min-height:var(--sa-header-bar-height)}.B_eZ{max-width:362px}@media(min-width:1200px){.B_eZ{max-width:430px}}@media(min-width:1540px){.B_eZ{max-width:604px}}.B_eZ .B_e0{--sa-searchbox-results-border-color:var(--navy-40-v2)}[data-color-scheme=dark] .B_eZ .B_e0:not([data-skip-color-scheme]){--sa-searchbox-results-border-color:var(--black-70-v2);--sa-search-category-bg:var(--black-80)}.B_e1{height:36px;width:36px}.B_e2{height:24px;width:120px}@media(min-width:1024px){.B_e2{height:32px;width:140px}}.B_0{--sa-btn-icon-size:18px;min-width:36px}.scrollLocked .B_e3{right:calc(var(--scrollbar-width,0)*-1)}.N_0:active,.N_0:focus,.N_0:hover{text-decoration:underline}.ag_hG{overflow:visible}@media(min-width:768px){.ag_hG{overflow:hidden}}.ag_hG :before{height:0}@media(min-width:768px){.ag_hH{align-items:center;background-color:#0000;box-shadow:none;display:flex;height:100%;max-width:100%}}.A_a{background:var(--white-100);border-bottom:1px solid var(--black-50);color:var(--sa-text-color-3);font-size:.875rem;line-height:1.125rem;padding:15px 0;width:100%;z-index:1}.A_eV{height:10px;width:10px}.A_eW{align-self:center;height:20px;width:20px}[data-color-scheme=dark] .A_eW:not([data-skip-color-scheme]){fill:var(--black-50)}.A_f{max-width:960px}.z_eU{background-color:var(--sa-aside-background-color);left:0;opacity:0;padding:12px;pointer-events:none;position:absolute;right:0;top:0;transform:translateY(-100%);transition:transform .1s ease .1s;z-index:1060}@media screen and (prefers-reduced-motion:reduce){.z_eU{transition:none}}.z_eU,.z_eU:focus,.z_eU:hover,.z_eU:visited{color:var(--white-100);text-decoration:none}.z_eU:focus,.z_eU:hover{text-decoration:underline}.z_eU:focus{opacity:1;pointer-events:auto;transform:translateY(0)}.S_gO{bottom:0;left:var(--sa-aside-width,0);position:fixed;right:0;z-index:1020}.S_gP{visibility:hidden}.S_u{bottom:var(--sa-mobile-bottom-navigation-height)}.aw_fd svg{fill:currentColor;display:block;height:100%;width:100%}.V_gX{height:var(--sa-mobile-bottom-navigation-height)}.V_gY{min-width:60px}@media(min-width:576px){.V_gY{min-width:78px}}.V_gY:last-child{min-width:60px}.l_K{left:0;position:fixed;z-index:1030}.l_K,.l_L{bottom:0;width:100%}.l_L{position:-webkit-sticky;position:sticky;z-index:1029}.P_g{--scrollbar-width:4px}.P_g:after,.P_g:before{content:"";height:24px;left:0;position:absolute;right:0}.P_gB{scrollbar-color:var(--black-50) var(--black-70);scrollbar-width:thin}.P_gB::-webkit-scrollbar-thumb{background-color:var(--black-50);border-radius:0}.P_gB::-webkit-scrollbar-track{background-color:var(--black-70);border-radius:0}.P_gB::-webkit-scrollbar{width:var(--scrollbar-width)}.P_gC:after,.P_gC:before,.P_gD:after,.P_gD:before{pointer-events:none}.P_gC:before{background:linear-gradient(180deg,var(--black-100),var(--black-100-alpha-0) 100%);content:"";top:0;z-index:1}@supports(scrollbar-width:thin){.P_gC:before{margin-right:14px}}@supports not (scrollbar-width:thin){.P_gC:before{margin-right:var(--scrollbar-width)}}.P_gD:after{background:linear-gradient(180deg,var(--black-100-alpha-0) 0,var(--black-100) 100%);bottom:0;content:""}@supports(scrollbar-width:thin){.P_gD:after{margin-right:14px}}@supports not (scrollbar-width:thin){.P_gD:after{margin-right:var(--scrollbar-width)}}.x_eQ{width:var(--sa-aside-width,0)}.x_h,.x_n{top:var(--sa-header-bar-height)}.x_h{transition:transform .3s;width:20rem}@media screen and (prefers-reduced-motion:reduce){.x_h{transition:none}}@media(min-width:768px){.x_h{width:21.875rem}}.x_eR .x_h{transform:translateX(-100%)}@media(min-width:1024px){.x_eS{width:var(--sa-aside-width)}.x_eR .x_eS,.x_eS{transform:translateX(0)}}.hydratingAsideCollapsed .x_eT{display:none}.cX_g{list-style:none;margin:0;padding-left:0}.cX_pf{background-color:var(--sa-accordion-caption-bg);width:100%}.cX_pg{align-items:baseline}@media(min-width:1024px){.cX_pg{align-items:center;padding:20px 0}}.cX_ph{align-items:center}.cX_pg,.cX_ph{text-align:left}@media(min-width:1024px){.cX_pg,.cX_ph{align-items:center}}.cX_pg:focus,.cX_pg:hover,.cX_ph:focus,.cX_ph:hover{text-decoration:underline}.cX_pi,.cX_pj{font-size:1.125rem;font-weight:700;line-height:1.375rem}@media(min-width:1024px){.cX_pi,.cX_pj{font-size:1rem;font-weight:700;line-height:1.25rem}}.cX_pk{--sa-accordion-caption-bg:var(--sa-card-bg-color-2);color:var(--sa-text-color-4);font-weight:500;justify-content:space-between;min-height:55px;position:relative}.cX_pl,.cX_pm{background-color:var(--black-10);border-radius:5px;flex-shrink:0;height:24px;transition:transform .1s linear;width:24px}@media screen and (prefers-reduced-motion:reduce){.cX_pl,.cX_pm{transition:none}}@media(min-width:1024px){.cX_pl,.cX_pm{height:20px;width:20px}}[data-color-scheme=dark] .cX_pl:not([data-skip-color-scheme]),[data-color-scheme=dark] .cX_pm:not([data-skip-color-scheme]){background-color:var(--black-95)}.cX_pm{background-color:var(--black-50);border-radius:0;transition:none}.cX_po{transform:rotate(-90deg)}.cX_pp{transform:rotate(0)}.cX_hI{flex-shrink:0}.cX_pq{fill:currentColor;transition:fill .1s linear;width:.75rem}@media screen and (prefers-reduced-motion:reduce){.cX_pq{transition:none}}.cX_pr,.cX_ps{fill:var(--sa-text-color-3);height:8px;width:14px}@media(min-width:1024px){.cX_pr,.cX_ps{height:6px;width:12px}}.cX_ps{fill:var(--white-100);transition:transform .1s linear}@media screen and (prefers-reduced-motion:reduce){.cX_ps{transition:none}}.cX_pt{order:-1}@media(min-width:1024px){.cX_pv,.cX_pw{margin-left:30px}}.cX_px,.cX_py{order:-1}@media(min-width:1024px){.cX_px,.cX_py{margin-right:30px}}.cX_pz{margin-left:18px;transform:rotate(-90deg);transition:transform .25s}@media screen and (prefers-reduced-motion:reduce){.cX_pz{transition:none}}.cX_pA{background-color:var(--sa-section-separator-color)}.cX_pB .cX_pl{background-color:var(--sa-text-color-3)}.cX_pB .cX_pr{fill:var(--sa-invert-default-color)}.cX_pB .cX_po{transform:rotate(0)}.cX_pB .cX_pp{transform:rotate(-180deg)}.cX_pB .cX_pz{transform:rotate(0)}.cX_pB .cX_pm{background-color:var(--black-50);transform:none}.cX_pB .cX_ps{fill:var(--white-100);transform:rotate(-180deg)}.cX_pB .cX_pA{background-color:var(--black-10)}.cX_pC,.cX_pD{font-size:1rem;font-weight:400;line-height:1.5rem}@media(min-width:1024px){.cX_pC,.cX_pD{font-size:.875rem;font-weight:400;line-height:1.25rem}.cX_pC,.cX_pE{padding-left:54px}}.cX_pF{color:var(--sa-text-color-4)}.cX_pG{border-bottom:1px solid var(--sa-section-separator-color)}.cX_pG:last-child,.cX_pG:only-child{border-bottom:0}.cX_pH:last-child{margin-bottom:0}.cV_eI{--sa-menu-active-color:var(--orange-60)}.cV_pa:after,.cV_pa:before{content:"";height:12px;left:0;pointer-events:none;position:absolute;right:0;width:100%}.cV_pa:before{top:-12px}.cV_pa:after{bottom:-12px}.cV_pa:hover:after,.cV_pa:hover:before{pointer-events:auto}.cV_nr{--sa-link-content-color:var(--black-20)}.cV_pb{pointer-events:none}.cV_pb:before{display:none}.cV_pb.cV_o{--sa-link-bg-color:var(--sa-aside-background-color);--sa-link-active-color:var(--orange-60)}.cV_pc{-ms-overflow-style:none;max-height:var(--sa-hovered-height);scrollbar-width:none}.cV_pc::-webkit-scrollbar{display:none}.dh_o{color:var(--sa-link-active-color)}.cv_oi{width:100%}.cv_oj{width:auto}.jQ_f{text-decoration:none;white-space:nowrap;width:0}.jQ_o4{color:var(--black-20)}.eY_gY{--sa-link-bg-color:var(--sa-aside-background-color);background-color:var(--sa-link-bg-color);min-height:2.75rem}@media(hover:hover)and (pointer:fine){.eY_gY:hover{--sa-link-bg-color:var(--black-30-alpha-20)}}.eY_gY:before{background-color:var(--sa-link-active-color);bottom:10px;content:"";left:0;position:absolute;top:10px;width:4px}@media(min-width:1024px){.eY_tu{min-height:1.875rem}.eY_tu .eY_G,.eY_tu.eY_G{padding-bottom:.25rem;padding-top:.25rem}.eY_tu:before{bottom:0;top:0}}.eY_o{--sa-link-active-color:var(--sa-menu-active-color,var(--orange-60));--sa-link-content-color:var(--orange-60)}.eY_f{color:var(--sa-link-content-color,var(--sa-link-active-color))}.eA_mY{--sa-hovered-menu-width:0;width:var(--sa-hovered-menu-width)}.eA_sB{--sa-hovered-menu-width:288px}.eL_rv{min-width:20px}.bX_m4 .bX_m5,.bX_m4:focus-within .bX_m6,.bX_m4:hover .bX_m6{display:none}.bX_m4:focus-within .bX_m5,.bX_m4:hover .bX_m5{display:flex}.do_a,.do_a:focus,.do_a:hover,.do_a:visited{color:inherit;text-decoration:none}.lV_a{border-width:.0625rem;width:100%}@media(min-width:576px){.lV_a{width:168px}}[data-color-scheme=dark] .lV_a:not([data-skip-color-scheme]){border-color:var(--black-30-alpha-20)}@media(min-width:576px){.lV_La{min-height:2.5rem}.lV_Lb{min-height:1.75rem}}.lV_fi{border-top:1px solid var(--black-10)}[data-color-scheme=dark] .lV_fi:not([data-skip-color-scheme]){border-top:1px solid var(--black-30-alpha-20)}@media(min-width:576px){[data-color-scheme=dark] .lV_fi:not([data-skip-color-scheme]){border-top:none}}.lV_gt{color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.hj_Bo{margin-left:-18px;margin-right:-18px}@media(min-width:576px){.hj_Bo{margin-left:2px;margin-right:2px}}[data-color-scheme=dark] .hj_Bp:not([data-skip-color-scheme]){background-color:var(--black-30-alpha-20)}@media(min-width:768px){.cB_eP{max-width:37.5rem;min-width:37.5rem}}.cU_fd{height:16px;width:16px}.bb_o{--sa-link-content-color:var(--blue-75);--sa-menu-active-color:var(--blue-75)}.C_e4{background:var(--largeTopBannerBackground);position:relative}@media(min-width:768px){.C_e4{margin-bottom:24px}}.C_e4.C_eH{max-width:375px}.C_e4.C_eG{max-width:768px}.C_e4.C_eF{max-width:100%}.C_e5.C_eH{height:60px;margin-bottom:18px}.C_e5.C_eG{margin-bottom:26px}.C_e5.C_eF{margin-bottom:36px;width:260px}.C_e5 img{max-height:100%;max-width:100%}.C_e6 p:last-of-type{margin:0}.C_e6.C_eH{text-align:center}.C_e6.C_eG,.C_e6.C_eH{margin-bottom:24px}.C_e6.C_eF{margin-bottom:36px}.C_e7.C_eH{align-items:center}.C_e8{height:100%;width:100%}.C_e8.C_eH{justify-content:center;max-width:339px}.C_e8.C_eG{max-width:331px}.C_e8.C_eF{max-width:535px}.C_e8 img{max-height:100%;max-width:100%}.C_0{background-color:var(--largeTopBannerButtonColor);max-width:235px;width:100%}.C_0,.C_0:visited{color:var(--largeTopBannerButtonCopyColor)}.C_0.C_eH{margin-bottom:12px;max-width:339px}.C_0.C_eG{max-width:272px}.C_0.C_eF{max-width:300px}.C_g{background-position:bottom;background-repeat:no-repeat}.C_g[data-is-asset-exist=false][data-template-type=top_bottom]{padding-bottom:36px}.C_g[data-template-type=left_right]{align-items:flex-end;gap:26px;justify-content:center}.C_g[data-template-type=left_right].C_eF{gap:48px}.C_g[data-template-type=left_right] .C_e7{align-self:center;padding-bottom:18px;padding-top:18px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eH{max-width:339px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eG{max-width:347px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eF{max-width:609px}.C_g[data-fixed-height=true].C_eG{min-height:349px}.C_g[data-fixed-height=true].C_eF{min-height:580px}.C_g[data-template-type=top_bottom]{align-items:center;flex-direction:column}.C_g[data-template-type=top_bottom].C_eH{padding-top:36px}.C_g[data-template-type=top_bottom].C_eF,.C_g[data-template-type=top_bottom].C_eG{padding-top:80px}.C_g[data-template-type=top_bottom] .C_e5{align-content:center;display:flex;flex-flow:column wrap}.C_g[data-template-type=top_bottom] .C_e7{align-items:center;text-align:center}.C_g[data-template-type=top_bottom] .C_e8{justify-content:center}.C_g[data-template-type=top_bottom] .C_0{margin-bottom:12px}.C_e9,[data-color-scheme=dark] .C_e9:not([data-skip-color-scheme]){background-color:#0000}.C_e9.C_eG{margin:0}.C_N{position:absolute;right:18px;top:18px}.C_O{color:var(--largeTopBannerCloseButtonColor);position:relative}.C_O:after{background-color:var(--largeTopBannerCloseButtonColor);content:"";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s ease-in-out;width:100%}.C_O:focus,.C_O:hover{background-color:#0000}.C_O:focus:after,.C_O:hover:after{opacity:.4}[data-color-scheme=dark] .C_O:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .C_O:hover:not([data-skip-color-scheme]){background-color:#0000}.bO_mW{color:var(--black-35);line-height:1.75}.b_d{max-height:100%}@media(orientation:landscape){.b_d{max-height:668px}}@media(min-width:768px){.b_d{max-height:unset}}.b_e.b_f{padding:0;width:100%}@media(min-width:768px){.b_e.b_f{height:668px;max-width:375px}}@media(min-width:1024px){.b_e.b_f{height:656px;max-width:700px}}@media(min-width:768px){.w_eO{display:flex;flex-flow:row}}@media(min-width:768px){.w_eP{flex-grow:0}}.e_a{left:0;position:fixed;right:0;top:90px;width:100%;z-index:1050}@media(min-width:1540px){.e_a{padding-left:26px;padding-right:26px}}</style><style data-href="/samw/static/styles/prerender.680caa56.css">:root{--sa-mobile-bottom-navigation-height:5rem;--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--twitter-color:#38a1f3;--reddit-color:#ff5700;--facebook-color:#3b5998;--linkedIn-color:#0077b5;--email-color:#999;--sa-sticky-top:calc(var(--headerHeight, 0px) + var(--stripBarHeight, 0px) + var(--headerBottomNav, 0px));--black-98-grad:linear-gradient(90deg,var(--black-98-alpha-0) 0%,var(--black-98) 100%);--black-95-grad:linear-gradient(90deg,var(--black-95-alpha-0) 0%,var(--black-95) 100%);--black-90-grad:linear-gradient(90deg,var(--black-90) 0%,var(--black-100-95) 100%);--black-80-grad:linear-gradient(90deg,var(--black-80) 0%,var(--black-95) 100%);--black-70-grad:linear-gradient(90deg,var(--black-70-alpha-0) 0%,var(--black-70) 100%);--black-60-grad:linear-gradient(180deg,var(--black-60-alpha-50) 0%,var(--black-60) 100%);--black-40-grad:linear-gradient(180deg,var(--black-40-alpha-50) 0%,var(--black-40) 100%);--black-10-grad:linear-gradient(90deg,var(--black-10) 0%,var(--white-100) 100%);--black-5-grad:linear-gradient(90deg,var(--black-5-alpha-0) 0%,var(--black-5) 100%);--white-100-grad:linear-gradient(90deg,var(--white-100-alpha-0) 0%,var(--white-100) 100%);--red-90-grad:linear-gradient(90deg,var(--red-90-alpha-50) 0%,var(--red-90) 100%);--orange-60-grad:linear-gradient(90deg,var(--orange-60-alpha-50) 0%,var(--orange-60) 100%);--teal-80-grad:linear-gradient(90deg,var(--teal-80-alpha-50) 0%,var(--teal-80) 100%);--box-shadow:0 8px 8px var(--black-100-alpha-15);--shadow-elevation-1:0 0 10px #0003;--shadow-elevation-2:0 4px 8px #00000040;--shadow-elevation-3:0 0 10px #000000bf;--shadow-elevation-4:0 4px 8px #000000bf;--black-100:#000;--black-100-alpha-80:#000c;--black-100-alpha-75:#000000bf;--black-100-alpha-50:#00000080;--black-100-alpha-25:#00000040;--black-100-alpha-15:#00000026;--black-100-alpha-10:#0000001a;--black-100-alpha-0:#0000;--black-98:#04080b;--black-98-alpha-0:#04080b00;--black-95:#111517;--black-95-alpha-0:#11151700;--black-90:#232a32;--black-90-alpha-0:#232a3200;--black-80:#2c3032;--black-80-alpha-0:#2c303200;--black-70:#333;--black-70-alpha-0:#3330;--black-70-alpha-50:#33333380;--black-60:#434348;--black-60-alpha-50:#43434880;--black-50:#555;--black-50-alpha-10:#55555580;--black-40:#697173;--black-40-alpha-50:#69717380;--black-35:#757575;--black-35-alpha-50:#75757580;--black-35-alpha-0:#75757500;--black-30:#838d8f;--black-30-alpha-30:#838d8f4d;--black-30-alpha-20:#838d8f33;--black-30-alpha-40:#838d8f66;--black-20:#acacac;--black-20-alpha-20:#acacac33;--black-10:#dbdbdb;--black-5:#f2f4f7;--black-5-alpha-0:#f2f4f700;--black-4:#f9f9f9;--black-90-v2:#101114;--black-85-v2:#1c1d20;--black-80-v2:#212224;--black-70-v2:#3f4248;--black-70-v2-alpha-60:#3f424899;--black-65-v2:#464b54;--black-60-v2:#5e6167;--black-55-v2:#72757b;--black-25-v2:#adb1ba;--black-20-v2:#e0e1e4;--black-15-v2:#e8e8e8;--black-10-v2:#f5f2f1;--black-5-v2:#fcfcfc;--white-96:#f3f4f7;--white-100:#fff;--white-100-alpha-75:#ffffffbf;--white-100-alpha-50:#ffffff80;--white-100-alpha-0:#fff0;--red-100:#c9392c;--red-100-alpha-80:#c9392ccc;--red-100-alpha-75:#c9392cbf;--red-100-alpha-20:#c9392c33;--red-95:#e32b30;--red-95-alpha-50:#e32b3080;--red-90:#d23f31;--red-90-alpha-50:#d23f3180;--red-80:#d94d41;--red-80-alpha-20:#d94d4133;--red-100-v2:#7c1f1f;--red-90-v2:#b94848;--red-80-v2:#bf1d1d;--red-70-v2:#ce3434;--red-60-v2:#d66363;--red-50-v2:#de4e4e;--red-40-v2:#e07575;--red-30-v2:#eb8888;--orange-100:#ff1a00;--orange-100-alpha-50:#ff1a0080;--orange-90:#ea4215;--orange-80:#ff3c00;--orange-70:#d15e00;--orange-60:#ff7200;--orange-60-alpha-50:#ff720080;--orange-60-alpha-0:#ff720000;--orange-100-v2:#ef6d0a;--orange-100-v2-alpha-50:#ef6d0a80;--orange-100-v2-alpha-12:#ef6d0a1f;--orange-95-v2:#f47819;--yellow-100:#e59310;--yellow-100-alpha-50:#e5931080;--yellow-90:#efa818;--yellow-90-alpha-50:#efa81880;--yellow-85:#fec20f;--yellow-80:#fcc131;--yellow-70:#dfbf18;--yellow-100-v2:#d6c100;--yellow-90-v2:#e8da58;--yellow-80-v2:#ebd517;--yellow-70-v2:#ffeb33;--yellow-60-v2:#f3e56a;--yellow-50-v2:#fcef7e;--green-100:#3d5f12;--green-90:#5d921c;--green-90-alpha-50:#5d921c80;--green-80:#70c30e;--green-80-alpha-50:#70c30e80;--green-75:#85c90e;--green-60:#9ace49;--green-60-alpha-50:#9ace4980;--green-50:#a9b667;--green-100-v2:#184515;--green-95-v2:#265523;--green-90-v2:#366332;--green-85-v2:#2c7a26;--green-80-v2:#408e3a;--green-75-v2:#489c43;--green-70-v2:#55a550;--green-65-v2:#59a353;--green-60-v2:#62b05d;--green-55-v2:#74bd6f;--green-50-v2:#87c782;--green-45-v2:#99d194;--teal-100:#0a7b44;--teal-100-alpha-75:#0a7b44bf;--teal-100-alpha-50:#0a7b4480;--teal-80:#0f9d58;--teal-80-alpha-50:#0f9d5880;--teal-75:#32a667;--teal-50:#00d885;--teal-45:#67d9a2;--blue-100:#410cda;--blue-80:#2867db;--blue-75:#1a98ff;--blue-75-alpha-20:#1a98ff33;--blue-75-alpha-50:#1a98ff80;--blue-75-alpha-66:#1a98ffa8;--blue-75-alpha-0:#1a98ff00;--blue-70:#5994ff;--blue-50:#7cb5ec;--blue-50-alpha-20:#7cb5ec33;--blue-10:#e8f5ff;--blue-100-v2:#11718f;--blue-30-v2:#b8c8e5;--navy-100-v2:#242832;--navy-95-v2:#373c49;--navy-80-v2:#414a5f;--navy-75-v2:#46526f;--navy-40-v2:#8d929f;--purple-100:#d423c3;--sa-pro-color:#cce55c;--sa-premium-color:#11718f;--seeking-alpha-color:#ff7200;--sa-body-bg-color:var(--white-96);--sa-body-bg-color-2:var(--white-100);--sa-body-bg-color-3:var(--black-5);--sa-body-bg-color-4:var(--black-10-v2);--sa-link-color:var(--blue-80);--sa-card-bg-color:var(--white-100);--sa-card-bg-color-2:var(--black-5);--sa-card-bg-color-3:var(--white-100);--sa-invert-default-color:var(--white-100);--sa-text-color-1:var(--black-100);--sa-text-color-2:var(--black-35);--sa-text-color-3:var(--black-50);--sa-text-color-4:var(--black-70);--sa-text-color-5:var(--black-100);--sa-text-color-6:var(--black-90-v2);--sa-negative-color:var(--red-100);--sa-negative-color-2:var(--red-70-v2);--sa-positive-color:var(--teal-100);--sa-positive-color-2:var(--green-80-v2);--sa-section-separator-color:var(--black-10);--sa-section-separator-thin-color:var(--black-10);--sa-very-bearish-color:var(--red-95);--sa-bearish-color:var(--orange-100);--sa-neutral-color:var(--yellow-90);--sa-bullish-color:var(--green-60);--sa-very-bullish-color:var(--green-90);--sa-modal-container-bg-color:var(--white-100);--sa-card-bg-transparent-color:#fff0;--sa-content-hide-gradient:linear-gradient(to top,var(--white-100),#ffffff80);--sa-spinner-color-1:var(--black-10);--sa-input-border-color:var(--black-10);--sa-disabled-text-color:var(--black-10);--sa-popup-shadow:var(--shadow-elevation-2);--sa-focus-outline-color:#05c;--sa-divider-color:var(--black-20-v2);--sa-aside-background-color:var(--black-100)}[data-color-scheme=dark]{--sa-body-bg-color:var(--black-98);--sa-body-bg-color-2:var(--black-98);--sa-body-bg-color-3:var(--black-98);--sa-body-bg-color-4:var(--black-98);--sa-link-color:var(--blue-70);--sa-card-bg-color:var(--black-95);--sa-card-bg-color-2:var(--black-80);--sa-card-bg-color-3:var(--black-85-v2);--sa-invert-default-color:var(--black-100);--sa-text-color-1:var(--black-10);--sa-text-color-2:var(--black-30);--sa-text-color-3:var(--black-30);--sa-text-color-4:var(--black-30);--sa-text-color-5:var(--black-30);--sa-text-color-6:var(--black-20-v2);--sa-negative-color:var(--red-80);--sa-negative-color-2:var(--red-70-v2);--sa-positive-color:var(--teal-75);--sa-positive-color-2:var(--green-80-v2);--sa-section-separator-color:var(--black-30);--sa-section-separator-thin-color:var(--black-80);--sa-modal-container-bg-color:var(--black-80);--sa-content-hide-gradient:linear-gradient(to top,var(--black-95),#0000);--sa-card-bg-transparent-color:#0000;--sa-spinner-color-1:var(--black-35);--sa-input-border-color:var(--black-30);--sa-disabled-text-color:var(--black-80);--sa-popup-shadow:var(--shadow-elevation-4);--sa-divider-color:var(--black-60-v2);--sa-aside-background-color:var(--black-95)}:root{--sa-border-r-4:4px;--sa-border-r-8:8px;--sa-border-r-10:10px;--sa-border-r-12:12px;--input-size-xs:1.5rem;--input-size-sm:1.875rem;--input-size-md:2.25rem;--input-size-lg:2.75rem;--sa-chart-loading-color:var(--black-100);--sa-chart-axis-label-color:var(--sa-text-color-3);--sa-chart-loading-background-color:var(--black-100-alpha-10);--sa-chart-axis-line-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-10);--sa-chart-tooltip-bg-color:var(--white-100);--sa-chart-tooltip-color:var(--black-70);--sa-chart-series-start-gradient-color:var(--white-100);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-bg-color:#0000;--sa-chart-flag-plot-line-color:var(--black-20);--sa-chart-flag-plot-fill-color:var(--white-100);--sa-chart-axis-tick-color:var(--black-10);--sa-chart-axis-plot-color:var(--black-5);--sa-chart-plot-option-pie-border-color:var(--white-100);--sa-chart-annotation-tooltip-bg-color:var(--black-100)}[data-color-scheme=dark]{--sa-chart-loading-background-color:var(--black-100-alpha-50);--sa-chart-loading-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-90);--sa-chart-tooltip-bg-color:var(--black-80);--sa-chart-tooltip-color:var(--black-30);--sa-chart-series-start-gradient-color:var(--orange-60-alpha-0);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-axis-line-color:var(--black-80);--sa-chart-flag-plot-line-color:var(--black-80);--sa-chart-flag-plot-fill-color:var(--white-96);--sa-chart-axis-tick-color:var(--black-30);--sa-chart-axis-plot-color:var(--black-100);--sa-chart-plot-option-pie-border-color:var(--black-95);--sa-chart-annotation-tooltip-bg-color:var(--black-90)}:root{--badge-gray:var(--black-10);--badge-dark-gray:var(--black-50);--badge-dark-green:var(--green-100);--badge-green:var(--green-90);--badge-light-green:var(--green-80);--sa-buy-color:var(--green-75);--badge-light-lime:var(--green-60);--badge-olive:var(--green-50);--badge-light-orange:var(--yellow-80);--badge-orange:var(--yellow-90);--badge-dark-orange:var(--yellow-100);--badge-light-red:var(--orange-80);--badge-red:var(--orange-100);--badge-amber:var(--orange-90);--badge-dark-red:var(--red-95);--badge-mint:var(--teal-50);--sa-not-covered-color:var(--black-20-v2);--sa-strong-sell-color:var(--red-100-v2);--sa-sell-color:var(--red-70-v2);--sa-hold-color:var(--yellow-80-v2);--sa-buy-color:var(--green-80-v2);--sa-strong-buy-color:var(--green-95-v2);--sa-grade-a-plus:var(--green-100-v2);--sa-grade-a:var(--green-95-v2);--sa-grade-a-minus:var(--green-90-v2);--sa-grade-b-plus:var(--green-85-v2);--sa-grade-b:var(--sa-buy-color);--sa-grade-b-minus:var(--green-65-v2);--sa-grade-c-plus:var(--yellow-100-v2);--sa-grade-c:var(--sa-hold-color);--sa-grade-c-minus:var(--yellow-70-v2);--sa-grade-d-plus:var(--red-50-v2);--sa-grade-d:var(--red-70-v2);--sa-grade-d-minus:var(--red-80-v2);--sa-grade-f:var(--sa-strong-sell-color)}[data-color-scheme=dark]{--sa-not-covered-color:var(--black-70-v2);--sa-strong-sell-color:var(--red-90-v2);--sa-sell-color:var(--red-40-v2);--sa-hold-color:var(--yellow-60-v2);--sa-buy-color:var(--green-50-v2);--sa-strong-buy-color:var(--green-70-v2);--sa-grade-a-plus:var(--green-75-v2);--sa-grade-a:var(--green-70-v2);--sa-grade-a-minus:var(--green-60-v2);--sa-grade-b-plus:var(--green-55-v2);--sa-grade-b:var(--sa-buy-color);--sa-grade-b-minus:var(--green-45-v2);--sa-grade-c-plus:var(--yellow-90-v2);--sa-grade-c-minus:var(--yellow-50-v2);--sa-grade-d-plus:var(--red-30-v2);--sa-grade-d:var(--red-40-v2);--sa-grade-d-minus:var(--red-60-v2)}*,:after,:before{border:0 solid;box-sizing:border-box}:after,:before{--tw-content:""}html{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;-ms-overflow-style:scrollbar;-webkit-tap-highlight-color:var(--black-100-alpha-0);font-family:sans-serif;font-size:16px;height:100%;line-height:1.15}html.ios-wrapper{width:100vw}#page_content_wrapper,.root,body,html{display:flex;flex-direction:column}#page_content_wrapper,.root,body{flex-grow:1;flex-shrink:0}@media print{.root,body{display:block}}.root,body,html{position:relative}body{height:var(--sa-window-inner-height);z-index:0}@media(min-width:1024px){body{overflow-y:scroll}}article,aside,figcaption,figure,footer,header,nav,section{display:block}body{background-color:var(--sa-body-bg-color-4);color:var(--black-100);font-family:-apple-system,BlinkMacSystemFont,Roboto,Arial,Segoe UI,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol;font-size:1rem;font-weight:400;line-height:1.5;margin:0;text-align:left}[data-color-scheme=dark] body:not([data-skip-color-scheme]){background-color:var(--black-100);color:var(--black-10)}[tabindex="-1"]:focus{outline:0!important}hr{box-sizing:initial;height:0;overflow:visible}h1,h2,h3,h4,h5,h6{margin-bottom:8px;margin-top:0}p{margin-bottom:18px;margin-top:0}abbr[data-original-title],abbr[title]{border-bottom:0;cursor:help;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}address{font-style:normal;line-height:inherit}address,dl,ol,ul{margin-bottom:18px}dl,ol,ul{margin-top:0}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}dt{font-weight:700}dd{margin-bottom:8px;margin-left:0}blockquote{margin:0 0 18px}dfn{font-style:italic}b,strong{font-weight:bolder}small{font-size:80%}sub,sup{font-size:75%;line-height:1;position:relative;vertical-align:initial}sub{bottom:-.25em}sup{top:-.5em}a{-webkit-text-decoration-skip:objects;background-color:#0000;color:var(--sa-link-color)}a,a:focus,a:hover,a:visited{text-decoration:none}a:hover{text-decoration:underline}a:not([href]):not([tabindex]),a:not([href]):not([tabindex]):focus,a:not([href]):not([tabindex]):hover,a:not([href]):not([tabindex]):visited{color:inherit;text-decoration:none}a:not([href]):not([tabindex]):focus{outline:0}code,kbd,pre,samp{font-family:SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}pre{-ms-overflow-style:scrollbar;margin-bottom:18px;margin-top:0;overflow:auto}figure{margin:0 0 18px}img{background-color:var(--white-96);border-style:none;font-size:.75rem;vertical-align:middle}[data-color-scheme=dark] img:not([data-skip-color-scheme]){background-color:var(--black-90)}svg{overflow:hidden;vertical-align:middle}iframe{border:none}table{border-collapse:collapse}caption{caption-side:bottom;color:var(--black-35);padding-bottom:12px;padding-top:12px;text-align:left}th{text-align:inherit}label{display:inline-block;margin-bottom:8px}button{border-radius:0;cursor:pointer;text-align:center}button,input,optgroup,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=reset],[type=submit],button,html [type=button]{-webkit-appearance:button}button{background:#0000;border:none;color:inherit;font:inherit;margin:0;overflow:hidden;padding:0;width:auto}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}button:focus{outline:1px dotted;outline:5px auto -webkit-focus-ring-color}@media(hover:none)and (pointer:coarse){a:active,a:focus,a:hover,button:active,button:focus,button:hover{outline:0!important;text-decoration:none!important}}input{border:1px solid #0000}input[type=password]{font-family:Arial,Helvetica Neue,Helvetica,sans-serif}input[type=checkbox],input[type=radio]{box-sizing:border-box;padding:0}input[type=date],input[type=datetime-local],input[type=month],input[type=time]{-webkit-appearance:listbox}textarea{overflow:auto;resize:vertical}fieldset{border:0;margin:0;min-width:0;padding:0}legend{color:inherit;display:block;font-size:1.5rem;line-height:inherit;margin-bottom:8px;max-width:100%;padding:0;white-space:normal;width:100%}progress{vertical-align:initial}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:none;outline-offset:-2px}[type=search]::-webkit-search-cancel-button,[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}output{display:inline-block}summary{cursor:pointer;display:list-item}template{display:none}[hidden]{display:none!important}[data-intent-mouse=true] [contentEditable=true]:focus,[data-intent-mouse=true] [tabindex="0"]:focus,[data-intent-mouse=true] a[href]:focus,[data-intent-mouse=true] area[href]:focus,[data-intent-mouse=true] button:not([disabled]):focus,[data-intent-mouse=true] iframe:focus,[data-intent-mouse=true] input:not([disabled]):focus,[data-intent-mouse=true] select:not([disabled]):focus,[data-intent-mouse=true] textarea:not([disabled]):focus{outline:0}[data-intent-mouse=false] [contentEditable=true]:focus,[data-intent-mouse=false] [tabindex="0"]:focus,[data-intent-mouse=false] a[href]:focus,[data-intent-mouse=false] area[href]:focus,[data-intent-mouse=false] button:not([disabled]):focus,[data-intent-mouse=false] iframe:focus,[data-intent-mouse=false] input:not([disabled]):focus,[data-intent-mouse=false] select:not([disabled]):focus,[data-intent-mouse=false] textarea:not([disabled]):focus{outline:2px solid var(--sa-focus-outline-color);outline-offset:-1px}@keyframes kef-shift-rightwards{0%{transform:translateX(-100%)}40%{transform:translateX(0)}60%{transform:translateX(0)}to{transform:translateX(100%)}}@keyframes kef-delay-visibility{0%{opacity:0}to{opacity:1}}.loading{align-items:center;background-color:var(--sa-body-bg-color-4);display:flex;justify-content:center;overflow:hidden;z-index:1}[data-color-scheme=dark] .loading:not([data-skip-color-scheme]){background-color:var(--black-90)}@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){[data-color-scheme=system] .loading{background-color:var(--black-90)}}@supports not (-webkit-touch-callout:none){@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){:not([data-color-scheme=dark]) .loading,:not([data-color-scheme=light]) .loading{background-color:var(--black-90)}}}[data-loading-position=fixed]{height:100vh;left:0;position:fixed;top:0;width:100%}[data-loading-position=absolute]{bottom:0;left:0;position:absolute;right:0;top:0}.loadingDelayed{animation:kef-delay-visibility 3s step-end 1}@media screen and (prefers-reduced-motion:reduce){.loadingDelayed{animation:none}}.appLoading{--env-safe-area-inset-top:env(safe-area-inset-top);animation:kef-shift-rightwards 1s ease-in-out infinite;animation-delay:.8s;background:var(--orange-60);height:2px;opacity:1;position:fixed;right:0;top:var(--env-safe-area-inset-top,0);transform:translateX(100%);width:100%;z-index:1051}.appLoaderInvisible{animation:none;opacity:0}@media screen and (prefers-reduced-motion:reduce){.appLoading{animation:none}}.noScript{padding-top:80px;position:relative;text-align:center;z-index:1030}.noScriptDescription,.noScriptTitle{color:var(--sa-text-color-3);font-size:1.125rem;margin-bottom:18px}.noScriptTitle{font-weight:700}*,:after,:before{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }::backdrop{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }.\!container{width:100%!important}.container{width:100%}@media (min-width:1264px){.\!container{max-width:1264px!important}.container{max-width:1264px}}@media (min-width:1300px){.\!container{max-width:1300px!important}.container{max-width:1300px}}.aspect-h-1{--tw-aspect-h:1}.aspect-w-1{--tw-aspect-w:1;padding-bottom:calc(var(--tw-aspect-h)/var(--tw-aspect-w)*100%);position:relative}.aspect-w-1>*{bottom:0;height:100%;left:0;position:absolute;right:0;top:0;width:100%}.spinner{display:block;height:1.25rem;width:1.25rem}.spinner,.spinner:before{border-radius:100%;position:absolute}.spinner:before{--tw-content:"";--tw-translate-y:-50%;--tw-translate-x:-50%;--tw-bg-opacity:1;background-color:rgb(255 255 255/var(--tw-bg-opacity));content:var(--tw-content);height:1rem;left:50%;top:50%;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));width:1rem}:is([data-color-scheme=dark] .spinner):before{--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity));content:var(--tw-content)}@keyframes spin{to{transform:rotate(1turn)}}.spinner{animation:spin 1s linear infinite;background-image:conic-gradient(var(--black-35),#0000)}@media (prefers-reduced-motion:reduce){.spinner{transition-property:none}}.sr-only{clip:rect(0,0,0,0);border-width:0;height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:1px}.pointer-events-none{pointer-events:none}.pointer-events-auto{pointer-events:auto}.\!visible{visibility:visible!important}.visible{visibility:visible}.collapse{visibility:collapse}.static{position:static}.fixed{position:fixed}.absolute{position:absolute}.relative{position:relative}.sticky{position:-webkit-sticky;position:sticky}.inset-0{inset:0}.inset-x-0{left:0;right:0}.-right-2{right:-.125rem}.-top-1{top:-.0625rem}.-top-2{top:-.125rem}.bottom-0{bottom:0}.bottom-10{bottom:.625rem}.bottom-full{bottom:100%}.left-0{left:0}.left-1\/2{left:50%}.left-full{left:100%}.right-0{right:0}.right-12{right:.75rem}.right-16{right:1rem}.right-6{right:.375rem}.right-full{right:100%}.top-0{top:0}.top-1{top:.0625rem}.top-1\/2{top:50%}.top-12{top:.75rem}.top-20{top:1.25rem}.top-full{top:100%}.z-0{z-index:0}.z-1{z-index:1}.z-auto{z-index:auto}.z-modal{z-index:1050}.z-modal-backdrop{z-index:1040}.z-sticky{z-index:1020}.z-tooltip{z-index:1070}.order-first{order:-9999}.m-0{margin:0}.m-4{margin:.25rem}.-mx-12{margin-left:-.75rem;margin-right:-.75rem}.-mx-18{margin-left:-1.125rem;margin-right:-1.125rem}.-my-4{margin-bottom:-.25rem;margin-top:-.25rem}.mx-12{margin-left:.75rem;margin-right:.75rem}.mx-18{margin-left:1.125rem;margin-right:1.125rem}.mx-24{margin-left:1.5rem;margin-right:1.5rem}.mx-auto{margin-left:auto;margin-right:auto}.my-0{margin-bottom:0;margin-top:0}.my-12{margin-bottom:.75rem;margin-top:.75rem}.my-14{margin-bottom:.875rem;margin-top:.875rem}.my-16{margin-bottom:1rem;margin-top:1rem}.my-24{margin-bottom:1.5rem;margin-top:1.5rem}.my-48{margin-bottom:3rem;margin-top:3rem}.-ml-12{margin-left:-.75rem}.-ml-18{margin-left:-1.125rem}.-mt-12{margin-top:-.75rem}.-mt-18{margin-top:-1.125rem}.mb-0{margin-bottom:0}.mb-10{margin-bottom:.625rem}.mb-12{margin-bottom:.75rem}.mb-14{margin-bottom:.875rem}.mb-16{margin-bottom:1rem}.mb-18{margin-bottom:1.125rem}.mb-20{margin-bottom:1.25rem}.mb-24{margin-bottom:1.5rem}.mb-28{margin-bottom:1.75rem}.mb-30{margin-bottom:1.875rem}.mb-32{margin-bottom:2rem}.mb-36{margin-bottom:2.25rem}.mb-4{margin-bottom:.25rem}.mb-40{margin-bottom:2.5rem}.mb-48{margin-bottom:3rem}.mb-6{margin-bottom:.375rem}.mb-8{margin-bottom:.5rem}.mb-auto{margin-bottom:auto}.ml-0{margin-left:0}.ml-12{margin-left:.75rem}.ml-14{margin-left:.875rem}.ml-16{margin-left:1rem}.ml-18{margin-left:1.125rem}.ml-2{margin-left:.125rem}.ml-36{margin-left:2.25rem}.ml-4{margin-left:.25rem}.ml-8{margin-left:.5rem}.ml-auto{margin-left:auto}.mr-10{margin-right:.625rem}.mr-12{margin-right:.75rem}.mr-14{margin-right:.875rem}.mr-16{margin-right:1rem}.mr-18{margin-right:1.125rem}.mr-2{margin-right:.125rem}.mr-24{margin-right:1.5rem}.mr-28{margin-right:1.75rem}.mr-30{margin-right:1.875rem}.mr-36{margin-right:2.25rem}.mr-4{margin-right:.25rem}.mr-6{margin-right:.375rem}.mr-8{margin-right:.5rem}.mr-auto{margin-right:auto}.mt-10{margin-top:.625rem}.mt-12{margin-top:.75rem}.mt-14{margin-top:.875rem}.mt-16{margin-top:1rem}.mt-18{margin-top:1.125rem}.mt-2{margin-top:.125rem}.mt-24{margin-top:1.5rem}.mt-32{margin-top:2rem}.mt-4{margin-top:.25rem}.mt-8{margin-top:.5rem}.mt-auto{margin-top:auto}.box-border{box-sizing:border-box}.block{display:block}.inline-block{display:inline-block}.inline{display:inline}.flex{display:flex}.inline-flex{display:inline-flex}.\!table{display:table!important}.table{display:table}.grid{display:grid}.contents{display:contents}.list-item{display:list-item}.\!hidden{display:none!important}.hidden{display:none}.h-0{height:0}.h-1{height:.0625rem}.h-10{height:.625rem}.h-100{height:6.25rem}.h-12{height:.75rem}.h-120{height:7.5rem}.h-14{height:.875rem}.h-16{height:1rem}.h-170{height:10.625rem}.h-18{height:1.125rem}.h-20{height:1.25rem}.h-24{height:1.5rem}.h-240{height:15rem}.h-26{height:1.625rem}.h-28{height:1.75rem}.h-30{height:1.875rem}.h-32{height:2rem}.h-34{height:2.125rem}.h-36{height:2.25rem}.h-38{height:2.375rem}.h-4{height:.25rem}.h-40{height:2.5rem}.h-44{height:2.75rem}.h-48{height:3rem}.h-50{height:3.125rem}.h-60{height:3.75rem}.h-8{height:.5rem}.h-80{height:5rem}.h-auto{height:auto}.h-full{height:100%}.h-screen{height:100vh}.max-h-24{max-height:1.5rem}.max-h-full{max-height:100%}.min-h-0{min-height:0}.min-h-full{min-height:100%}.min-h-min{min-height:-webkit-min-content;min-height:min-content}.w-0{width:0}.w-1\/2{width:50%}.w-1\/4{width:25%}.w-10{width:.625rem}.w-100{width:6.25rem}.w-12{width:.75rem}.w-120{width:7.5rem}.w-14{width:.875rem}.w-16{width:1rem}.w-170{width:10.625rem}.w-18{width:1.125rem}.w-20{width:1.25rem}.w-24{width:1.5rem}.w-240{width:15rem}.w-26{width:1.625rem}.w-3\/4{width:75%}.w-30{width:1.875rem}.w-32{width:2rem}.w-36{width:2.25rem}.w-40{width:2.5rem}.w-44{width:2.75rem}.w-48{width:3rem}.w-50{width:3.125rem}.w-60{width:3.75rem}.w-8{width:.5rem}.w-80{width:5rem}.w-auto{width:auto}.w-full{width:100%}.w-max{width:-webkit-max-content;width:max-content}.min-w-0{min-width:0}.min-w-full{min-width:100%}.max-w-0{max-width:0}.max-w-5xl{max-width:64rem}.max-w-full{max-width:100%}.flex-1{flex:1 1 0%}.flex-auto{flex:1 1 auto}.flex-none{flex:none}.flex-shrink{flex-shrink:1}.flex-shrink-0,.shrink-0{flex-shrink:0}.flex-grow{flex-grow:1}.flex-grow-0{flex-grow:0}.grow{flex-grow:1}.grow-0{flex-grow:0}.basis-0{flex-basis:0px}.basis-full{flex-basis:100%}.-translate-x-1\/2{--tw-translate-x:-50%}.-translate-x-1\/2,.-translate-y-1\/2{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-1\/2{--tw-translate-y:-50%}.translate-x-0{--tw-translate-x:0px}.translate-x-0,.translate-x-12{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-12{--tw-translate-x:0.75rem}.translate-y-1{--tw-translate-y:0.0625rem}.-rotate-90,.translate-y-1{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-rotate-90{--tw-rotate:-90deg}.rotate-0{--tw-rotate:0deg}.rotate-0,.rotate-180{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-180{--tw-rotate:180deg}.rotate-90{--tw-rotate:90deg}.rotate-90,.transform{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.cursor-default{cursor:default}.cursor-none{cursor:none}.cursor-pointer{cursor:pointer}.cursor-text{cursor:text}.select-none{-webkit-user-select:none;user-select:none}.resize{resize:both}.list-inside{list-style-position:inside}.list-none{list-style-type:none}.grid-cols-1{grid-template-columns:repeat(1,minmax(0,1fr))}.flex-row{flex-direction:row}.flex-row-reverse{flex-direction:row-reverse}.flex-col{flex-direction:column}.flex-col-reverse{flex-direction:column-reverse}.flex-wrap{flex-wrap:wrap}.flex-nowrap{flex-wrap:nowrap}.items-start{align-items:flex-start}.items-end{align-items:flex-end}.items-center{align-items:center}.items-baseline{align-items:baseline}.items-stretch{align-items:stretch}.justify-start{justify-content:flex-start}.justify-end{justify-content:flex-end}.justify-center{justify-content:center}.justify-between{justify-content:space-between}.justify-items-center{justify-items:center}.gap-16{gap:1rem}.gap-28{gap:1.75rem}.gap-32{gap:2rem}.gap-y-8{row-gap:.5rem}.self-start{align-self:flex-start}.self-stretch{align-self:stretch}.overflow-auto{overflow:auto}.overflow-hidden{overflow:hidden}.overflow-visible{overflow:visible}.overflow-y-auto{overflow-y:auto}.overflow-x-hidden{overflow-x:hidden}.overscroll-contain{overscroll-behavior:contain}.truncate{overflow:hidden;white-space:nowrap}.text-ellipsis,.truncate{text-overflow:ellipsis}.whitespace-nowrap{white-space:nowrap}.whitespace-pre-line{white-space:pre-line}.rounded-0{border-radius:0}.rounded-3{border-radius:.1875rem}.rounded-4{border-radius:.25rem}.rounded-8{border-radius:.5rem}.rounded-full{border-radius:100%}.rounded-b-0{border-bottom-left-radius:0;border-bottom-right-radius:0}.rounded-b-4{border-bottom-left-radius:.25rem;border-bottom-right-radius:.25rem}.rounded-r-8{border-bottom-right-radius:.5rem;border-top-right-radius:.5rem}.rounded-t-4{border-top-left-radius:.25rem;border-top-right-radius:.25rem}.rounded-bl-8{border-bottom-left-radius:.5rem}.rounded-tl-0{border-top-left-radius:0}.border{border-width:.0625rem}.border-0{border-width:0}.border-2{border-width:.125rem}.border-6{border-width:.375rem}.border-y{border-bottom-width:.0625rem;border-top-width:.0625rem}.border-y-0{border-bottom-width:0;border-top-width:0}.border-b{border-bottom-width:.0625rem}.border-b-0{border-bottom-width:0}.border-l-6{border-left-width:.375rem}.border-r-0{border-right-width:0}.border-r-4{border-right-width:.25rem}.border-t{border-top-width:.0625rem}.border-t-0{border-top-width:0}.border-solid{border-style:solid}.border-black{--tw-border-opacity:1;border-color:rgb(0 0 0/var(--tw-border-opacity))}.border-black-10{--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}.border-black-35{--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}.border-black-50{--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}.border-blue-75{--tw-border-opacity:1;border-color:rgb(26 152 255/var(--tw-border-opacity))}.border-blue-75\/25{border-color:#1a98ff40}.border-blue-75\/50{border-color:#1a98ff80}.border-blue-75\/75{border-color:#1a98ffbf}.border-navy{--tw-border-opacity:1;border-color:rgb(36 40 50/var(--tw-border-opacity))}.border-navy-40{--tw-border-opacity:1;border-color:rgb(141 146 159/var(--tw-border-opacity))}.border-red{--tw-border-opacity:1;border-color:rgb(201 57 44/var(--tw-border-opacity))}.border-share-bg-4{border-color:var(--sa-body-bg-color-4)}.border-share-negative{border-color:var(--sa-negative-color)}.border-share-separator-thin{border-color:var(--sa-section-separator-thin-color)}.border-share-text-2{border-color:var(--sa-text-color-2)}.border-transparent{border-color:#0000}.border-y-black-10{border-top-color:rgb(219 219 219/var(--tw-border-opacity))}.border-b-black-10,.border-y-black-10{--tw-border-opacity:1;border-bottom-color:rgb(219 219 219/var(--tw-border-opacity))}.border-l-blue-75{--tw-border-opacity:1;border-left-color:rgb(26 152 255/var(--tw-border-opacity))}.border-l-transparent{border-left-color:#0000}.border-r-transparent{border-right-color:#0000}.border-t-transparent{border-top-color:#0000}.\!bg-green-90{--tw-bg-opacity:1!important;background-color:rgb(93 146 28/var(--tw-bg-opacity))!important}.bg-black{--tw-bg-opacity:1;background-color:rgb(0 0 0/var(--tw-bg-opacity))}.bg-black-10{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.bg-black-20{--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}.bg-black-30\/40{background-color:#838d8f66}.bg-black-35{--tw-bg-opacity:1;background-color:rgb(117 117 117/var(--tw-bg-opacity))}.bg-black-4{--tw-bg-opacity:1;background-color:rgb(249 249 249/var(--tw-bg-opacity))}.bg-black-5{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.bg-black-50{--tw-bg-opacity:1;background-color:rgb(85 85 85/var(--tw-bg-opacity))}.bg-black-v2-20{--tw-bg-opacity:1;background-color:rgb(224 225 228/var(--tw-bg-opacity))}.bg-black-v2-90{--tw-bg-opacity:1;background-color:rgb(16 17 20/var(--tw-bg-opacity))}.bg-black\/60{background-color:#0009}.bg-blue-75{--tw-bg-opacity:1;background-color:rgb(26 152 255/var(--tw-bg-opacity))}.bg-brand-sa{background-color:var(--seeking-alpha-color)}.bg-green{--tw-bg-opacity:1;background-color:rgb(61 95 18/var(--tw-bg-opacity))}.bg-green-v2{--tw-bg-opacity:1;background-color:rgb(24 69 21/var(--tw-bg-opacity))}.bg-green-v2-65{--tw-bg-opacity:1;background-color:rgb(89 163 83/var(--tw-bg-opacity))}.bg-green-v2-80{--tw-bg-opacity:1;background-color:rgb(64 142 58/var(--tw-bg-opacity))}.bg-green-v2-85{--tw-bg-opacity:1;background-color:rgb(44 122 38/var(--tw-bg-opacity))}.bg-green-v2-90{--tw-bg-opacity:1;background-color:rgb(54 99 50/var(--tw-bg-opacity))}.bg-green-v2-95{--tw-bg-opacity:1;background-color:rgb(38 85 35/var(--tw-bg-opacity))}.bg-navy{--tw-bg-opacity:1;background-color:rgb(36 40 50/var(--tw-bg-opacity))}.bg-orange-60{--tw-bg-opacity:1;background-color:rgb(255 114 0/var(--tw-bg-opacity))}.bg-red{--tw-bg-opacity:1;background-color:rgb(201 57 44/var(--tw-bg-opacity))}.bg-red-v2{--tw-bg-opacity:1;background-color:rgb(124 31 31/var(--tw-bg-opacity))}.bg-red-v2-50{--tw-bg-opacity:1;background-color:rgb(222 78 78/var(--tw-bg-opacity))}.bg-red-v2-70{--tw-bg-opacity:1;background-color:rgb(206 52 52/var(--tw-bg-opacity))}.bg-red-v2-80{--tw-bg-opacity:1;background-color:rgb(191 29 29/var(--tw-bg-opacity))}.bg-share-aside-bg{background-color:var(--sa-aside-background-color)}.bg-share-bg-2{background-color:var(--sa-body-bg-color-2)}.bg-share-bg-4{background-color:var(--sa-body-bg-color-4)}.bg-share-card-bg{background-color:var(--sa-card-bg-color)}.bg-share-link{background-color:var(--sa-link-color)}.bg-share-modal-container{background-color:var(--sa-modal-container-bg-color)}.bg-share-negative{background-color:var(--sa-negative-color)}.bg-share-positive{background-color:var(--sa-positive-color)}.bg-share-text{background-color:var(--sa-text-color-1)}.bg-share-text-2{background-color:var(--sa-text-color-2)}.bg-share-text-3{background-color:var(--sa-text-color-3)}.bg-teal{--tw-bg-opacity:1;background-color:rgb(10 123 68/var(--tw-bg-opacity))}.bg-transparent{background-color:initial}.bg-white{--tw-bg-opacity:1;background-color:rgb(255 255 255/var(--tw-bg-opacity))}.bg-white-96{--tw-bg-opacity:1;background-color:rgb(243 244 247/var(--tw-bg-opacity))}.bg-yellow-85{--tw-bg-opacity:1;background-color:rgb(254 194 15/var(--tw-bg-opacity))}.bg-yellow-v2{--tw-bg-opacity:1;background-color:rgb(214 193 0/var(--tw-bg-opacity))}.bg-yellow-v2-70{--tw-bg-opacity:1;background-color:rgb(255 235 51/var(--tw-bg-opacity))}.bg-yellow-v2-80{--tw-bg-opacity:1;background-color:rgb(235 213 23/var(--tw-bg-opacity))}.bg-gradient-to-r{background-image:linear-gradient(to right,var(--tw-gradient-stops))}.from-black-10{--tw-gradient-from:#dbdbdb var(--tw-gradient-from-position);--tw-gradient-to:#dbdbdb00 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.to-white{--tw-gradient-to:#fff var(--tw-gradient-to-position)}.bg-cover{background-size:cover}.bg-clip-padding{background-clip:padding-box}.bg-center{background-position:50%}.bg-no-repeat{background-repeat:no-repeat}.fill-black{fill:#000}.fill-black-10{fill:#dbdbdb}.fill-black-20{fill:#acacac}.fill-black-35{fill:#757575}.fill-black-50{fill:#555}.fill-current{fill:currentColor}.fill-red{fill:#c9392c}.fill-share-negative{fill:var(--sa-negative-color)}.fill-share-positive{fill:var(--sa-positive-color)}.fill-share-text-2{fill:var(--sa-text-color-2)}.fill-share-text-6{fill:var(--sa-text-color-6)}.fill-teal{fill:#0a7b44}.fill-transparent{fill:#0000}.fill-white{fill:#fff}.fill-yellow-90{fill:#efa818}.stroke-black-35{stroke:#757575}.stroke-yellow-90{stroke:#efa818}.object-contain{object-fit:contain}.p-0{padding:0}.p-12{padding:.75rem}.p-16{padding:1rem}.p-18{padding:1.125rem}.p-2{padding:.125rem}.p-4{padding:.25rem}.p-6{padding:.375rem}.p-8{padding:.5rem}.px-0{padding-left:0;padding-right:0}.px-12{padding-left:.75rem;padding-right:.75rem}.px-14{padding-left:.875rem;padding-right:.875rem}.px-18{padding-left:1.125rem;padding-right:1.125rem}.px-20{padding-left:1.25rem;padding-right:1.25rem}.px-24{padding-left:1.5rem;padding-right:1.5rem}.px-32{padding-left:2rem;padding-right:2rem}.px-36{padding-left:2.25rem;padding-right:2.25rem}.px-38{padding-left:2.375rem;padding-right:2.375rem}.px-4{padding-left:.25rem;padding-right:.25rem}.px-6{padding-left:.375rem;padding-right:.375rem}.px-8{padding-left:.5rem;padding-right:.5rem}.py-0{padding-bottom:0;padding-top:0}.py-10{padding-bottom:.625rem;padding-top:.625rem}.py-12{padding-bottom:.75rem;padding-top:.75rem}.py-14{padding-bottom:.875rem;padding-top:.875rem}.py-16{padding-bottom:1rem;padding-top:1rem}.py-18{padding-bottom:1.125rem;padding-top:1.125rem}.py-2{padding-bottom:.125rem;padding-top:.125rem}.py-20{padding-bottom:1.25rem;padding-top:1.25rem}.py-24{padding-bottom:1.5rem;padding-top:1.5rem}.py-26{padding-bottom:1.625rem;padding-top:1.625rem}.py-4{padding-bottom:.25rem;padding-top:.25rem}.py-48{padding-bottom:3rem;padding-top:3rem}.py-6{padding-bottom:.375rem;padding-top:.375rem}.py-8{padding-bottom:.5rem;padding-top:.5rem}.pb-0{padding-bottom:0}.pb-10{padding-bottom:.625rem}.pb-12{padding-bottom:.75rem}.pb-18{padding-bottom:1.125rem}.pb-20{padding-bottom:1.25rem}.pb-24{padding-bottom:1.5rem}.pb-28{padding-bottom:1.75rem}.pb-4{padding-bottom:.25rem}.pb-40{padding-bottom:2.5rem}.pb-48{padding-bottom:3rem}.pb-6{padding-bottom:.375rem}.pb-8{padding-bottom:.5rem}.pl-0{padding-left:0}.pl-12{padding-left:.75rem}.pl-14{padding-left:.875rem}.pl-18{padding-left:1.125rem}.pl-20{padding-left:1.25rem}.pl-24{padding-left:1.5rem}.pl-28{padding-left:1.75rem}.pl-32{padding-left:2rem}.pl-36{padding-left:2.25rem}.pl-40{padding-left:2.5rem}.pr-24{padding-right:1.5rem}.pr-30{padding-right:1.875rem}.pr-38{padding-right:2.375rem}.pr-48{padding-right:3rem}.ps-0{padding-inline-start:0}.pt-0{padding-top:0}.pt-10{padding-top:.625rem}.pt-12{padding-top:.75rem}.pt-14{padding-top:.875rem}.pt-16{padding-top:1rem}.pt-18{padding-top:1.125rem}.pt-2{padding-top:.125rem}.pt-20{padding-top:1.25rem}.pt-24{padding-top:1.5rem}.pt-32{padding-top:2rem}.pt-4{padding-top:.25rem}.pt-42{padding-top:2.625rem}.pt-48{padding-top:3rem}.pt-8{padding-top:.5rem}.text-left{text-align:left}.text-center{text-align:center}.text-right{text-align:right}.align-top{vertical-align:top}.align-middle{vertical-align:middle}.text-2x-large-2-r{font-size:1.25rem;font-weight:400;line-height:1.875rem}.text-2x-large-r{font-size:1.25rem;font-weight:400;line-height:1.5rem}.text-2x-small-b{font-weight:700}.text-2x-small-b,.text-2x-small-r{font-size:.625rem;line-height:.75rem}.text-2x-small-r{font-weight:400}.text-3x-large-2-b{font-size:1.375rem;font-weight:700;line-height:2rem}.text-3x-large-b{font-size:1.375rem;font-weight:700;line-height:1.625rem}.text-4x-large-2-b{font-size:1.5rem;font-weight:700;line-height:2.25rem}.text-4x-large-b{font-weight:700}.text-4x-large-b,.text-4x-large-r{font-size:1.5rem;line-height:1.875rem}.text-4x-large-r{font-weight:400}.text-5x-large-b{font-weight:700}.text-5x-large-b,.text-5x-large-r{font-size:1.75rem;line-height:2.125rem}.text-5x-large-r{font-weight:400}.text-6x-large-b{font-size:2rem;font-weight:700;line-height:2.375rem}.text-7x-large-b{font-weight:700}.text-7x-large-b,.text-7x-large-r{font-size:2.25rem;line-height:2.75rem}.text-7x-large-r{font-weight:400}.text-large-2-r{font-size:1rem;font-weight:400;line-height:1.5rem}.text-large-b{font-weight:700}.text-large-b,.text-large-r{font-size:1rem;line-height:1.25rem}.text-large-r{font-weight:400}.text-medium-2-r{font-size:.875rem;font-weight:400;line-height:1.25rem}.text-medium-3-r{font-size:.875rem;font-weight:400;line-height:1.75rem}.text-medium-b{font-weight:700}.text-medium-b,.text-medium-r{font-size:.875rem;line-height:1rem}.text-medium-r{font-weight:400}.text-small-2-r{font-size:.75rem;font-weight:400;line-height:1.25rem}.text-small-b{font-weight:700}.text-small-b,.text-small-r{font-size:.75rem;line-height:.875rem}.text-small-r{font-weight:400}.text-x-large-2-b{font-weight:700}.text-x-large-2-b,.text-x-large-2-r{font-size:1.125rem;line-height:1.625rem}.text-x-large-2-r{font-weight:400}.text-x-large-b{font-weight:700}.text-x-large-b,.text-x-large-r{font-size:1.125rem;line-height:1.375rem}.text-x-large-r{font-weight:400}.text-x-small-r{font-size:.6875rem;font-weight:400;line-height:.8125rem}.font-bold{font-weight:700}.font-medium{font-weight:500}.font-semibold{font-weight:600}.uppercase{text-transform:uppercase}.capitalize{text-transform:capitalize}.italic{font-style:italic}.ordinal{--tw-ordinal:ordinal;font-variant-numeric:var(--tw-ordinal) var(--tw-slashed-zero) var(--tw-numeric-figure) var(--tw-numeric-spacing) var(--tw-numeric-fraction)}.leading-3{line-height:.75rem}.leading-none{line-height:1}.text-black{--tw-text-opacity:1;color:rgb(0 0 0/var(--tw-text-opacity))}.text-black-10{--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}.text-black-20{--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}.text-black-35{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.text-black-50{--tw-text-opacity:1;color:rgb(85 85 85/var(--tw-text-opacity))}.text-black-60{--tw-text-opacity:1;color:rgb(67 67 72/var(--tw-text-opacity))}.text-black-70{--tw-text-opacity:1;color:rgb(51 51 51/var(--tw-text-opacity))}.text-black-v2-70{--tw-text-opacity:1;color:rgb(63 66 72/var(--tw-text-opacity))}.text-black-v2-90{--tw-text-opacity:1;color:rgb(16 17 20/var(--tw-text-opacity))}.text-blue-75{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity))}.text-blue-80{--tw-text-opacity:1;color:rgb(40 103 219/var(--tw-text-opacity))}.text-brand-premium{--tw-text-opacity:1;color:rgb(17 113 143/var(--tw-text-opacity))}.text-brand-pro{--tw-text-opacity:1;color:rgb(204 229 92/var(--tw-text-opacity))}.text-brand-sa{color:var(--seeking-alpha-color)}.text-orange-60{--tw-text-opacity:1;color:rgb(255 114 0/var(--tw-text-opacity))}.text-red{--tw-text-opacity:1;color:rgb(201 57 44/var(--tw-text-opacity))}.text-share-link{color:var(--sa-link-color)}.text-share-negative{color:var(--sa-negative-color)}.text-share-positive{color:var(--sa-positive-color)}.text-share-text{color:var(--sa-text-color-1)}.text-share-text-2{color:var(--sa-text-color-2)}.text-share-text-3{color:var(--sa-text-color-3)}.text-share-text-6{color:var(--sa-text-color-6)}.text-white{--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}.text-white-96{--tw-text-opacity:1;color:rgb(243 244 247/var(--tw-text-opacity))}.text-yellow-85{--tw-text-opacity:1;color:rgb(254 194 15/var(--tw-text-opacity))}.underline{text-decoration-line:underline}.no-underline{text-decoration-line:none}.opacity-0{opacity:0}.opacity-100{opacity:1}.opacity-30{opacity:.3}.opacity-50{opacity:.5}.opacity-60{opacity:.6}.shadow{--tw-shadow:0 1px 3px 0 #0000001a,0 1px 2px -1px #0000001a;--tw-shadow-colored:0 1px 3px 0 var(--tw-shadow-color),0 1px 2px -1px var(--tw-shadow-color)}.shadow,.shadow-none{box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-none{--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000}.shadow-transparent{--tw-shadow-color:#0000;--tw-shadow:var(--tw-shadow-colored)}.outline-none{outline:2px solid #0000;outline-offset:2px}.outline{outline-style:solid}.blur{--tw-blur:blur(8px)}.blur,.invert{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.invert{--tw-invert:invert(100%)}.\!filter{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)!important}.filter{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.filter-none{filter:none}.transition{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,-webkit-backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter,-webkit-backdrop-filter;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-colors{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke;transition-timing-function:cubic-bezier(.4,0,.2,1)}.pl-safe{padding-left:env(safe-area-inset-left)}.px-safe-offset-10{padding-left:calc(env(safe-area-inset-left) + .625rem);padding-right:calc(env(safe-area-inset-right) + .625rem)}.px-safe-offset-12{padding-left:calc(env(safe-area-inset-left) + .75rem);padding-right:calc(env(safe-area-inset-right) + .75rem)}.px-safe-offset-18{padding-left:calc(env(safe-area-inset-left) + 1.125rem);padding-right:calc(env(safe-area-inset-right) + 1.125rem)}.px-safe-offset-20{padding-left:calc(env(safe-area-inset-left) + 1.25rem);padding-right:calc(env(safe-area-inset-right) + 1.25rem)}.p-safe-or-20{padding:max(env(safe-area-inset-top),1.25rem) max(env(safe-area-inset-right),1.25rem) max(env(safe-area-inset-bottom),1.25rem) max(env(safe-area-inset-left),1.25rem)}.pt-safe-or-18{padding-top:max(env(safe-area-inset-top),1.125rem)}.pt-safe-or-24{padding-top:max(env(safe-area-inset-top),1.5rem)}.pt-safe-or-6{padding-top:max(env(safe-area-inset-top),.375rem)}.px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.px-safe-or-20{padding-left:max(env(safe-area-inset-left),1.25rem);padding-right:max(env(safe-area-inset-right),1.25rem)}.sa-row-gap-18{margin-bottom:1.125rem;margin-left:-1.125rem;margin-top:-1.125rem}.sa-row-gap-18>*{padding-left:1.125rem;padding-top:1.125rem}.sa-row-gap-20{margin-bottom:1.25rem;margin-left:-1.25rem;margin-top:-1.25rem}.sa-row-gap-20>*{padding-left:1.25rem;padding-top:1.25rem}.sa-row-gap-22{margin-bottom:1.375rem;margin-left:-1.375rem;margin-top:-1.375rem}.sa-row-gap-22>*{padding-left:1.375rem;padding-top:1.375rem}.sa-row-gap-24{margin-bottom:1.5rem;margin-left:-1.5rem;margin-top:-1.5rem}.sa-row-gap-24>*{padding-left:1.5rem;padding-top:1.5rem}.sa-row-gap-32{margin-bottom:2rem;margin-left:-2rem;margin-top:-2rem}.sa-row-gap-32>*{padding-left:2rem;padding-top:2rem}.sa-row-gap-36{margin-bottom:2.25rem;margin-left:-2.25rem;margin-top:-2.25rem}.sa-row-gap-36>*{padding-left:2.25rem;padding-top:2.25rem}.sa-row-gap-48{margin-bottom:3rem;margin-left:-3rem;margin-top:-3rem}.sa-row-gap-48>*{padding-left:3rem;padding-top:3rem}.sa-row-collapse-gutter{margin-left:0;margin-top:0}.sa-row-collapse-gutter>*{padding-left:0;padding-top:0}.sa-row-collapse-v-gutter{margin-bottom:0;margin-top:0}.sa-row-collapse-v-gutter>*{padding-top:0}.sa-row-stretch-content>.sa-col>*{flex-grow:1}.vendor-clear-input-button{-moz-appearance:textfield}.vendor-clear-input-button::-webkit-calendar-picker-indicator,.vendor-clear-input-button::-webkit-clear-button,.vendor-clear-input-button::-webkit-inner-spin-button{-webkit-appearance:none;appearance:none;display:none}.vendor-clear-input-button::-webkit-autofill{--shadow-color:#fff;--fill-color:#000;-webkit-text-fill-color:var(--fill-color);box-shadow:0 0 0 1000px var(--shadow-color) inset}[data-color-scheme=dark] .vendor-clear-input-button::-webkit-autofill{--shadow-color:#04080b;--fill-color:#dbdbdb}.vendor-clear-input-button::-ms-clear{display:none}.\[prop\:string\]{prop:string}.marker\:text-blue-75 ::marker{color:#1a98ff}.marker\:text-blue-75::marker{color:#1a98ff}.placeholder\:text-black-35::placeholder{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.placeholder\:text-navy-80::placeholder{--tw-text-opacity:1;color:rgb(65 74 95/var(--tw-text-opacity))}.before\:inline-flex:before{content:var(--tw-content);display:inline-flex}.before\:flex-none:before{content:var(--tw-content);flex:none}.before\:items-center:before{align-items:center;content:var(--tw-content)}.before\:justify-center:before{content:var(--tw-content);justify-content:center}.before\:rounded-full:before{border-radius:100%;content:var(--tw-content)}.before\:border:before{border-width:.0625rem;content:var(--tw-content)}.before\:border-solid:before{border-style:solid;content:var(--tw-content)}.before\:border-blue-75:before{--tw-border-opacity:1;border-color:rgb(26 152 255/var(--tw-border-opacity));content:var(--tw-content)}.before\:text-blue-75:before{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity));content:var(--tw-content)}.before\:content-\[counter\(myCounter\)\]:before{--tw-content:counter(myCounter);content:var(--tw-content)}.after\:absolute:after{content:var(--tw-content);position:absolute}.after\:inset-x-20:after{content:var(--tw-content);left:1.25rem;right:1.25rem}.after\:bottom-0:after{bottom:0;content:var(--tw-content)}.after\:right-18:after{content:var(--tw-content);right:1.125rem}.after\:z-1:after{content:var(--tw-content);z-index:1}.after\:block:after{content:var(--tw-content);display:block}.after\:hidden:after{content:var(--tw-content);display:none}.after\:h-1:after{content:var(--tw-content);height:.0625rem}.after\:h-16:after{content:var(--tw-content);height:1rem}.after\:h-8:after{content:var(--tw-content);height:.5rem}.after\:w-16:after{content:var(--tw-content);width:1rem}.after\:w-8:after{content:var(--tw-content);width:.5rem}.after\:w-full:after{content:var(--tw-content);width:100%}.after\:rotate-180:after{content:var(--tw-content);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.after\:rotate-180:after{--tw-rotate:180deg}.after\:bg-black-v2-25:after{--tw-bg-opacity:1;background-color:rgb(173 177 186/var(--tw-bg-opacity));content:var(--tw-content)}.after\:content-\[\'\'\]:after{--tw-content:"";content:var(--tw-content)}.first\:pl-0:first-child{padding-left:0}.first\:text-left:first-child{text-align:left}.first\:pt-safe-offset-0:first-child{padding-top:calc(env(safe-area-inset-top))}.first\:px-safe-offset-18:first-child{padding-left:calc(env(safe-area-inset-left) + 1.125rem);padding-right:calc(env(safe-area-inset-right) + 1.125rem)}.last\:mb-0:last-child{margin-bottom:0}.last\:mr-0:last-child{margin-right:0}.last\:border-0:last-child{border-width:0}.last\:border-none:last-child{border-style:none}.last\:pr-0:last-child{padding-right:0}.last\:pr-30:last-child{padding-right:1.875rem}.last\:after\:hidden:last-child:after{content:var(--tw-content);display:none}.only\:mb-18:only-child{margin-bottom:1.125rem}.last-of-type\:mr-0:last-of-type{margin-right:0}.visited\:text-black-60:visited{color:#434348}.visited\:text-black-70:visited{color:#333}.visited\:text-share-text:visited{color:var(--sa-text-color-1)}.visited\:text-share-text-6:visited{color:var(--sa-text-color-6)}.visited\:no-underline:visited{text-decoration-line:none}.invalid\:shadow-none:invalid{--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.read-only\:bg-black-5:read-only{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.read-only\:text-black-35:read-only{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.read-only\:text-navy-80:read-only{--tw-text-opacity:1;color:rgb(65 74 95/var(--tw-text-opacity))}.read-only\:opacity-100:read-only{opacity:1}.empty\:hidden:empty{display:none}.focus-within\:border-navy-40:focus-within{--tw-border-opacity:1;border-color:rgb(141 146 159/var(--tw-border-opacity))}.focus-within\:border-share-negative:focus-within{border-color:var(--sa-negative-color)}.hover\:border-black-50:hover{--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}.hover\:bg-black-10:hover{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.hover\:bg-black-5:hover{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.hover\:bg-black-50:hover{--tw-bg-opacity:1;background-color:rgb(85 85 85/var(--tw-bg-opacity))}.hover\:fill-black-50:hover{fill:#555}.hover\:text-black-80:hover{--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}.hover\:text-blue-75:hover{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity))}.hover\:text-share-text:hover{color:var(--sa-text-color-1)}.hover\:text-share-text-6:hover{color:var(--sa-text-color-6)}.hover\:text-white:hover{--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}.hover\:underline:hover{text-decoration-line:underline}.hover\:no-underline:hover{text-decoration-line:none}.focus\:border-black-35:focus{--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}.focus\:border-red:focus{--tw-border-opacity:1;border-color:rgb(201 57 44/var(--tw-border-opacity))}.focus\:fill-black-50:focus{fill:#555}.focus\:text-share-text:focus{color:var(--sa-text-color-1)}.focus\:text-share-text-6:focus{color:var(--sa-text-color-6)}.focus\:underline:focus{text-decoration-line:underline}.focus\:no-underline:focus{text-decoration-line:none}.active\:bg-black-10:active{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.disabled\:pointer-events-none:disabled{pointer-events:none}.disabled\:cursor-default:disabled{cursor:default}.disabled\:cursor-none:disabled{cursor:none}.disabled\:border-black-10:disabled{--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}.disabled\:bg-black-5:disabled{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.disabled\:text-black-10:disabled{--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}.disabled\:opacity-100:disabled{opacity:1}.disabled\:opacity-40:disabled{opacity:.4}.group:hover .group-hover\:fill-black-35\/50{fill:#75757580}.group:hover .group-hover\:fill-yellow-90\/50{fill:#efa81880}:is([data-color-scheme=dark] .dark\:border-black-10){--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-30){--tw-border-opacity:1;border-color:rgb(131 141 143/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-50){--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-80){--tw-border-opacity:1;border-color:rgb(44 48 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-90){--tw-border-opacity:1;border-color:rgb(35 42 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-v2-70){--tw-border-opacity:1;border-color:rgb(63 66 72/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-blue-70){--tw-border-opacity:1;border-color:rgb(89 148 255/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-red-80){--tw-border-opacity:1;border-color:rgb(217 77 65/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:bg-black){--tw-bg-opacity:1;background-color:rgb(0 0 0/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-10){--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-30){--tw-bg-opacity:1;background-color:rgb(131 141 143/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-30\/20){background-color:#838d8f33}:is([data-color-scheme=dark] .dark\:bg-black-80){--tw-bg-opacity:1;background-color:rgb(44 48 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-90){--tw-bg-opacity:1;background-color:rgb(35 42 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-95){--tw-bg-opacity:1;background-color:rgb(17 21 23/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-98){--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-v2-70){--tw-bg-opacity:1;background-color:rgb(63 66 72/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-v2-80){--tw-bg-opacity:1;background-color:rgb(33 34 36/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-blue-70){--tw-bg-opacity:1;background-color:rgb(89 148 255/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-45){--tw-bg-opacity:1;background-color:rgb(153 209 148/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-50){--tw-bg-opacity:1;background-color:rgb(135 199 130/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-55){--tw-bg-opacity:1;background-color:rgb(116 189 111/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-60){--tw-bg-opacity:1;background-color:rgb(98 176 93/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-70){--tw-bg-opacity:1;background-color:rgb(85 165 80/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-75){--tw-bg-opacity:1;background-color:rgb(72 156 67/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-orange-v2){--tw-bg-opacity:1;background-color:rgb(239 109 10/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-80){--tw-bg-opacity:1;background-color:rgb(217 77 65/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-30){--tw-bg-opacity:1;background-color:rgb(235 136 136/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-40){--tw-bg-opacity:1;background-color:rgb(224 117 117/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-60){--tw-bg-opacity:1;background-color:rgb(214 99 99/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-90){--tw-bg-opacity:1;background-color:rgb(185 72 72/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-teal-75){--tw-bg-opacity:1;background-color:rgb(50 166 103/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-transparent){background-color:initial}:is([data-color-scheme=dark] .dark\:bg-yellow-v2-50){--tw-bg-opacity:1;background-color:rgb(252 239 126/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-yellow-v2-90){--tw-bg-opacity:1;background-color:rgb(232 218 88/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:from-black-60){--tw-gradient-from:#434348 var(--tw-gradient-from-position);--tw-gradient-to:#43434800 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}:is([data-color-scheme=dark] .dark\:to-black-80){--tw-gradient-to:#2c3032 var(--tw-gradient-to-position)}:is([data-color-scheme=dark] .dark\:fill-black-10){fill:#dbdbdb}:is([data-color-scheme=dark] .dark\:fill-black-30){fill:#838d8f}:is([data-color-scheme=dark] .dark\:fill-black-35){fill:#757575}:is([data-color-scheme=dark] .dark\:fill-black-50){fill:#555}:is([data-color-scheme=dark] .dark\:fill-black-80){fill:#2c3032}:is([data-color-scheme=dark] .dark\:fill-black-95){fill:#111517}:is([data-color-scheme=dark] .dark\:text-black){--tw-text-opacity:1;color:rgb(0 0 0/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-10){--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-20){--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-30){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-80){--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-95){--tw-text-opacity:1;color:rgb(17 21 23/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-v2-20){--tw-text-opacity:1;color:rgb(224 225 228/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-v2-90){--tw-text-opacity:1;color:rgb(16 17 20/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-blue-70){--tw-text-opacity:1;color:rgb(89 148 255/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-white){--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:placeholder\:text-black-30)::placeholder{--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:visited\:text-black-10:visited){color:#dbdbdb}:is([data-color-scheme=dark] .dark\:visited\:text-black-20:visited){color:#acacac}:is([data-color-scheme=dark] .dark\:read-only\:text-black-30:read-only){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:focus-within\:border-black-v2-70:focus-within){--tw-border-opacity:1;border-color:rgb(63 66 72/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-20:hover){--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-5:hover){--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-80:hover){--tw-bg-opacity:1;background-color:rgb(44 48 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-90:hover){--tw-bg-opacity:1;background-color:rgb(35 42 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:fill-black-10:hover){fill:#dbdbdb}:is([data-color-scheme=dark] .dark\:hover\:text-black-20:hover){--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:hover\:text-share-link:hover){color:var(--sa-link-color)}:is([data-color-scheme=dark] .dark\:focus\:border-black-30:focus){--tw-border-opacity:1;border-color:rgb(131 141 143/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:border-black-35:focus){--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:border-red-80:focus){--tw-border-opacity:1;border-color:rgb(217 77 65/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:text-share-link:focus){color:var(--sa-link-color)}:is([data-color-scheme=dark] .dark\:active\:bg-black-20:active){--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:border-black-80:disabled){--tw-border-opacity:1;border-color:rgb(44 48 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:bg-black-98:disabled){--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:text-black-80:disabled){--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}@media print{.print\:block{display:block}.print\:hidden{display:none}}@media (min-width:375px){.xs\:block{display:block}.xs\:w-0{width:0}.xs\:w-auto{width:auto}.xs\:max-w-full{max-width:100%}.xs\:grow{flex-grow:1}.xs\:basis-1\/12{flex-basis:8.333333%}.xs\:basis-10\/12{flex-basis:83.333333%}.xs\:basis-11\/12{flex-basis:91.666667%}.xs\:basis-2\/12{flex-basis:16.666667%}.xs\:basis-3\/12{flex-basis:25%}.xs\:basis-4\/12{flex-basis:33.333333%}.xs\:basis-5\/12{flex-basis:41.666667%}.xs\:basis-6\/12{flex-basis:50%}.xs\:basis-7\/12{flex-basis:58.333333%}.xs\:basis-8\/12{flex-basis:66.666667%}.xs\:basis-9\/12{flex-basis:75%}.xs\:basis-auto{flex-basis:auto}.xs\:basis-full{flex-basis:100%}}@media (min-width:576px){.sm\:my-0{margin-top:0}.sm\:mb-0,.sm\:my-0{margin-bottom:0}.sm\:mb-10{margin-bottom:.625rem}.sm\:mb-24{margin-bottom:1.5rem}.sm\:mr-0{margin-right:0}.sm\:mt-0{margin-top:0}.sm\:flex{display:flex}.sm\:hidden{display:none}.sm\:h-10{height:.625rem}.sm\:w-0{width:0}.sm\:w-auto{width:auto}.sm\:max-w-full{max-width:100%}.sm\:grow{flex-grow:1}.sm\:basis-1\/12{flex-basis:8.333333%}.sm\:basis-10\/12{flex-basis:83.333333%}.sm\:basis-11\/12{flex-basis:91.666667%}.sm\:basis-2\/12{flex-basis:16.666667%}.sm\:basis-3\/12{flex-basis:25%}.sm\:basis-4\/12{flex-basis:33.333333%}.sm\:basis-5\/12{flex-basis:41.666667%}.sm\:basis-6\/12{flex-basis:50%}.sm\:basis-7\/12{flex-basis:58.333333%}.sm\:basis-8\/12{flex-basis:66.666667%}.sm\:basis-9\/12{flex-basis:75%}.sm\:basis-auto{flex-basis:auto}.sm\:basis-full{flex-basis:100%}.sm\:flex-row{flex-direction:row}.sm\:flex-col{flex-direction:column}.sm\:self-auto{align-self:auto}.sm\:self-start{align-self:flex-start}.sm\:bg-transparent{background-color:initial}.sm\:p-0{padding:0}.sm\:px-12{padding-left:.75rem;padding-right:.75rem}.sm\:px-18{padding-left:1.125rem;padding-right:1.125rem}.sm\:py-10{padding-bottom:.625rem;padding-top:.625rem}.sm\:pb-24{padding-bottom:1.5rem}.sm\:pb-32{padding-bottom:2rem}.sm\:pt-24{padding-top:1.5rem}.sm\:pt-32{padding-top:2rem}.sm\:text-center{text-align:center}.sm\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.sm\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.sm\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.sm\:text-small-2-b{font-size:.75rem;font-weight:700;line-height:1.25rem}.sm\:text-small-b{font-size:.75rem;font-weight:700;line-height:.875rem}.sm\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}:is([data-color-scheme=dark] .dark\:sm\:bg-transparent){background-color:initial}:is([data-color-scheme=dark] .sm\:dark\:bg-transparent){background-color:initial}}@media (min-width:768px){.md\:absolute{position:absolute}.md\:-mx-24{margin-left:-1.5rem;margin-right:-1.5rem}.md\:-mx-48{margin-left:-3rem;margin-right:-3rem}.md\:-my-16{margin-bottom:-1rem;margin-top:-1rem}.md\:mx-48{margin-left:3rem;margin-right:3rem}.md\:my-0{margin-bottom:0;margin-top:0}.md\:my-32{margin-bottom:2rem;margin-top:2rem}.md\:-mt-40{margin-top:-2.5rem}.md\:mb-0{margin-bottom:0}.md\:mb-12{margin-bottom:.75rem}.md\:mb-16{margin-bottom:1rem}.md\:mb-18{margin-bottom:1.125rem}.md\:mb-20{margin-bottom:1.25rem}.md\:mb-24{margin-bottom:1.5rem}.md\:mb-30{margin-bottom:1.875rem}.md\:mb-32{margin-bottom:2rem}.md\:mb-40{margin-bottom:2.5rem}.md\:mb-6{margin-bottom:.375rem}.md\:mb-8{margin-bottom:.5rem}.md\:ml-60{margin-left:3.75rem}.md\:ml-8{margin-left:.5rem}.md\:mr-20{margin-right:1.25rem}.md\:mr-48{margin-right:3rem}.md\:mr-6{margin-right:.375rem}.md\:mt-0{margin-top:0}.md\:mt-12{margin-top:.75rem}.md\:mt-16{margin-top:1rem}.md\:mt-18{margin-top:1.125rem}.md\:mt-30{margin-top:1.875rem}.md\:mt-32{margin-top:2rem}.md\:mt-8{margin-top:.5rem}.md\:block{display:block}.md\:flex{display:flex}.md\:inline-flex{display:inline-flex}.md\:hidden{display:none}.md\:h-10{height:.625rem}.md\:h-120{height:7.5rem}.md\:h-14{height:.875rem}.md\:h-170{height:10.625rem}.md\:h-240{height:15rem}.md\:h-30{height:1.875rem}.md\:h-36{height:2.25rem}.md\:h-52{height:3.25rem}.md\:h-auto{height:auto}.md\:max-h-full{max-height:100%}.md\:w-0{width:0}.md\:w-1{width:.0625rem}.md\:w-120{width:7.5rem}.md\:w-14{width:.875rem}.md\:w-170{width:10.625rem}.md\:w-240{width:15rem}.md\:w-36{width:2.25rem}.md\:w-52{width:3.25rem}.md\:w-auto{width:auto}.md\:max-w-full{max-width:100%}.md\:flex-auto{flex:1 1 auto}.md\:flex-none{flex:none}.md\:grow{flex-grow:1}.md\:grow-0{flex-grow:0}.md\:basis-1\/12{flex-basis:8.333333%}.md\:basis-1\/2{flex-basis:50%}.md\:basis-10\/12{flex-basis:83.333333%}.md\:basis-11\/12{flex-basis:91.666667%}.md\:basis-2\/12{flex-basis:16.666667%}.md\:basis-3\/12{flex-basis:25%}.md\:basis-4\/12{flex-basis:33.333333%}.md\:basis-5\/12{flex-basis:41.666667%}.md\:basis-6\/12{flex-basis:50%}.md\:basis-7\/12{flex-basis:58.333333%}.md\:basis-8\/12{flex-basis:66.666667%}.md\:basis-9\/12{flex-basis:75%}.md\:basis-auto{flex-basis:auto}.md\:basis-full{flex-basis:100%}.md\:grid-flow-col{grid-auto-flow:column}.md\:flex-row{flex-direction:row}.md\:flex-row-reverse{flex-direction:row-reverse}.md\:flex-col{flex-direction:column}.md\:flex-wrap{flex-wrap:wrap}.md\:items-center{align-items:center}.md\:justify-start{justify-content:flex-start}.md\:justify-between{justify-content:space-between}.md\:gap-20{gap:1.25rem}.md\:gap-24{gap:1.5rem}.md\:self-auto{align-self:auto}.md\:self-end{align-self:flex-end}.md\:overflow-hidden{overflow:hidden}.md\:overflow-y-auto{overflow-y:auto}.md\:border-l-4{border-left-width:.25rem}.md\:border-solid{border-style:solid}.md\:border-l-blue-75{--tw-border-opacity:1;border-left-color:rgb(26 152 255/var(--tw-border-opacity))}.md\:p-0{padding:0}.md\:p-24{padding:1.5rem}.md\:p-36{padding:2.25rem}.md\:px-0{padding-left:0;padding-right:0}.md\:px-10{padding-left:.625rem;padding-right:.625rem}.md\:px-14{padding-left:.875rem;padding-right:.875rem}.md\:px-18{padding-left:1.125rem;padding-right:1.125rem}.md\:px-2{padding-left:.125rem;padding-right:.125rem}.md\:px-20{padding-left:1.25rem;padding-right:1.25rem}.md\:px-24{padding-left:1.5rem;padding-right:1.5rem}.md\:px-32{padding-left:2rem;padding-right:2rem}.md\:px-36{padding-left:2.25rem;padding-right:2.25rem}.md\:px-4{padding-left:.25rem;padding-right:.25rem}.md\:px-48{padding-left:3rem;padding-right:3rem}.md\:px-52{padding-left:3.25rem;padding-right:3.25rem}.md\:py-10{padding-bottom:.625rem;padding-top:.625rem}.md\:py-16{padding-bottom:1rem;padding-top:1rem}.md\:py-18{padding-bottom:1.125rem;padding-top:1.125rem}.md\:py-2{padding-bottom:.125rem;padding-top:.125rem}.md\:py-20{padding-bottom:1.25rem;padding-top:1.25rem}.md\:py-32{padding-bottom:2rem;padding-top:2rem}.md\:py-4{padding-bottom:.25rem;padding-top:.25rem}.md\:py-48{padding-bottom:3rem;padding-top:3rem}.md\:pb-0{padding-bottom:0}.md\:pb-10{padding-bottom:.625rem}.md\:pb-16{padding-bottom:1rem}.md\:pb-2{padding-bottom:.125rem}.md\:pb-20{padding-bottom:1.25rem}.md\:pb-24{padding-bottom:1.5rem}.md\:pb-28{padding-bottom:1.75rem}.md\:pb-32{padding-bottom:2rem}.md\:pb-36{padding-bottom:2.25rem}.md\:pb-40{padding-bottom:2.5rem}.md\:pl-0{padding-left:0}.md\:pl-24{padding-left:1.5rem}.md\:pr-32{padding-right:2rem}.md\:pt-0{padding-top:0}.md\:pt-12{padding-top:.75rem}.md\:pt-16{padding-top:1rem}.md\:pt-20{padding-top:1.25rem}.md\:pt-28{padding-top:1.75rem}.md\:pt-32{padding-top:2rem}.md\:pt-40{padding-top:2.5rem}.md\:pt-48{padding-top:3rem}.md\:pt-8{padding-top:.5rem}.md\:text-left{text-align:left}.md\:text-center{text-align:center}.md\:text-2x-large-2-r{font-size:1.25rem;font-weight:400;line-height:1.875rem}.md\:text-2x-large-b{font-size:1.25rem;font-weight:700;line-height:1.5rem}.md\:text-2x-small-b{font-size:.625rem;font-weight:700;line-height:.75rem}.md\:text-3x-large-2-r{font-size:1.375rem;font-weight:400;line-height:2rem}.md\:text-3x-large-b{font-size:1.375rem;font-weight:700;line-height:1.625rem}.md\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.md\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.md\:text-large-2-r{font-size:1rem;font-weight:400;line-height:1.5rem}.md\:text-large-3-r{font-size:1rem;font-weight:400;line-height:1.75rem}.md\:text-large-b{font-size:1rem;font-weight:700;line-height:1.25rem}.md\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.md\:text-medium-2-b{font-size:.875rem;font-weight:700;line-height:1.25rem}.md\:text-medium-r{font-size:.875rem;font-weight:400;line-height:1rem}.md\:text-small-b{font-weight:700}.md\:text-small-b,.md\:text-small-r{font-size:.75rem;line-height:.875rem}.md\:text-small-r{font-weight:400}.md\:text-x-large-2-r{font-size:1.125rem;font-weight:400;line-height:1.625rem}.md\:text-x-large-b{font-size:1.125rem;font-weight:700;line-height:1.375rem}.md\:text-x-large-r{font-size:1.125rem;font-weight:400;line-height:1.375rem}.md\:px-safe-offset-24{padding-left:calc(env(safe-area-inset-left) + 1.5rem);padding-right:calc(env(safe-area-inset-right) + 1.5rem)}.md\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.md\:px-safe-or-24{padding-left:max(env(safe-area-inset-left),1.5rem);padding-right:max(env(safe-area-inset-right),1.5rem)}.md\:after\:h-8:after{content:var(--tw-content);height:.5rem}.md\:after\:w-8:after{content:var(--tw-content);width:.5rem}.md\:hover\:underline:hover{text-decoration-line:underline}}@media (min-width:1024px){.lg\:sticky{position:-webkit-sticky;position:sticky}.lg\:top-0{top:0}.lg\:my-12{margin-bottom:.75rem;margin-top:.75rem}.lg\:mb-0{margin-bottom:0}.lg\:mb-12{margin-bottom:.75rem}.lg\:mb-16{margin-bottom:1rem}.lg\:mb-18{margin-bottom:1.125rem}.lg\:mb-2{margin-bottom:.125rem}.lg\:mb-26{margin-bottom:1.625rem}.lg\:mb-32{margin-bottom:2rem}.lg\:mb-48{margin-bottom:3rem}.lg\:mb-64{margin-bottom:4rem}.lg\:mb-8{margin-bottom:.5rem}.lg\:ml-0{margin-left:0}.lg\:mr-12{margin-right:.75rem}.lg\:mr-4{margin-right:.25rem}.lg\:mt-12{margin-top:.75rem}.lg\:mt-16{margin-top:1rem}.lg\:mt-20{margin-top:1.25rem}.lg\:block{display:block}.lg\:flex{display:flex}.lg\:hidden{display:none}.lg\:h-120{height:7.5rem}.lg\:h-16{height:1rem}.lg\:h-28{height:1.75rem}.lg\:h-32{height:2rem}.lg\:h-60{height:3.75rem}.lg\:w-0{width:0}.lg\:w-120{width:7.5rem}.lg\:w-16{width:1rem}.lg\:w-60{width:3.75rem}.lg\:w-auto{width:auto}.lg\:max-w-full{max-width:100%}.lg\:grow{flex-grow:1}.lg\:basis-1\/12{flex-basis:8.333333%}.lg\:basis-10\/12{flex-basis:83.333333%}.lg\:basis-11\/12{flex-basis:91.666667%}.lg\:basis-2\/12{flex-basis:16.666667%}.lg\:basis-3\/12{flex-basis:25%}.lg\:basis-4\/12{flex-basis:33.333333%}.lg\:basis-5\/12{flex-basis:41.666667%}.lg\:basis-6\/12{flex-basis:50%}.lg\:basis-7\/12{flex-basis:58.333333%}.lg\:basis-8\/12{flex-basis:66.666667%}.lg\:basis-9\/12{flex-basis:75%}.lg\:basis-auto{flex-basis:auto}.lg\:basis-full{flex-basis:100%}.lg\:flex-col{flex-direction:column}.lg\:border-0{border-width:0}.lg\:bg-share-bg-4{background-color:var(--sa-body-bg-color-4)}.lg\:fill-share-text-2{fill:var(--sa-text-color-2)}.lg\:p-18{padding:1.125rem}.lg\:py-10{padding-bottom:.625rem;padding-top:.625rem}.lg\:py-20{padding-bottom:1.25rem;padding-top:1.25rem}.lg\:pb-18{padding-bottom:1.125rem}.lg\:pl-30{padding-left:1.875rem}.lg\:pt-0{padding-top:0}.lg\:pt-40{padding-top:2.5rem}.lg\:text-2x-small-b{font-size:.625rem;font-weight:700;line-height:.75rem}.lg\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.lg\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.lg\:text-5x-large-b{font-size:1.75rem;font-weight:700;line-height:2.125rem}.lg\:text-8x-large-b{font-size:2.375rem;font-weight:700;line-height:2.875rem}.lg\:text-medium-2-r{font-size:.875rem;font-weight:400;line-height:1.25rem}.lg\:text-medium-b{font-size:.875rem;font-weight:700;line-height:1rem}.lg\:text-medium-r{font-size:.875rem;font-weight:400;line-height:1rem}.lg\:text-small-r{font-size:.75rem;font-weight:400;line-height:.875rem}.lg\:text-x-large-2-r{font-size:1.125rem;font-weight:400;line-height:1.625rem}.lg\:text-x-large-b{font-size:1.125rem;font-weight:700;line-height:1.375rem}.lg\:text-black-35{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.lg\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}:is([data-color-scheme=dark] .dark\:lg\:text-black-30){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}}@media (min-width:1200px){.xl\:mx-0{margin-left:0;margin-right:0}.xl\:mx-auto{margin-left:auto;margin-right:auto}.xl\:my-48{margin-bottom:3rem;margin-top:3rem}.xl\:mb-24{margin-bottom:1.5rem}.xl\:mb-38{margin-bottom:2.375rem}.xl\:ml-38{margin-left:2.375rem}.xl\:ml-8{margin-left:.5rem}.xl\:mr-38{margin-right:2.375rem}.xl\:mr-40{margin-right:2.5rem}.xl\:block{display:block}.xl\:flex{display:flex}.xl\:hidden{display:none}.xl\:h-1{height:.0625rem}.xl\:w-0{width:0}.xl\:w-auto{width:auto}.xl\:w-full{width:100%}.xl\:max-w-full{max-width:100%}.xl\:grow{flex-grow:1}.xl\:basis-1\/12{flex-basis:8.333333%}.xl\:basis-10\/12{flex-basis:83.333333%}.xl\:basis-11\/12{flex-basis:91.666667%}.xl\:basis-2\/12{flex-basis:16.666667%}.xl\:basis-3\/12{flex-basis:25%}.xl\:basis-4\/12{flex-basis:33.333333%}.xl\:basis-5\/12{flex-basis:41.666667%}.xl\:basis-6\/12{flex-basis:50%}.xl\:basis-7\/12{flex-basis:58.333333%}.xl\:basis-8\/12{flex-basis:66.666667%}.xl\:basis-9\/12{flex-basis:75%}.xl\:basis-auto{flex-basis:auto}.xl\:basis-full{flex-basis:100%}.xl\:flex-row{flex-direction:row}.xl\:flex-col{flex-direction:column}.xl\:justify-center{justify-content:center}.xl\:p-24{padding:1.5rem}.xl\:px-0{padding-left:0;padding-right:0}.xl\:px-18{padding-left:1.125rem;padding-right:1.125rem}.xl\:px-24{padding-left:1.5rem;padding-right:1.5rem}.xl\:px-48{padding-left:3rem;padding-right:3rem}.xl\:py-0{padding-bottom:0;padding-top:0}.xl\:py-12{padding-bottom:.75rem;padding-top:.75rem}.xl\:py-40{padding-bottom:2.5rem;padding-top:2.5rem}.xl\:py-60{padding-bottom:3.75rem;padding-top:3.75rem}.xl\:pb-40{padding-bottom:2.5rem}.xl\:pt-0{padding-top:0}.xl\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.xl\:text-5x-large-b{font-size:1.75rem;font-weight:700;line-height:2.125rem}.xl\:text-5x-large-r{font-size:1.75rem;font-weight:400;line-height:2.125rem}.xl\:text-6x-large-b{font-size:2rem;font-weight:700;line-height:2.375rem}.xl\:text-9x-large-b{font-size:3.125rem;font-weight:700;line-height:3.125rem}.xl\:text-large-b{font-size:1rem;font-weight:700;line-height:1.25rem}.xl\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.xl\:text-x-large-r{font-size:1.125rem;font-weight:400;line-height:1.375rem}.xl\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.xl\:sa-row-gap-36{margin-bottom:2.25rem;margin-left:-2.25rem;margin-top:-2.25rem}.xl\:sa-row-gap-36>*{padding-left:2.25rem;padding-top:2.25rem}}@media (min-width:1540px){.xxl\:-mx-24{margin-left:-1.5rem;margin-right:-1.5rem}.xxl\:mx-48{margin-left:3rem;margin-right:3rem}.xxl\:my-0{margin-bottom:0;margin-top:0}.xxl\:mr-80{margin-right:5rem}.xxl\:flex{display:flex}.xxl\:hidden{display:none}.xxl\:h-auto{height:auto}.xxl\:w-0{width:0}.xxl\:w-1{width:.0625rem}.xxl\:w-auto{width:auto}.xxl\:max-w-full{max-width:100%}.xxl\:grow{flex-grow:1}.xxl\:basis-1\/12{flex-basis:8.333333%}.xxl\:basis-10\/12{flex-basis:83.333333%}.xxl\:basis-11\/12{flex-basis:91.666667%}.xxl\:basis-2\/12{flex-basis:16.666667%}.xxl\:basis-3\/12{flex-basis:25%}.xxl\:basis-4\/12{flex-basis:33.333333%}.xxl\:basis-5\/12{flex-basis:41.666667%}.xxl\:basis-6\/12{flex-basis:50%}.xxl\:basis-7\/12{flex-basis:58.333333%}.xxl\:basis-8\/12{flex-basis:66.666667%}.xxl\:basis-9\/12{flex-basis:75%}.xxl\:basis-auto{flex-basis:auto}.xxl\:basis-full{flex-basis:100%}.xxl\:flex-row{flex-direction:row}.xxl\:flex-row-reverse{flex-direction:row-reverse}.xxl\:flex-col{flex-direction:column}.xxl\:px-24{padding-left:1.5rem;padding-right:1.5rem}.xxl\:px-36{padding-left:2.25rem;padding-right:2.25rem}.xxl\:px-64{padding-left:4rem;padding-right:4rem}.xxl\:px-safe-or-36{padding-left:max(env(safe-area-inset-left),2.25rem);padding-right:max(env(safe-area-inset-right),2.25rem)}}</style><meta name="theme-color" content="#333333" ><link rel="manifest" href="/samw/manifest.52d7d67ec34303436765800b76c0582e.json" > <link rel="preload" href="/samw/static/js/app.982fa237.js" as="script"> <link rel="preload" href="/samw/static/js/c.7611.2265ccf6.js" as="script"> <link rel="preload" href="/samw/static/js/c.9048.a372a116.js" as="script"> <link rel="preload" href="/samw/static/js/c.7309.221713ab.js" as="script"> <link rel="preload" href="/samw/static/js/c.7024.e4f9a632.js" as="script"> <link rel="preload" href="/samw/static/js/c.1037.2cb8d213.js" as="script"> <link rel="preload" href="/samw/static/js/c.2971.8a739675.js" as="script"> <link rel="preload" href="/samw/static/js/c.693.b6c2b13b.js" as="script"> <link rel="preload" href="/samw/static/js/c.7723.a12f5d5f.js" as="script"> <link rel="preload" href="/samw/static/js/c.8940.ea3985c6.js" as="script"> <link rel="preload" href="/samw/static/js/c.9323.415f29a9.js" as="script"> <link rel="preload" href="/samw/static/js/c.5169.48e2c582.js" as="script"> <link rel="preload" href="/samw/static/js/c.7683.37daf487.js" as="script"> <link rel="preload" href="/samw/static/js/c.9340.0f228286.js" as="script"> <link rel="preload" href="/samw/static/js/c.3661.f42a537a.js" as="script"> <link rel="preload" href="/samw/static/js/c.9638.453e6eb8.js" as="script"> <link rel="preload" href="/samw/static/js/c.5075.5f3a0046.js" as="script"> <link rel="preload" href="/samw/static/js/c.7103.3b3a4c05.js" as="script"> <link rel="preload" href="/samw/static/js/c.6144.7d7e839c.js" as="script"> <link rel="preload" href="/samw/static/js/c.8383.0a755660.js" as="script"> <link rel="preload" href="/samw/static/js/c.Article-S.a6f4701e.js" as="script"> <link rel="preload" href="/samw/static/js/c.3918.3b2d278a.js" as="script"> <link rel="preload" href="/samw/static/js/c.BelowContentCards-W.0bca6b0a.js" as="script"> <link rel="preload" href="/samw/static/js/c.9340.0f228286.js" as="script"> <link rel="preload" href="/samw/static/js/c.6144.7d7e839c.js" as="script"> <link rel="preload" href="/samw/static/js/c.7531.716caf1b.js" as="script"><link href="https://seekingalpha.com/javascripts/seeking.xml" rel="search" title="Vical Incorporated. Q2 2010 Earnings Call Transcript" type="application/opensearchdescription+xml" data-render="ssr"><link href="https://seekingalpha.com/article/218361-vical-incorporated-q2-2010-earnings-call-transcript" rel="canonical" data-render="ssr"><meta name="description" content="Vical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ETExecutivesAlan Engbring - Executive Director, IRVijay Samant -..." data-render="ssr"><meta name="robots" content="noarchive, max-image-preview:large" data-render="ssr"><meta name="twitter:title" content="Vical Incorporated. Q2 2010 Earnings Call Transcript" data-render="ssr"><meta name="twitter:description" content="Vical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ETExecutivesAlan Engbring - Executive Director, IRVijay Samant -..." data-render="ssr"><meta name="twitter:card" content="summary_large_image" data-render="ssr"><meta name="twitter:site" content="@SeekingAlpha" data-render="ssr"><meta name="twitter:image" content="https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png" data-render="ssr"><meta property="og:title" content="Vical Incorporated. Q2 2010 Earnings Call Transcript" data-render="ssr"><meta property="og:description" content="Vical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ETExecutivesAlan Engbring - Executive Director, IRVijay Samant -..." data-render="ssr"><meta property="og:type" content="article" data-render="ssr"><meta property="article:publisher" content="https://www.facebook.com/Seekingalpha" data-render="ssr"><meta name="author" content="SA Transcripts" data-render="ssr"><meta property="article:author" content="https://seekingalpha.com/author/sa-transcripts" data-render="ssr"><meta property="article:published_time" content="2010-08-03T16:06:21-04:00" data-render="ssr"><meta property="article:modified_time" content="2010-08-03T16:06:21-04:00" data-render="ssr"><meta property="og:url" content="https://seekingalpha.com/article/218361-vical-incorporated-q2-2010-earnings-call-transcript" data-render="ssr"><meta property="og:image" content="https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png" data-render="ssr"><script>window.SA_PRELOAD_DATA = {"statusCode":200,"moneData":{"params":"ssr_poc=yes&financial_statements=show&paywalled_article_content=control&ab_test_distribution_fastly=show&test_mcm_was_ever_pro=test"},"show_cookie_settings_link":false};</script><style>
    :root {
      --headerHeight: 50px;
    }

    @media (min-width: 1024px) {
      :root {
        --headerHeight: 68px;
        --sa-aside-width: 15rem;
      }
    }
  </style><link href="/samw/static/styles/3863.d1c4a9bb.css" rel="stylesheet" ><link href="/samw/static/styles/3661.40ac902e.css" rel="stylesheet" ><link href="/samw/static/styles/Article-S.80fc25df.css" rel="stylesheet" ><link href="/samw/static/styles/BelowContentCards-W.e27d7834.css" rel="stylesheet" ><link href="/samw/static/styles/CommentsContent-W.88e3efad.css" rel="stylesheet" >
        <script>window.SSR_DATA = {"article":{"response":{"data":{"id":"218361","type":"fullArticle","attributes":{"publishOn":"2010-08-03T16:06:21-04:00","isLockedPro":false,"commentCount":1,"gettyImageUrl":null,"videoPreviewUrl":null,"themes":{"sa-transcripts":{"id":96991,"slug":"sa-transcripts","kind":"common","non_theme":true},"frtx":{"id":6489,"slug":"frtx","kind":"common","non_theme":true},"healthcare":{"id":17896,"slug":"healthcare","kind":"common","path":"\u002Fstock-ideas\u002Fhealthcare","title":"Healthcare ","non_theme":true},"transcripts":{"id":49,"slug":"transcripts","kind":"general","path":"\u002Fearnings\u002Fearnings-call-transcripts","title":"Transcripts"},"us":{"id":326,"slug":"us","kind":"common","non_theme":true},"biotechnology":{"id":17897,"slug":"biotechnology","kind":"common","non_theme":true},"health-care":{"id":35,"slug":"health-care","kind":"sector","path":"\u002Fstock-ideas\u002Fhealthcare","title":"Healthcare ","sasource":"theme_breadcrumb"}},"title":"Vical Incorporated. Q2 2010 Earnings Call Transcript","summary":[],"isPaywalled":false,"lastModified":"2010-08-03T16:06:21-04:00","closestTradingDate":"2010-08-04","beforeOpeningHours":false,"proPublishOn":"2010-08-03T16:06:21-04:00","isEarningsSlides":false,"isExclusive":false,"isTranscript":true,"excludedByTag":false,"transcriptPath":null,"likesCount":0,"disabledStatus":"allowed","disabledMessage":null,"status":"published","disclosure":"","articleActionableItem":null,"inEmbargo":false,"isNoindex":false,"isNoarchive":true,"content":"\u003Cp\u003EVical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ET\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EExecutives\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EAlan Engbring - Executive Director, IR\u003C\u002Fp\u003E \u003Cp\u003EVijay Samant - President &amp; CEO\u003C\u002Fp\u003E \u003Cp\u003EJill Broadfoot - SVP, CFO &amp; Secretary\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EAnalysts\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EAlan Carr - Needham &amp; Co\u003C\u002Fp\u003E \u003Cp\u003EEric Schmidt - Cowen &amp; Company\u003C\u002Fp\u003E \u003Cp\u003ESteven Willey - Stifel Nicolaus\u003C\u002Fp\u003E \u003Cp\u003EReni Benjamin - Rodman &amp; Renshaw\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EGood day and welcome ladies and gentleman to the Vical Incorporated financial results conference call. At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for question-and-answers from invited participants after the presentation. \u003C\u002Fp\u003E \u003Cp\u003EI will now turn the conference over to Mr. Alan Engbring, Executive Director of Investor Relations. Please go ahead sir.\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EAlan Engbring\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EHello everyone, welcome to our second quarter 2010 financial results conference call. Participating on the call today are Vical’s President and Chief Executive Officer, Mr. Vijay Samant and Vical’s Chief Financial Officer, Ms. Jill Broadfoot. I will begin with a brief notice concerning projections and forecast.\u003C\u002Fp\u003E \u003Cp\u003EThis call includes forward-looking statements including financial expectations and projections of progress in our research and development programs that are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including the risks set forth in Vical’s annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission as well as the specific risks and uncertainties noted in Vical’s news release on second quarter 2010 financial results. These forward-looking statements represent the company’s judgment as of today. The company disclaims, however, any intent or obligation to update these forward-looking statements.\u003C\u002Fp\u003E \u003Cp\u003ENow, I would like to introduce Vical’s President and Chief Executive Officer, Mr. Vijay\u003Cspan class=\"paywall-full-content\"\u003E Samant\u003C\u002Fspan\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content\"\u003EThank you and welcome to all our listeners I’ll review the highlights of our recent developments in our call today, update our outlook for the remainder of the year and will then open the call to questions from invited participants, but before I do that let\u003Cspan class=\"paywall-full-content no-summary-bullets\"\u003E me have our CFO Jill Broadfoot to give you financial update for this quarter.\u003C\u002Fspan\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EJill Broadfoot\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you, Vijay. Financial results for the second quarter and first half of 2010 were consistent with expectations. Revenue for the first half of 2010 was $3.5 million compared with $6.2 million for the first half of 2009 reflecting the reduction in revenue recognized from AnGes as we approach completion of our Phase 3 Allovectin-7 trial. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ELast year’s revenues also included a $1.5 million milestone payment from Merck for its cancer vaccine program. Operating expenses were generally consistent year-over-year and net loss was $16.9 million in the first half of 2010 compared with $14.3 million in the first half of 2009. We ended the first half of 2010 with cash and investments of approximately $40 million.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur cash used during the first half was approximately $18 million which was partially offset by inflows of approximately $5 million from more exercise which was consistent with our projections for the full year.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAs a reminder, our forecast range included anticipated cash receipts from new or expanded partnerships not currently contracted. We continue to make progress towards those potential partnerships. With that I will turn the call back to Vijay.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThank you Jill, I will cover the highlights in our development programs today beginning with an update on Allovectin-7 immunotherapy for patients with metastatic melanoma. The recent approval of [Provenge] coupled with BMS’s second line melanoma data [task] therapy has created additional visibility for immunotherapy. I won’t go in to details about those data, but want to make a few observations.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EFirst on safety, in our Phase 2 trial, there were no drug-related Grade 3 or Grade 4 adverse events, there were no discontinuations due to tolerability. We believe that’s more impressive when you consider the average of patients enrolled in that Phase 3 was 60 and we treated several patients in the 90s.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIn our ongoing Phase 3 trial and Independent Safety Monitoring Board recently completed fourth scheduled safety analysis and recommended continuation of the trial for protocol. We believe safety profile of A-7 if it receives marketing approval would make it a compelling choice especially for patients who are not able tolerate toxic chemotherapy or biotherapy agents. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESecond on efficacy, our Phase 3 trial was designed under an SPA to support approval as the first line therapy. We are comparing A-7 head-to-head against the chemotherapy standard of care. We believe our primary endpoint of response rate at 24 weeks or more would represent the meaningful benefits to patients. We will also evaluate survival of the historical chemotherapy controls have been typically demonstrated median survival of nine to 12 months. A-7 achieved a median survival of almost 19 months in our Phase 2 trial. If we reach our accepted goals in Phase 3, we believe A-7 would be an attractive treatment option for metastatic melanoma.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo on approach, while both EP and A-7 of immunotherapies that rely on different and potentially complementary mechanism of action, A7 is designed to make tumor cells more visible target for destruction by T-Cells, EP is designed to reactivate T-Cells that have been down regulated by cancer, both products because of their unique mechanisms would have the opportunity to address significant unmet need for patients with metastatic melanoma.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAs a reminder we completed an enrollment on our Phase 3 in February with a total of 390 subjects. We expect to log the clinical trial database in the second half of 2011, as we gain further clarity by monitoring a trial progress. Over the coming months, we will provide you periodic updates and timelines.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ENext I'll review the status of our Phase 2 trial for our TransVax CMV Vaccine. As we have noted previously these are primarily leukemia and lymphoma patients receiving transplants. We enrolled CMV-seropositive patients who are at high risk for CMV reactivation during the recovery period, our TransVax Vaccine is intended to reduce the need for toxic and expensive anti-viral drug therapy used to control CMV while the patients’ immune system is being restored.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThere are three important datasets to consider in our Phase 2 trial and pay attention to this very carefully. The first as in most trials is safety. We had a clean safety review early in the study. There were no serious safety issues that prevented us from completing the trial per protocol. As part of our final data analysis, we'll be comparing the full safety profile of the TransVax vaccine versus placebo.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIn our last quarterly call, we received the second dataset which is immunogenicity for our TransVax Vaccine versus placebo through the final 12 month follow up. These data have been presented on our conference in the April and are available in the CMV section of our website. We are pleased that our vaccine was able to elicit sustained T-Cell and anti-body responses to the encoded CMV antigens.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe believe this is the first time a vaccine has demonstrated success in immunocompromised patients. We also noted a boost in both T-Cell and antibody responses after the fourth injection which is relevant for the late onset of CMV reactivation.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe third dataset involves efficacy. We are evaluating a broad range of possibilities in this endpoint defining study, our four-month interim analysis last summer which is available on our website started to help us focus on the most important virological endpoints such as time to initial viremia duration of viremia, the number of viremic episodes and peak viral load.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur goal for the 12-month analysis in the crux of this study is to complete that process and identify the most relevant efficacy endpoints for a Phase 3 trial. We look forward to presenting the final Phase 2 data and we’ll announce the presentation details when they are confirmed. We’ve been working with the leading CMV experts and transplantation experts throughout the Phase 2 trial and we have enlisted their help in designing an appropriate Phase 3 trial.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe expect to review our proposed trial design with the FDA as soon as possible in order to secure the necessary approvals to allow us to begin a Phase 3 trial next year. I will shift now to our Pandemic Influenza program, our ongoing Phase 1 trial of our H1 vaccine has been supported by funding from the US Navy and the Department of Defense’s Transformational Medical Technologies Program or TMT.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThis trial expands on the success of our H5N1 vaccine. Enrollment in this trial took longer than expected primarily because of higher than percentage of our volunteers tested positive to the H1N1 influenza virus. Remember we just started the trial in the late second quarter and by that time the H1N1 flu season had swept through the US. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo it was hard to find patients.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EHowever we were able to find enough healthy volunteers to complete enrollment and are now back on track with the trial progress. I am going to provide an update today on one of our most exciting pre-clinical programs, our vaccine for Herpes Simplex 2 or HSV-2. The last week at our Herpes conference, we presented pre-clinical data we believe were quite impressive.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EFirst a little background of the disease, HSV-2 is a Herpes virus which means by the way same family of CMV. It means once that you are infected, you are infected for life. After the initial sexually transferred infection, the virus resides in a latent state in the ganglia. Periodic outbreaks and general lesions lead to additional virus shedding a disease transmission.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAt least 40 million people in the United States are infected with the HSV-2 and about 1.6 million additional people are infected each year. About one out of six individuals of the US and one out of four worldwide is infected with HSV-2 by age 50, so it’s a really pandemic in the true sense. HSV-2 infection has also significantly increases the risk of acquiring HIV.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThere is no proved vaccine for HSV-2, patients are typically treated with antiviral drugs, but they are inconvenient, expensive and prone to drug resistance. Cost of treating HSV-2 in the United States are in billion of dollars primarily related to drugs and outpatient medical care.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EBetter approaches are clearly needed to reduce the HSV-2 lesion’s shedding and transmission. A prophylactic vaccine encoding HSV-2 glycoprotein D antigen, by the way, it’s a DNA vaccine was formulated with our Vaxfectin adjuvant. It produced encouraging results in our pre-clinical studies.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ELet me summarize those for you. The vaccine elicited antibody responses in 100% of mice against encoded antigen. It protected 100% of mice against subsequent challenge of the lethal dose of live virus. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIt reduced viral shedding in mice both at primary and latent infection sites. It elicited sterilizing immunity in 80% of the mice as evidenced by no detectable virus after challenge, either the primary or latent infection sites.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe therapeutic vaccine encoded glycoprotein D as well as HSV-2 tegument proteins and was tested in the guinea pig model. Compared with placebo, our vaccine significantly reduced the recurrence of HSV-2 lesion in animals with latent infection with a P value of less than 0.05.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe are excited by the progress so far and pleased that the grant has been extended for another year. We intend to continue to develop this vaccine to address the significant and medical need. We will keep you posted on our progress.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAngiogenesis programs, Sanofi-aventis has now passed the final 12-month follow up point in this multi-national pivotal Phase 3 of Temusi, the clinical trial is known as TAMARIS. It is a gene therapy for advanced PAD. This double-blind placebo-controlled trial enrolled more than 500 patients and was designed to expand the safety and efficacy database from the successful Phase 2 trials.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESanofi expects to present the data in the fourth quarter of this year and if all goes well, this could put this product in the market as early as next year. In conclusion we are advancing well on our independent and partnered programs and are looking forward to two important milestones before the year end.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe expect to present final data from our Phase 2 double-blind TransVax CMV vaccine study in September. Sanofi, our partner for a long period of time expects to present the final results for the Phase 3 Temusi PAD trial in the fourth quarter. We’ll be presenting at multiple investor conferences throughout the fall and look forward to seeing some of you personally there in the future. That’s concludes our prepared comments. Operator, we are now ready to open call to questions from our invited participants. Thank you \u003C\u002Fp\u003E \u003Cp id=\"question-answer-session\" class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EQuestion-and-Answer Session\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E(Operator Instructions). And our first question comes from Alan Carr, Needham &amp; Co.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EAlan Carr - Needham &amp; Co\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYou mentioned earlier that when you were talking about burn, Jill that you all were factoring in potential partnership revenue. Can you give us a sense of where things stand with and the various programs that you are seeking to partner in and the extent of revenue that you are expecting from these partnerships this year?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWell, it’s a excellent question Alan, obviously we had an active discussion, but we don’t have a partnership in hand, because if we had one we would have told you. The revenue projections that we have included in our burn rate are not so huge that it is going to blow our burn rate out of line if we don’t accomplish this particular partnership goal.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think the issue is not whether we are going to accomplish the partnership goal Jill, but the timing of when that’s going to occur. Good probability, it may occur before the end of the year and it doesn’t occur, it may shift one quarter, but independent of that we have sufficient cash.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EAlan Carr - Needham &amp; Co\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay and then thanks for going over the HSV-2 program, when do you think this one might move into the clinic?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWell as I said in my formal presentation that the grant has been extended for one year. That means we want to do some additional work. We want to put the program through some additional stringent challenges, fine tune the make up of the vaccine to make sure even further improve on the data that we have gotten.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo I think sometime in the second half of the year, we should be in a position based on the data to decide how where we want to take this program, but the data so far is very encouraging and HSV as you know as.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe data that I kind of mentioned and I hope you guys captured it, one out of four individuals in the world is infected with HSV-2 and those numbers may understated, so this is the pretty nasty part.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EAlan Carr - Needham &amp; Co\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnything new on Collategene approval in Japan?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI didn’t mention anything specifically, not that we haven’t heard nothing new, and the outcome of that is certainly in hands of the Japanese regulatory authorities. Our partner has told they are going to hear it sometime in the second half of this year, so we wait patiently for the outcome.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EAlan Carr - Needham &amp; Co\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd just sticking to the guidance of the second half this year?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes, it better be because it’s been going for sometime, there are not that many patients for the agency to go through now and I think both they and the agency is under pressure to make a call on this.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur next question comes from Eric Schmidt with Cowen &amp; Company.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EEric Schmidt - Cowen &amp; Company\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EJust on the AnGes front, since we were discussing the approval with Japan. Is there any update on the Japanese study starting up?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EUnidentified Company Representative\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe PAD study you mean?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EEric Schmidt - Cowen &amp; Company\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ENo, as we have said previously that they are waiting the outcome of the approval in Japan before embarking in that study because obviously that will be a pivotal point for them to even raise some more money for funding that study.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThey have sufficient cash to start the study, but they want to raise more money to get the study to its completion. So, I think those events are both tied from a science perspective as well as from a financial perspective.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EEric Schmidt - Cowen &amp; Company\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ETurning to your own pipeline and a couple of milestones, do you expect immunogenicity data from the H1N1 study this year?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYes. I would say hopefully by second half of this year. Alain, what do we say?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EAlain Roland\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOur original guidance was delayed because of the longer time to enroll patients, but we should have something out by the end of the year.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EFourth quarter we should have the data.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EEric Schmidt - Cowen &amp; Company\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOkay, and then I know would you can't say exactly when the Allovectin results might be out, but is mid next year still a decent estimate there.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe should have some good idea going into first quarter, remember there are two issues in Allovectin-7? We have a minimum of 12 months follow up and that 12 months follow up ends in Feb? At that point in time if all the patients are off treatment, then it’s a matter of closing the database, but there are still a lot of patients on the study, then we are not going to close the database and continue to treat the patients because we want to make sure we get responders out, the study is blinded to us.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo, I think by Feb of next year, we should have an idea of where we going to be and the second important point is survival, we want to make sure that when we close the data base, we also lock in the survival. So, I think at this point in time, middle of the year or second half should be a reasonable time but we will give you a better understanding in the first quarter of next year.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EEric Schmidt - Cowen &amp; Company\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EIn terms of TransVax’s progression to Phase 3, is that a study that you could start on your own or would that be partner dependent?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe would love to partner the European component of it because the study that we have done so far is in United States and unlike Provenge where there are differences in terms of treatment modalities between US and Europe. The transplant modalities or the treatment modalities between US and Europe are pretty identical, so doing a study in Europe would allow us to recruit the study faster, would also allow us to get after the European market and that’s what our focus is right now, is to see who we can rope in to help on the European segment of the study.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ECan we do the study on our own. Right now, yes we can start the study, but obviously we need to raise more money to continue to study, but I think our efforts right now are focused on getting that CMV data out, particularly on TransVax to make sure the Is are dotted and the Ts are crossed for our September hopefully at a important meeting release and then the Allovectin-7 data collection which is really a top priority, but don’t forget and TransVax right, now we are in the process of developing our Phase 3 trial design.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe are looking at approaches how to engage the FDA in terms of the end points for the study which we’ve not publicly disclosed, which we have been working with a whole bunch of experts and proceed with that and that itself is a task right now.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ENext we will go to Steven Willey of Stifel Nicolaus.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003ESteven Willey - Stifel Nicolaus\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EYou talked about some of the endpoints in the TransVax trial are going to be a little bit complex with respect to some of the virological endpoints. Can you maybe talk about whether or not you feel a partner in the US, given the complexity of that trial design would want to be involved in these current discussions around trial design and anything you might go to the FDA with?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think the first thing partner will want to see the data from the Phase 2 12 month follow up, and if that virological data is exciting, then all bets are off right because the devil is in the detail, it is all in the data. I can stand here and tell you virological endpoints are good enough, but if we can show immunocompromised patient that those virological endpoints indeed can be achieved, then you can get a partner excited.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESecondly everybody knows that this is a slam dunk. Normally if you get a Phase 2 study done and if you can complete a Phase 3 study done with an agreed upon endpoint with the FDA and the vaccine is efficacious as we have seen so far. This is a locked up market, we’ve [awful] drug status. The people are getting as a matter of point cell transplants or CMV positive, they will take this vaccine okay.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo there is not issue of market penetrability or unknowns about how to achieve the commercial goal. So those are two very clear, the third thing everybody knows that, CMV disease is not a valid endpoint because the entire treatment paradigm is based on virological endpoints and if the FDA is going to insist on doing CMV disease, it will require a huge trial and this will make the full program removed. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd so everybody knows including the clinical experts who are working with us. Remember how they treat people, they used PCR or whatever local assays and they look at the number of [copies] in the blood every week.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd then they put on an antiviral such as Ganciclovir. CMV disease occurs in less than 2% or 3% of the patient. So that’s not a relevant endpoint and that’s the goal and that’s the pieces and that’s the expert opinion that we are taking to the agency.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think the European agency on the other hand already understands the importance of our virological endpoints. We have to do some convincing to do with the FDA.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003ESteven Willey - Stifel Nicolaus\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ESo the ultimate goal then I guess pre-Phase 3 be locking down in SPA and with that make it easier for a potential partner to come on board kind of halfway through the process?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think we would love to have the partner come on board after they see the Phase 2 12-month data. So they are part of the discussions with us, with the agency particularly in the trial design.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003ESteven Willey - Stifel Nicolaus\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EJust with respect to AnGes, have you got any color on whether or not Collategene would be a bit of a restricted launch if and when it’s approved in Japan because the trial was our stopped so early and I know, we’ve seen this before in some of the previous Japanese Phase 3 trials that were stopped early. They typically have a pretty tapered, immediate launch following that?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThe answer to that question is I don’t know, the Japanese are being quite mum on this issue. So we are awaiting, all we know is we are going to hear something in the second half of this year definitely.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003ESteven Willey - Stifel Nicolaus\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EOn A-7 spending, I believe you worked through all of the reimburseful expenses under the AnGes agreement correct?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EJill Boardfoot\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWe are still recognizing revenue from that and we’re recognizing that ratably over the end of the period of the trial, but there is still some that we are burning through.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E(Operator Instructions). We’ll go next to Reni Benjamin with Rodman &amp; Renshaw.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EReni Benjamin - Rodman &amp; Renshaw\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ERegarding the Allovectin-7 program, Vijay can you remind me how many more SMB meetings there will be and about how often are they going to be occurring.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think every six month is when we have a meeting, so I would guess another two meetings at most.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EReni Benjamin - Rodman &amp; Renshaw\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAnd just regarding the data set that will be presented in September. I am assuming that it will be around or at the [ICEC] conference and we’ve already seeing some of those data. So wanted to see if you can get to some specifics as to what new and additional data we would be looking, is it extended follow up and will P values will be associated with all the data that we are looking as coming up?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ELet me remind the audience, first of all the data that we’ve presented so far is as follows, we presented safety data which was early safety look on the study. So we are going to show you all complete safety data in the entire 12-month follow up after the last injection. We showed virological endpoints with no P values only up to 4 months of our two injection, average is about two injection. Here we are going to show you all the virological endpoints by the way which are on our website.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EAfter 12-month follow-up with all P values. We are not going to hold anything back and we already presented the 12-month immunogenecity data. So that’s already behind us, so the real efficacy data 12-months follow up after all sets of injections will be covered such as all the virological endpoints that we covered at 4 months with P value.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EReni Benjamin - Rodman &amp; Renshaw\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ECan you just give us an update if there is one regarding the HIV vaccine and when we might expect completion of enrollment?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EI think it’s a long program, the program is continuing as you know it’s the old VRC vaccine which kind of got slowed down because of the adverse data that came out of the Merck HIV trial. There are lot of plus points in the studies, so I would say the enrolment will continue through the end of 2011, middle of 2011 at least before meaningful data comes out sometime in 2012, 2013. So, it’s a long trial.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EThere are no further questions, so I'll now turn the call back over to Mr. Samant.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EVijay Samant\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003EWell, thank you very much. We look forward to seeing some of you at the upcoming investor conferences come this fall.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content no-summary-bullets\"\u003ELadies and gentlemen this concludes our conference for today, you may now disconnect.\u003C\u002Fp\u003E","twitContent":"$FRTX - Vical Incorporated. Q2 2010 Earnings Call Transcript. https:\u002F\u002Fseekingalpha.com\u002Farticle\u002F218361-vical-incorporated-q2-2010-earnings-call-transcript?source=tweet ","innerMarketing":null,"marketingBullet":null,"isReit":false,"videoData":null,"marketingBulletVariant":null,"marketingBio":null},"relationships":{"author":{"data":{"id":"44211","type":"author"}},"sentiments":{"data":[]},"primaryTickers":{"data":[{"id":"6489","type":"tag"}]},"secondaryTickers":{"data":[]},"otherTags":{"data":[{"id":"96991","type":"tag"},{"id":"17896","type":"tag"},{"id":"49","type":"tag"},{"id":"326","type":"tag"},{"id":"17897","type":"tag"}]},"coAuthors":{"data":[]},"presentations":{"data":[]},"updates":{"data":[]},"corrections":{"data":[]}},"links":{"self":"\u002Farticle\u002F218361-vical-incorporated-q2-2010-earnings-call-transcript","canonical":"https:\u002F\u002Fseekingalpha.com\u002Farticle\u002F218361-vical-incorporated-q2-2010-earnings-call-transcript","uriImage":"https:\u002F\u002Fstatic.seekingalpha.com\u002Fassets\u002Fog_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","schemaImage":null}},"included":[{"id":"44211","type":"author","attributes":{"company":null,"slug":"sa-transcripts","userId":101639,"tagId":96991,"image":{"small":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fsmall_pic.png","medium":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fmedium_pic.png","big":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fbig_pic.png","extra_large":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fextra_large_pic.png"},"nick":"SA Transcripts","bio":"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team","deactivated":null,"memberSince":2007,"contributorSince":2013,"followersCount":140691},"relationships":{"user":{"data":{"id":"101639","type":"user"}},"userBioTags":{"data":[{"id":"958652","type":"userBioTag"}]},"authorResearch":{"data":null}},"links":{"self":"\u002Fauthor\u002Fsa-transcripts","profileUrl":"\u002Fauthor\u002Fsa-transcripts","site":null,"linkedinUrl":null,"twitterUrl":null}},{"id":"6489","type":"tag","attributes":{"slug":"frtx","name":"FRTX","company":"Fresh Tracks Therapeutics, Inc.","tagKind":"Tags::Ticker","equityType":"currency","exchange":"NASDAQ","fundTypeId":0,"isDefunct":false,"currency":"USD","isBdc":false,"isReit":false,"isEtf":false},"relationships":{"sector":{},"subIndustry":{}},"links":{"self":"\u002Fsymbol\u002FFRTX"}},{"id":"96991","type":"tag","attributes":{"slug":"sa-transcripts","name":"SA Transcripts","company":null,"tagKind":"Tags::AuthorTag"},"links":{"self":"\u002Fauthor\u002Fsa-transcripts"}},{"id":"17896","type":"tag","attributes":{"slug":"healthcare","name":"Healthcare","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fhealthcare"}},{"id":"49","type":"tag","attributes":{"slug":"transcripts","name":"Transcripts","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Ftranscripts"}},{"id":"326","type":"tag","attributes":{"slug":"us","name":"United States","company":null,"tagKind":"Tags::Country"},"links":{"self":"\u002Farticles?filters=us"}},{"id":"17897","type":"tag","attributes":{"slug":"biotechnology","name":"Biotechnology","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fbiotechnology"}}],"meta":{"proStatus":0,"page":{"title":"Vical Incorporated. Q2 2010 Earnings Call Transcript","description":"Vical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ETExecutivesAlan Engbring - Executive Director, IRVijay Samant -..."},"path":"\u002Fapi\u002Fv3\u002Farticles\u002F218361"}},"type":"article","authorData":{"response":{"data":{"id":"44211","type":"fullAuthor","attributes":{"company":null,"slug":"sa-transcripts","userId":101639,"tagId":96991,"image":{"small":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fsmall_pic.png","medium":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fmedium_pic.png","big":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fbig_pic.png","extra_large":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fextra_large_pic.png"},"nick":"SA Transcripts","bio":"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team","deactivated":null,"memberSince":2007,"contributorSince":2013,"followersCount":140691,"count":{"followers":140691,"articles":334318,"instablogs":0,"marketing_instablogs":0,"following":4,"comments":1,"likes":0,"comment_likes":1,"news":0,"mp_articles":0},"createdAt":"2013-02-20T14:49:48-05:00","showHeadlines":null,"podcasts":{}},"relationships":{"user":{"data":{"id":"101639","type":"user"}},"userBioTags":{"data":[{"id":"958652","type":"userBioTag"}]},"authorResearch":{"data":null}},"links":{"self":"\u002Fauthor\u002Fsa-transcripts","profileUrl":"\u002Fauthor\u002Fsa-transcripts","site":{"url":"https:\u002F\u002Fseekingalpha.com\u002Fearnings\u002Fearnings-call-transcripts","name":"Recent earnings call transcripts","clicks":38681},"linkedinUrl":"","twitterUrl":""}},"included":[{"id":"958652","type":"userBioTag","attributes":{"priority":0,"name":"We cover over 4K calls\u002Fquarter"}}]},"type":"fullAuthor"}}};</script></head><body><script>
        (() => {
          try {
            if (
              window.matchMedia &&
              window.matchMedia('(min-width: 1024px)').matches &&
              window.localStorage.getItem('isAsideOpened') === 'false'
            ) {
              window.document.documentElement.style.setProperty('--sa-aside-width', '3rem')
              window.document.body.classList.add('hydratingAsideCollapsed');
            }
          } catch (err) {
            console.error(err);
          }
        })()
      </script><div class="appLoading appLoaderInvisible" id="app-loader"></div><span id="sprite-source"><svg style="position:absolute;width:0;height:0;visibility:hidden" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><symbol viewBox="0 0 16 16" id="alpha" xmlns="http://www.w3.org/2000/svg"><path d="M3.763 8.396c0 2.468 1.209 4.508 2.82 4.458 2.257-.065 2.918-2.007 2.918-4.474 0-2.468-1.306-4.492-2.917-4.475-1.983.016-2.82 2.023-2.82 4.491Zm-1.756 0C2.345 3.116 6.407 3 6.407 3c2.949.016 3.787 3.225 3.787 3.225.048.18 1.756-2.995 1.756-2.995h.967c-1.982 4.36-1.901 6.137-1.901 6.137-.161 2.352 1.128 3.158 1.128 3.158 1.209.79 1.29-1.513 1.29-1.513.273-.099.434-.197.434-.197.645 3.191-1.289 2.977-1.289 2.977-1.499.165-2.144-2.336-2.144-2.336-2.127 2.863-4.577 2.238-4.577 2.238-4.19-.527-3.851-5.298-3.851-5.298Z"></path></symbol><symbol fill="none" viewBox="0 0 24 23" id="alpha-picks" xmlns="http://www.w3.org/2000/svg"><path fill="#1A98FF" d="M22.562 16.845s-.159 4.545-2.544 2.987c0 0-2.545-1.591-2.227-6.234 0 0-.068-1.54 1.022-5.081-.412.54-.805 1.066-1.172 1.606a35.72 35.72 0 0 0-1.361 2.2l-.008.014-.01.014c-.378.624-.74 1.28-1.076 1.95l-.01.019-.01.019c-.305.565-.569 1.16-.849 1.788l-.003.007-.002.005c-.024.053-.05.104-.078.155-.743 2.465-2.305 4.103-5.189 4.187-3.18.097-5.565-3.928-5.565-8.798s1.653-8.83 5.565-8.863c2.006-.02 3.77 1.56 4.8 3.952.193-.218.382-.419.565-.61.098-.104.197-.207.295-.313l.018-.02.019-.018.363-.366.17-.17c-1.018-1.842-3.017-4.22-6.58-4.24 0 0-8.014.227-8.682 10.648 0 0-.668 9.415 7.601 10.454 0 0 4.834 1.233 9.032-4.415 0 0 1.273 4.934 4.23 4.61 0 0 3.817.421 2.545-5.877 0 0-.318.195-.859.39Z" opacity=".75"></path><path fill="#1A98FF" d="M5.668 7.958c-.213.118-.284.377-.047.637a62.52 62.52 0 0 1 1.605 1.91c.78.92 1.394 1.957 1.937 3.042.33.66.614 1.344.944 2.005.296.612.787.897 1.455.897l.08-.001c.567 0 1.134-.378 1.37-.896.283-.637.566-1.274.897-1.887.354-.707.732-1.391 1.133-2.052.45-.778.921-1.556 1.417-2.287a45.491 45.491 0 0 1 1.582-2.146c.45-.566.898-1.132 1.394-1.675a88.988 88.988 0 0 1 2.078-2.146c.566-.566 1.18-1.108 1.77-1.65.19-.19.378-.354.567-.52.166-.14.19-.306.095-.495A.304.304 0 0 0 23.644.5a.546.546 0 0 0-.077.006.83.83 0 0 0-.33.141c-.284.212-.59.401-.874.613-.662.472-1.346.967-2.007 1.462-.59.449-1.134.92-1.7 1.392-.496.4-.969.825-1.418 1.25-.519.471-.991.967-1.487 1.462-.307.33-.614.637-.921.99-.496.59-.992 1.156-1.464 1.746a56.8 56.8 0 0 0-1.44 1.886c-.237.307-.45.637-.685.967a6.364 6.364 0 0 0-.709-.684c-.496-.495-.968-.99-1.487-1.462-.425-.4-.898-.755-1.346-1.108-.496-.401-1.04-.779-1.559-1.156a.416.416 0 0 0-.267-.105.412.412 0 0 0-.205.058Z"></path></symbol><symbol viewBox="0 0 16 16" id="analysis-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M11.275 3.108 10.125 2l-3.18 3.064 3.18 3.065 1.15-1.107-1.219-1.175H14V4.282h-3.944l1.219-1.174Zm-5.212 2.74H2V4.281h4.063v1.565Zm-1.338 7.049 1.15 1.107 3.18-3.063-3.18-3.066-1.15 1.108 1.219 1.174H2v1.566h3.944l-1.219 1.174Zm5.212-2.74H14v1.565H9.937v-1.565Z"></path></symbol><symbol viewBox="0 0 16 16" id="arrow-icon" xmlns="http://www.w3.org/2000/svg"><path d="m7.9 4.6-.8.8 2.2 2.1H5.5v1h3.8l-2.2 2.1.8.8L11.2 8 7.9 4.6Z"></path></symbol><symbol viewBox="0 0 16 16" id="authors-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M10 5a2 2 0 1 1-4 0 2 2 0 0 1 4 0Zm.935 2.718a4 4 0 1 0-5.87 0C3.235 8.68 2 10.518 2 12.625V15h12v-2.375c0-2.107-1.236-3.944-3.065-4.907ZM8 9c-2.333 0-4 1.743-4 3.625V13h8v-.375C12 10.743 10.333 9 8 9Z"></path></symbol><symbol viewBox="0 0 20 24" id="bell" xmlns="http://www.w3.org/2000/svg"><path d="M16.88 10.49c0-3.54-2.02-5.98-3.54-6.4-1.52-.43-1.46-2.05-1.46-2.05C11.88.91 11.04 0 10 0S8.12.91 8.12 2.04c0 0 .06 1.62-1.46 2.05-1.52.42-3.54 2.86-3.54 6.4C3.12 18 0 17.56 0 20.16h20c0-2.6-3.12-2.15-3.12-9.67zM6.46 21.12A3.72 3.72 0 0 0 10 24a3.7 3.7 0 0 0 3.54-2.88H6.46z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="beta" xmlns="http://www.w3.org/2000/svg"><path fill="#555" d="M0 0h16v16H0z"></path><path d="M5.322 14.11h1.02v-3.053h.094c.316.65.984 1.06 1.927 1.06 1.524 0 2.631-1.101 2.631-2.666V9.44c0-1.171-.615-1.95-1.781-2.244v-.093c.744-.323 1.195-.99 1.195-1.776v-.012c0-1.365-.99-2.255-2.49-2.255-1.64 0-2.596 1.066-2.596 2.912v8.138Zm2.989-2.895c-1.172 0-1.97-.844-1.97-2.186V6.076c0-1.394.54-2.115 1.606-2.115.885 0 1.453.562 1.453 1.412v.012c0 .914-.568 1.406-1.564 1.406h-.522v.902h.516c1.377 0 2.121.61 2.121 1.776v.011c0 .997-.726 1.735-1.64 1.735Z" fill="#fff"></path></symbol><symbol viewBox="0 0 31 25" id="chat" xmlns="http://www.w3.org/2000/svg"><path d="M28.92 5.18a14.04 14.04 0 0 0-5.64-3.79A21.22 21.22 0 0 0 15.5 0c-2.1 0-4.1.28-6.02.82a17.31 17.31 0 0 0-4.95 2.22 11.4 11.4 0 0 0-3.3 3.33A7.42 7.42 0 0 0 0 10.41c0 1.63.52 3.16 1.57 4.58a12.47 12.47 0 0 0 4.28 3.58 9.93 9.93 0 0 1-1.48 3.02c-.17.23-.35.44-.54.65l-.6.62a56.87 56.87 0 0 0-.67.7l-.12.14-.1.15c-.06.08-.09.13-.08.15a.3.3 0 0 1-.04.16c-.03.1-.02.16.01.2v.02c.04.18.15.35.3.47a.7.7 0 0 0 .53.14A19.33 19.33 0 0 0 13 20.7c.87.1 1.7.14 2.51.14 2.81 0 5.41-.46 7.78-1.4a13.88 13.88 0 0 0 5.64-3.78A7.84 7.84 0 0 0 31 10.4c0-1.88-.7-3.63-2.08-5.23z"></path></symbol><symbol viewBox="0 0 16 16" id="chevron-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="m8.793 8-2.647 2.646.708.707L10.207 8 6.854 4.646l-.708.708L8.793 8Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 16 16" id="comparison-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m11.767 1-1.132 1.137 1.3 1.307H9.068v1.608h2.87L10.635 6.36l1.132 1.137L15 4.248 11.767 1ZM3.098 3.068h2.335v2.36H3.098v-2.36Zm-1.5-1.5h5.335V6.928H1.598V1.568Zm8.969 9.004h2.335v2.36h-2.335v-2.36Zm-1.5-1.5h5.335V14.432H9.067V9.072Zm-3.702.569L4.233 8.504 1 11.752 4.233 15l1.132-1.137-1.3-1.307h2.868V10.95h-2.87L5.365 9.64Z"></path></symbol><symbol viewBox="0 0 24 24" fill="none" id="contributor-icon" xmlns="http://www.w3.org/2000/svg"><path d="M4.333 2.125c-1.45.002-2.581 1.293-2.583 2.833v13.46c.002 1.539 1.134 2.83 2.583 2.832h13.095c1.449-.002 2.581-1.293 2.583-2.832V13.83c0-.399-.298-.766-.717-.766s-.716.367-.716.766v4.586c-.001.742-.539 1.3-1.15 1.3H4.333c-.612 0-1.15-.558-1.15-1.3V4.957c0-.74.538-1.298 1.15-1.299h4.143c.419 0 .717-.367.717-.766s-.298-.767-.717-.767H4.333Z" fill="currentColor" stroke="currentColor" stroke-width=".5"></path><path d="M21.898 3.964c.46-.46.526-1.143.15-1.526L20.588.96c-.222-.225-.548-.296-.873-.223a1.332 1.332 0 0 0-.644.362l-.62.62 2.827 2.865.62-.619ZM8.74 11.418c-.27.271-2.032 4.873-2.032 4.873s4.587-1.737 4.857-2.007L19.74 6.12l-2.827-2.865-8.173 8.163Z" fill="currentColor"></path></symbol><symbol fill="none" viewBox="0 0 16 16" id="crown" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" fill-rule="evenodd" d="M10.438 7.927 8 4.558l-2.438 3.37-2.555-1.093.898 4.665h8.19l.898-4.665-2.555 1.092ZM15 4.346 13.334 13H2.666L1 4.346l4.05 1.73L8 2l2.95 4.077L15 4.346Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 20 20" id="drag" xmlns="http://www.w3.org/2000/svg"><path d="M7 2a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4m6-8a2 2 0 1 0 0-4 2 2 0 0 0 0 4m0 2a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4"></path></symbol><symbol viewBox="0 0 5 21" id="info" xmlns="http://www.w3.org/2000/svg"><circle cx="2.5" cy="2.5" r="2.5"></circle><circle cx="2.5" cy="10.5" r="2.5"></circle><circle cx="2.5" cy="18.5" r="2.5"></circle></symbol><symbol viewBox="0 0 9 10" id="lock" xmlns="http://www.w3.org/2000/svg"><path d="M7.77 4.36h-.36V3.08A3 3 0 0 0 4.5 0a3 3 0 0 0-2.9 3.08v1.28h-.37c-.4 0-.73.34-.73.77v4.1c0 .43.33.77.73.77h6.54c.4 0 .73-.34.73-.77v-4.1a.75.75 0 0 0-.73-.77zm-5.12 0V3.08A1.9 1.9 0 0 1 4.5 1.12a1.9 1.9 0 0 1 1.85 1.96v1.28h-3.7z"></path></symbol><symbol viewBox="0 0 131 26" id="logo" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M.4 18a9.26 9.26 0 0 1-.4 1.82C.7 20.58 2.34 21 3.34 21c2.8 0 5.07-1.74 5.07-4.68 0-4.37-6.46-2.85-6.46-6.63 0-1.45 1.17-2.4 2.58-2.4 1.21 0 2.12.68 2.55 1.79h.2c.17-.58.31-1.15.56-1.68a4.6 4.6 0 0 0-2.94-.99c-2.46 0-4.55 1.3-4.55 3.94 0 4.64 6.42 2.95 6.42 6.77 0 1.62-1.19 3-2.85 3-1.6 0-2.52-.82-3.32-2.14H.4zm11.33-3.28c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.59 3.6a4.55 4.55 0 0 1-3.04 1.42c-2.48 0-3.73-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.89-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.52-1.2l.03-1.08zm3.92-3.6c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.58 3.6a4.54 4.54 0 0 1-3.03 1.42c-2.48 0-3.74-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.9-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.53-1.2l.01-1.08zm3.77-13.07c-.31.03-.56.07-.83.07-.28 0-.55-.04-.82-.07v15.41c.27-.02.54-.06.82-.06.27 0 .52.04.83.06v-4.18c0-.89.28-.95.73-.43 1.32 1.5 2.94 3.32 3.92 4.61.33-.02.66-.06 1.03-.06.33 0 .61.04 1 .06v-.1c-1.62-1.85-3.34-3.9-4.82-5.6 1.9-1.79 3.7-3.22 4.52-3.96v-.14c-.31.01-.56.06-.8.06-.3 0-.56-.05-.82-.06l-1.6 1.76-1.28 1.3c-.26.26-1.35 1.43-1.78 1.2-.19-.1-.1-.4-.1-.67v-9.2zm10.37 2.22c0-.58-.5-1.05-1.04-1.05a1.05 1.05 0 0 0 0 2.1c.55 0 1.04-.48 1.04-1.05zm-.22 3.5c-.31.03-.56.07-.82.07-.3 0-.56-.04-.83-.06v9.8c.27-.02.54-.06.83-.06.26 0 .5.04.82.06v-9.8zm1.63 9.47c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-4.76c0-2.53.54-4.1 2.7-4.1 1.92 0 2.27 1.5 2.27 3.4v5.46c.26-.02.53-.06.82-.06.26 0 .51.04.82.06V14.5c0-2.7-.92-4-3.3-4-1.46 0-2.59.74-3.3 1.99v-1.87c-.31.02-.56.06-.83.06-.28 0-.55-.04-.82-.06v9.8zm11.21-6.68c0-1.56.84-2.7 2.32-2.7 1.62 0 2.2 1.22 2.2 2.8 0 1.4-.79 2.69-2.28 2.69-1.5 0-2.3-1.34-2.24-2.8zm6.9-3.18c-.48.08-.97.1-1.47.04l-2.85-.1c-2.99-.1-4.14 1.27-4.14 3.26 0 1.51.76 2.36 1.99 2.93-.8.35-1.41.78-1.41 1.77 0 1.25.65 1.55 1.25 1.66v.16c-1.28.23-2.14 1-2.14 2.48 0 2.16 2.03 3.02 3.72 3.02 3.13 0 5.2-1.64 5.2-4.04 0-1.75-1.12-2.73-3.54-2.73h-1.32c-1.23 0-1.97-.12-1.97-.99 0-1.19 1.24-.98 1.48-.98 2.38 0 4.37-.95 4.37-3.18 0-1.15-.57-2.05-1.41-2.7l2.25.18v-.78zm-4.34 9.7c1.54 0 3.02.14 3.02 2.28 0 1.93-1.77 2.62-3.24 2.62-1.7 0-2.95-.82-2.95-2.48 0-1.66 1.04-2.44 3.17-2.42zm19.16-5.92h-4.5l2.23-5.25 2.28 5.25zm-1.53-7.94h-.47l-6.4 14.34c.22-.02.45-.06.71-.06.25 0 .47.04.76.06.58-1.93 1.32-3.73 2.03-5.54h5.21a77.59 77.59 0 0 1 2.16 5.54c.35-.02.7-.06 1.09-.06.34 0 .67.04 1.06.06L75.77 6.42zm7.73 14.24c.26-.02.52-.06.81-.06.27 0 .51.04.82.06V5.26c-.3.02-.55.06-.82.06-.29 0-.55-.04-.82-.07v15.41zm5.13-2.03h.04c.68 1.28 1.69 1.97 3.16 1.97 2.63 0 4.43-2.03 4.43-5.4 0-2.45-1.47-4.7-4.12-4.7-2.48 0-3.12 1.5-3.47 2.2h-.04v-2.07c-.3.02-.55.06-.82.06-.28 0-.55-.04-.82-.06V25.7c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-7.06zm0-2.83c0-1.9.62-4.6 3-4.6 2.21 0 2.83 2.08 2.83 4.09 0 2.38-.74 4.45-2.81 4.45-2.1 0-3.02-1.74-3.02-3.94zm9.46 4.86c.26-.02.53-.06.82-.06.26 0 .51.04.82.06v-5.58c0-2.13.84-3.28 2.68-3.28 1.75 0 2.28 1.13 2.28 3.4v5.46c.27-.02.53-.06.82-.06.27 0 .52.04.82.06v-5.93c0-2.58-.92-4-3.3-4-1.45 0-2.58.74-3.3 2V5.24c-.31.03-.56.07-.82.07-.29 0-.56-.04-.82-.07v15.41zm15.23-2.34c0 .15-.41.5-.56.64-.39.4-1.08.78-1.64.78-1.25 0-2-.63-2-1.93 0-1.86 2.08-2.07 3.48-2.34l.72-.14v3zm1.64-4.36c0-2.32-1.17-3.45-3.33-3.45-1.2 0-2.31.45-3.3 1.13v1.15h.23c.14-.45.94-1.42 2.44-1.42 1.54 0 2.4.88 2.4 2.4 0 .99-.56 1.1-2.18 1.38-1.93.3-3.8.61-3.8 2.95 0 1.52 1.28 2.5 2.74 2.5 1.23 0 2.17-.43 3.03-1.29l.19-.18c.16 1.2 1.05 1.37 2.11 1.19.23-.04.47-.15.62-.2v-.46c-1.21.27-1.15-.14-1.15-.94v-4.76z"></path><path color="currentColor" d="M116.78 6.12c.38-5.99 5.1-6.12 5.1-6.12 3.4.02 4.37 3.65 4.37 3.65.04.2 2.02-3.4 2.02-3.4h1.12c-2.28 4.95-2.19 6.98-2.19 6.98-.19 2.66 1.31 3.57 1.31 3.57 1.4.9 1.49-1.71 1.49-1.71.3-.12.5-.22.5-.22.74 3.62-1.49 3.37-1.49 3.37-1.74.18-2.48-2.64-2.48-2.64-2.46 3.24-5.3 2.54-5.3 2.54-4.85-.62-4.45-6.02-4.45-6.02m2.03 0c0 2.8 1.4 5.1 3.26 5.05 2.62-.08 3.38-2.27 3.38-5.08 0-2.8-1.51-5.1-3.38-5.07-2.3.03-3.26 2.3-3.26 5.1"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="marketplace-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.196 3.257a2.667 2.667 0 0 0-2.152 4.471C.945 8.308.168 9.357.023 10.584A3.558 3.558 0 0 0 0 11v1.583h2v-.896c0-.378.039-.747.113-1.104H2.06c.03-.105.073-.21.126-.31A5.662 5.662 0 0 1 4.15 7.325a4.317 4.317 0 0 1-.484-1.992c0-.752.191-1.46.529-2.076ZM13.814 10.273a5.661 5.661 0 0 0-1.964-2.948 4.317 4.317 0 0 0 .484-1.992c0-.752-.192-1.46-.53-2.076a2.667 2.667 0 0 1 2.152 4.471c1.098.579 1.875 1.628 2.02 2.855.016.137.024.276.024.417v1.583h-2v-.896c0-.378-.039-.747-.113-1.104h.052a1.66 1.66 0 0 0-.125-.31Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M9.333 5.333a1.333 1.333 0 1 1-2.666 0 1.333 1.333 0 0 1 2.666 0Zm1.113 2.265a3.333 3.333 0 1 0-4.892 0C4.036 8.398 3.008 9.92 3 11.667v2h10v-2c-.008-1.748-1.036-3.269-2.554-4.069ZM5 11.667C5.012 10.309 6.23 9 8 9s2.988 1.31 3 2.667H5Z" fill="currentColor"></path></symbol><symbol viewBox="0 0 16 16" id="news-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M11.75 2v3H14v9H9.875v-1.5H12.5v-6H4.625a2.25 2.25 0 0 1-2.24-2.467A2.293 2.293 0 0 1 4.69 2h7.059ZM4.659 5h5.591V3.5H4.625a.75.75 0 0 0-.75.825A.772.772 0 0 0 4.66 5Z"></path><path d="M10.625 10.25a.75.75 0 1 0 0-1.5.75.75 0 0 0 0 1.5ZM6.875 13.25V14h1.5v-.938a5.626 5.626 0 0 0-5.438-5.437H2v1.5h.75a4.125 4.125 0 0 1 4.125 4.125Z"></path><path d="M3.875 14v-.75a1.124 1.124 0 0 0-1.125-1.125H2v-1.5h.938v.01a2.625 2.625 0 0 1 2.428 2.427h.01V14H3.874Z"></path></symbol><symbol viewBox="0 0 16 16" id="performance-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M5.429 6.385H2V14h12V8.923h-3.429V3H5.43v3.385Zm1.714-1.693v3.384h.001v4.23H5.43v-4.23H3.714v4.232h8.572v-1.693H10.57v1.692H8.855v-4.23h.002V4.691H7.143Z"></path></symbol><symbol viewBox="0 0 16 16" id="plus-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M8.5 8.5V11h-1V8.5H5v-1h2.5V5h1v2.5H11v1H8.5Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 16 16" id="portfolios-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m15 3.581-1.126 3.384h-1.929l-1.99 3.988-1.931-.966L6.018 13l-2.224-2.228-2.214.739L1 9.768 4.29 8.67l1.443 1.446 1.663-2.498 1.738.87 1.678-3.36h1.74L13.26 3l1.74.581Z"></path></symbol><symbol fill="none" viewBox="0 0 14 12" id="premium" xmlns="http://www.w3.org/2000/svg"><path stroke="#00D885" d="M9 2h4v4"></path><path stroke="#00D885" d="M13 2 7.24 7.65 5.32 5.76 1 10"></path></symbol><symbol viewBox="0 0 22 26" id="presentation" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M9 0h4v2H9V0zm4 9a1 1 0 0 1 1-1h3a1 1 0 1 1 0 2h-3a1 1 0 0 1-1-1zm0 3a1 1 0 0 1 1-1h3a1 1 0 1 1 0 2h-3a1 1 0 0 1-1-1zm-4 5v2h.14l-4.79 4.8c-.3.29-.3.77 0 1.07.29.3.77.3 1.06 0L11 19.28l5.59 5.6a.76.76 0 0 0 1.06-1.09L12.85 19H13v-2h7a1 1 0 0 0 1-1V5h1V3H0v2h1v11a1 1 0 0 0 1 1h7zM19 6H3v9h16V6zm-9.5 6.67A3 3 0 0 0 10 11H7V8a3 3 0 1 0 2.5 4.67z"></path><path opacity=".5" d="M11 10a3 3 0 0 0-3-3v3h3z"></path></symbol><symbol viewBox="0 0 23 16" id="pressRelease" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M16.52 3.16a.5.5 0 0 0 .03.7l.15.14c.2.2.52.18.7-.02l2.61-2.8a.5.5 0 0 0-.03-.7l-.14-.14a.5.5 0 0 0-.71.03l-2.6 2.79zM1.21 8.1l9.96-6.64c.15-.16.31-.28.5-.34 1.27-.38 3.1 1.88 4.07 5.06.97 3.18.73 6.08-.55 6.46-.19.06-.39.06-.6 0l-3.25.02a3.01 3.01 0 1 1-6.02.04l-2.7.01c-.64.2-1.47-.68-1.86-1.95C.37 9.49.57 8.3 1.21 8.1zm5.32 4.59a1.8 1.8 0 0 0 2.33 1.9 1.8 1.8 0 0 0 1.27-1.92l-3.6.02zm8.05-6.16c.78 2.55.9 4.77.26 4.96-.64.2-1.78-1.7-2.56-4.25s-.9-4.77-.26-4.96c.64-.2 1.79 1.7 2.56 4.25zm3.94-1.2a.5.5 0 0 0-.33.63l.06.2a.5.5 0 0 0 .62.32l3.65-1.11a.5.5 0 0 0 .33-.63l-.06-.2a.5.5 0 0 0-.62-.33l-3.65 1.12zm-.44 3.1a.5.5 0 0 1 .6-.37l3.72.86a.5.5 0 0 1 .37.6l-.04.2a.5.5 0 0 1-.6.38l-3.72-.86a.5.5 0 0 1-.38-.6l.05-.2z"></path></symbol><symbol viewBox="0 0 35 12" id="pro" xmlns="http://www.w3.org/2000/svg"><path fill="#fff" d="M4.17.09H0V11.9h.85V8.06h3.32c2.93 0 4.7-1.5 4.7-3.98C8.86 1.57 7.1.1 4.16.1zm0 7.18H.85V.87h3.32C6.67.86 8 2.02 8 4.06c0 2.03-1.33 3.2-3.83 3.2zm16.6 4.64-2.91-4.14a3.62 3.62 0 0 0 2.72-3.7c0-2.5-1.76-3.99-4.68-3.99h-4.18v11.83h.85V8.04h3.33c.4 0 .76-.03 1.13-.08l2.77 3.95h.97zm-8.2-4.63V.86h3.33c2.49 0 3.82 1.17 3.82 3.21 0 2.03-1.33 3.22-3.82 3.22h-3.33zM28.63 12c3.46 0 6.05-2.55 6.05-6s-2.6-6-6.05-6c-3.48 0-6.06 2.57-6.06 6s2.58 6 6.06 6zm0-.8a5.07 5.07 0 0 1-5.2-5.2c0-3 2.22-5.2 5.2-5.2A5.07 5.07 0 0 1 33.8 6c0 3-2.22 5.2-5.18 5.2z"></path></symbol><symbol viewBox="0 0 16 16" id="rated-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m4.1 3.5 1.4 3.7c-.5.3-.9.6-1.2 1L2 2h4.8l1.7 4.5H8c-.189 0-.355.022-.531.046A4.719 4.719 0 0 1 6.8 6.6L5.7 3.5H4.1Zm6.1 0h1.6l-1.4 3.7c.5.3.9.6 1.2 1L14 2H9.2l-.4 1.1.8 2.2.6-1.8ZM8 8c-1.9 0-3.5 1.6-3.5 3.5S6.1 15 8 15s3.5-1.6 3.5-3.5S9.9 8 8 8Zm1.3 5.5L8 12.7l-1.3.8.4-1.5-1.2-1 1.5-.1.6-1.4.6 1.4 1.5.1-1.2 1 .4 1.5Z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="save" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M13.746.004A.364.364 0 0 0 13.685 0H2.333c-.032.001-.063.007-.095.009L2.237.01A2.333 2.333 0 0 0 .008 2.263l-.007.007L0 2.268V15.53a.47.47 0 0 0 .69.416l5.62-2.942 5.62 2.942a.472.472 0 0 0 .69-.416V6.971h2.91c.26 0 .47-.21.47-.468V1.95C16 .813 14.896.046 13.746.004Zm-2.625 1.702c-.016.07-.032.144-.042.221a1.65 1.65 0 0 0-.014.231v11.696L6.53 11.479a.476.476 0 0 0-.439 0l-4.534 2.375V2.33c0-.503.408-.912.911-.912h8.754a1.835 1.835 0 0 0-.1.287Zm3.323 3.847H12.62V2.33a.912.912 0 0 1 1.824 0v3.222Z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="saved" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M13.746.004A.364.364 0 0 0 13.685 0H2.333c-.032.001-.063.007-.095.009L2.237.01A2.333 2.333 0 0 0 .008 2.263l-.007.007L0 2.268V15.53a.47.47 0 0 0 .69.416l5.62-2.942 5.62 2.942a.472.472 0 0 0 .69-.416V6.971h2.91c.26 0 .47-.21.47-.468V1.95C16 .813 14.896.046 13.746.004Zm.698 5.549H12.62V2.33a.912.912 0 0 1 1.824 0v3.222Z"></path></symbol><symbol viewBox="0 0 32 32" id="search" xmlns="http://www.w3.org/2000/svg"><path d="m27.64 25.91-7.16-7.16a9.13 9.13 0 0 0-.8-12.06A9.12 9.12 0 0 0 13.18 4c-2.45 0-4.75.96-6.49 2.7A9.12 9.12 0 0 0 4 13.18c0 2.45.96 4.76 2.7 6.5a9.12 9.12 0 0 0 12.05.8l7.16 7.15a1.22 1.22 0 0 0 1.73 0c.48-.48.48-1.25 0-1.73zM8.42 17.95a6.7 6.7 0 0 1 0-9.53 6.7 6.7 0 0 1 9.52 0 6.7 6.7 0 0 1 1.98 4.77 6.7 6.7 0 0 1-11.5 4.76z"></path></symbol><symbol viewBox="0 0 16 16" id="star" xmlns="http://www.w3.org/2000/svg"><path d="m8 11.706 3.608 1.829-.687-3.867 2.873-2.699-3.974-.557L8 2.86 6.18 6.412l-3.974.557L5.08 9.668l-.688 3.867L8 11.706Zm-4.945 3.627L4 10.026 0 6.269l5.528-.775L8 .666l2.473 4.828L16 6.269l-4 3.757.944 5.307L8 12.827l-4.945 2.506Z"></path></symbol><symbol viewBox="0 0 28 24" id="temple" xmlns="http://www.w3.org/2000/svg"><path d="m14.16.39 11.35 4.08a.98.98 0 0 1 .6 1.27 1 1 0 0 1-1.28.59l-11.14-4-11.42 4.1A1 1 0 0 1 1 5.83a.98.98 0 0 1 .59-1.26L13.3.35a1 1 0 0 1 .85.04zM24 8a1 1 0 0 1-1 1H4a1 1 0 1 1 0-2h19a1 1 0 0 1 1 1zM8 11a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1zm14 10a1 1 0 1 0 0-2H5a1 1 0 0 0 0 2h17zm2 3a1 1 0 0 0 0-2H3a1 1 0 0 0 0 2h21zM13 11a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1zm4 1a1 1 0 0 0 0-2h-2a1 1 0 0 0 0 2v5a1 1 0 0 0 2 0v-5zm6-1a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1z"></path></symbol><symbol viewBox="0 0 20 23" id="transcripts" xmlns="http://www.w3.org/2000/svg"><path d="M12.98 7.9a1 1 0 0 0 .14-.12l5.66-5.66A1 1 0 0 0 17.36.71l-5.08 5.08-3.16-3.15a1 1 0 0 0-1.08-.23 1 1 0 0 0-.68.3L1.71 8.36a1 1 0 1 0 1.41 1.42l5.16-5.16 3.28 3.28a1 1 0 0 0 1.41 0zM1 13a1 1 0 1 0 0 2h18a1 1 0 1 0 0-2H1zm0 4a1 1 0 1 0 0 2h18a1 1 0 1 0 0-2H1zm-1 5a1 1 0 0 1 1-1h8a1 1 0 1 1 0 2H1a1 1 0 0 1-1-1z"></path></symbol><symbol viewBox="0 0 16 16" id="upgrade-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M16 0H0v16h16V0ZM4 8.662h5.465l-2.401 2.402L8 12l4-4-4-4-.936.937 2.4 2.4H4v1.325Z"></path></symbol><symbol fill="none" viewBox="0 0 36 36" id="warning" xmlns="http://www.w3.org/2000/svg"><path d="M18 36a18 18 0 1 0 0-36 18 18 0 0 0 0 36z" fill="#C9392C"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M19.7 9.7a2 2 0 0 0-3.4 0L8.2 22.97A2 2 0 0 0 9.92 26h16.16a2 2 0 0 0 1.7-3.04L19.72 9.7zm-.46 7.51v-3.94h-2.11v3.94c0 .43.02.85.08 1.27.05.41.12.83.2 1.26h1.54c.09-.43.16-.85.2-1.26.06-.42.09-.84.09-1.27zm-2.27 4.56a1.18 1.18 0 0 0 0 .93c.07.15.16.27.27.38a1.4 1.4 0 0 0 .92.34 1.39 1.39 0 0 0 .91-.34c.12-.11.2-.23.27-.38a1.1 1.1 0 0 0 0-.93 1.1 1.1 0 0 0-.27-.37 1.3 1.3 0 0 0-.91-.34c-.18 0-.35.03-.5.1a1.1 1.1 0 0 0-.69.61z" fill="#fff"></path></symbol></svg></span><div class="root" id="root"><div class="flex h-full flex-col"><div class="j_w r_4 aB_iS"><aside class="shrink-0 print:hidden x_eQ x_eR lg:ml-0 lg:pt-0" data-test-id="aside-nav-panel"><div class="flex max-w-full flex-col bg-share-aside-bg pl-safe fixed bottom-0 z-modal border-t border-solid border-navy lg:border-0 lg:pt-0 x_h x_eS lg:top-0"><div class="x_eT flex grow flex-col"><div class="aa_g6"><div class="flex items-center justify-between bg-share-aside-bg px-12 pt-18 mb-8 only:mb-18" data-test-id="aside-menu-header"><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj"><svg class="aj_gy aj_gi aj_hL"><use xlink:href="#logo"></use></svg></span></a><button aria-label="Collapse main menu" class="inline-flex h-24 w-24 items-center justify-center bg-black-50 p-4 ml-auto translate-x-12" type="button"><svg viewBox="0 0 18 11" xmlns="http://www.w3.org/2000/svg" class="h-14 w-14 shrink-0 fill-white rotate-90" data-test-id="expand-collapse-arrow-button"><path d="M2.1 0 9 6.84 15.9 0 18 2.08 9 11 0 2.08z"></path></svg></button></div></div><nav class="h-0 grow" data-test-id="main-sidebar-nav" id="main-sidebar-nav"><div class="P_g relative h-full w-full P_gC P_gD"><div class="P_gB relative h-full overflow-y-auto overflow-x-hidden"><div></div><div class="pb-24 pt-14 lg:pt-0"><a class="z_eU" href="#content">Skip to content</a><div class="aa_g5"><ul class="cX_g r_4 r_am" data-test-id="account-menu"><li class=""><button aria-controls="accordion-section-account-menu" aria-expanded="false" class="cX_pf r_4 r_6 cX_ph s_as aS_jq aS_jH aS_jS aS_kz aS_kN aS_k2 px-12 py-0 text-white" id="accordion-caption-account-menu" type="button"><span class="flex w-0 grow items-center"><div class="mr-14 flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div><span class="w-0 grow truncate text-left text-large-b">No username</span></span><span class="cX_pm r_4 r_6 r_ab cX_pw s_cR cX_pp" data-test-id="accordion-arrow-wrapper"><svg viewBox="0 0 18 11" xmlns="http://www.w3.org/2000/svg" class="cX_hI cX_ps"><path d="M2.1 0 9 6.84 15.9 0 18 2.08 9 11 0 2.08z"></path></svg></span></button><div aria-labelledby="accordion-caption-account-menu" class="cX_pC s_by" data-test-id="accordion-content" hidden="" id="accordion-section-account-menu"><!--$--><div class="cV_eI relative"><ul class="m-0 list-none pl-0"><li data-test-id="set-username-menu-button"><button class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" type="button"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Set Username</span></span></button></li><li data-test-id="account-settings-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/user_settings"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Account Settings</span></span></a></li><li data-test-id="manage-alerts-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/edit_stocks"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Manage Emails &amp; Alerts</span></span></a></li><li data-test-id="saved-articles-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/saved_articles"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Saved Articles</span></span></a></li><li data-test-id="read-articles-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/history"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Read Articles</span></span></a></li><li data-test-id="my-notes-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/my-notes"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">My Notes</span></span></a></li><li data-test-id="sign-out-menu-button"><button class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" type="button"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Sign out</span></span></button></li></ul></div><!--/$--></div></li></ul></div><div class="hidden lg:hidden mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative lg:hidden mb-18" data-test-id="upgrade-menu-top"><ul class="m-0 list-none pl-0 lg:flex-col flex flex-col-reverse"><li data-test-id="alpha-picks-top-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/alpha-picks/subscribe?source=explore_alpha_picks%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha-picks"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="alpha-picks-link-menu-button-top">Explore Alpha Picks</span></span></span></a></li><li data-test-id="upgrade-top-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/subscriptions?source=upgrade_to_pro%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16 text-brand-pro"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#upgrade-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="upgrade-link-menu-button-top">Upgrade To PRO</span></span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="general-menu-module"><ul class="m-0 list-none pl-0"><li data-test-id="home-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/?source=home%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Home</span></span></a></li><li data-test-id="analysis-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/latest-articles?source=analysis%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#analysis-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Analysis</span></span></a></li><li data-test-id="news-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/market-news?source=news%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#news-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">News</span></span></a></li><li data-test-id="market-performance-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/etfs-and-funds/etf-tables/key_markets?source=market_performance%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#performance-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Market Data</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="experts-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#marketplace-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Investing Groups</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="all-experts-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/marketplace/directory?source=investing_groups%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Explore Investing Groups</span></span><span class="jQ_Hx s_cH jQ_Hv r_ar"><div class="flex items-center"><div class="ml-12 flex"></div></div></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="portfolios-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#portfolios-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Portfolios</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="create-portfolio-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/portfolio?source=portfolio%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Create Portfolio</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="find-and-compare-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#comparison-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Find &amp; Compare</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="top-stocks-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/96793299-Top-Rated-Stocks?source=top_stocks%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Top Stocks</span></span></a></li><li data-test-id="top-et-fs-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/etfs/922b797269-Top-Rated-ETFs?source=top_etfs%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Top ETFs</span></span></a></li><li data-test-id="stock-screener-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners?source=stock_screener%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Stock Screener</span></span></a></li><li data-test-id="etf-screener-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/etfs?source=etf_screener%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">ETF Screener</span></span></a></li><li data-test-id="comparisons-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/comparison?source=comparisons%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Comparisons</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative hidden lg:block mb-18" data-test-id="upgrade-menu-bottom"><ul class="m-0 list-none pl-0"><li data-test-id="alpha-picks-bottom-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/alpha-picks/subscribe?source=explore_alpha_picks%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha-picks"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="alpha-picks-link-menu-button-bottom">Explore Alpha Picks</span></span></span></a></li><li data-test-id="upgrade-bottom-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/subscriptions?source=upgrade_to_pro%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16 text-brand-pro"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#upgrade-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="upgrade-link-menu-button-bottom">Upgrade To PRO</span></span></span></a></li></ul></div><div></div></div><div></div></div></div></nav></div></div></aside><div class="j_a r_4 r_am r_ap"><header class="B_B fixed left-0 top-0 w-full lg:sticky B_eX aQ_jg"><div class="container max-w-full xxl:px-safe-or-36 px-safe-or-18 bg-black-v2-90 pt-safe-or-6 flex w-full items-center pb-6 B_eY lg:bg-share-bg-4 shadow-none lg:py-20" data-test-id="grid-container"><div class="grow aa_g6"><!--$--><div class="relative align-middle B_eZ mr-24 grow" data-test-id="search-block"><div class="flex flex-wrap w-full flex-col"><div class="relative w-full"><input autoComplete="on" placeholder="Symbols, Analysts, Keywords" spellcheck="true" aria-label="Symbols, Analysts, Keywords" class="inline-block text-ellipsis bg-clip-padding h-50 py-12 px-12 text-medium-r border border-navy-40 text-black-v2-90 read-only:text-navy-80 placeholder:text-navy-80 bg-white focus-within:border-navy-40 dark:border-black-v2-70 dark:text-black-v2-20 dark:bg-black-v2-80 dark:placeholder:text-black-v2-30 dark:read-only:text-black-v2-30 dark:focus-within:border-black-v2-70 focus:border-black-35 dark:focus:border-black-30 disabled:text-black-10 disabled:bg-black-5 disabled:border-black-10 disabled:opacity-100 dark:disabled:border-black-80 dark:disabled:text-black-80 dark:disabled:bg-black-98 w-full read-only:opacity-100 invalid:shadow-none vendor-clear-input-button dark:placeholder:text-black-30 dark:read-only:text-black-30 pr-38" data-test-id="search-input" type="search" value=""/><span class="sr-only">Entering text into the input field will update the search result below</span><svg class="right-12 w-20 h-20 absolute top-1/2 shrink-0 -translate-y-1/2 pointer-events-none fill-current text-black-35 dark:text-black-30"><use xlink:href="#search"></use></svg></div></div></div><!--/$--></div><div class="aa_g7"><div class="flex items-center"><button aria-controls="main-sidebar-nav" aria-expanded="false" aria-haspopup="true" aria-label="Main menu" class="I_0 r_5 r_6 r_ab I_fz aS_jo aS_jE aS_jT I_fx B_0 mr-8 shrink-0 text-white" type="button"><span class="I_gk r_4 r_6 r_ab r_ar I_gl"><span class="R_gL t_eE"><span class="R_gM t_eD" data-test-id="hamburger-menu-button"></span></span></span><span class="I_gn"></span></button><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj h-24 lg:mr-4 lg:h-32"><svg class="aj_gy aj_gi aj_hL B_e2"><use xlink:href="#logo"></use></svg></span></a></div></div><div class="Q_gE r_4 r_6"><div class="Q_0 s_dm r_4 r_6 r_ab aa_g7"><a aria-label="Search for Symbols, analysts, keywords" title="Search" class="I_0 r_5 r_6 r_ab I_fO aS_jn aS_jC aS_jS I_fx L_G L_gv text-white" href="/basic-search"><span class="I_gk r_4 r_6 r_ab r_ar I_gl"><svg width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M10.53 4a6.53 6.53 0 1 1 0 13.07 6.53 6.53 0 0 1 0-13.07Zm0 1.54a5 5 0 1 0 0 9.99 5 5 0 0 0 0-10Zm9.43 13.38L18.86 20l-2.55-2.59-.01-2.2 3.66 3.71Z" fill="currentColor"></path></svg></span><span class="I_gn">Search for Symbols, analysts, keywords</span></a></div></div></div><div class="absolute inset-x-0 top-full"></div><div></div></header><main class="j_t j_x r_4 r_am r_ap r_4 r_am j_y" id="content"><div class="j_z aQ_jg"></div><!--$--><div class="bL_mL r_4 r_am r_ap"><article class="container xxl:px-safe-or-36 md:px-safe-or-18" data-test-id="article-page"><script type="application/ld+json">{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/218361-vical-incorporated-q2-2010-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@type":"Organization","name":"Seeking Alpha","logo":{"@type":"ImageObject","height":60,"url":"https://seekingalpha.com/samw/static/images/PublisherLogo.1a0fb372.png","width":360}},"datePublished":"2010-08-03T20:06:21.000Z","dateModified":"2010-08-03T20:06:21.000Z","description":"Vical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ETExecutivesAlan Engbring - Executive Director, IRVijay Samant -...","headline":"Vical Incorporated. Q2 2010 Earnings Call Transcript","about":[{"@type":"Corporation","name":"Fresh Tracks Therapeutics, Inc.","tickerSymbol":"NASDAQ:FRTX","url":"https://seekingalpha.com/symbol/FRTX"}],"image":{"@type":"ImageObject","url":"https://seekingalpha.com/samw/static/images/DefaultArticleImage.f1f9250c.png","height":1200,"width":1200}}</script><div class="cC_ox"><div class="sa-row-gap-18 xl:sa-row-gap-36 sa-row-collapse-v-gutter flex-wrap flex grow last:mb-0 print:block sa-row-gap-18 xl:sa-row-gap-36" data-test-id="grid-row"><div class="grow w-0 basis-0 empty:hidden relative min-h-1 min-w-0 w-full max-w-full grow sa-col" data-test-id="grid-col"><div class="" data-test-id="article-section"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="lI_qh s_aG s_aZ s_bm s_aE"><div class="lI_KU s_ed"><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj"><svg class="aj_gy aj_fP aj_hM"><use xlink:href="#logo"></use></svg></span></a></div><header class="sQ_G3 r_4 r_7 r_af r_am"><div class="wv_g r_4 r_7 r_af s_eb cv_oi" data-test-id="quick-links"><div class="wv_Y4 r_4 r_6 r_ah r_ap s_cM s_b7"><div class="wv_Xo s_aW s_aA s_bf"><div class="zi_io" data-test-id="themes-list"><ul class="zi_mY r_4"><li class="zi_mZ r_4 r_6 s_d1"><a data-test-id="theme-links-item" class="I_0 r_5 r_6 r_ab I_f9 I_fw aS_jn aS_jC aS_jT L_G" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="zi_1y it_w0">Transcripts</span></span></a></li></ul></div></div></div><div class="wv_Y3 r_4 r_6 r_af"></div></div><div class="nW_i6 r_4 r_af"><h1 class="nW_Y s_eb aS_jv aS_jN aS_jT aS_kG aS_kY aS_k3" data-test-id="post-title">Vical Incorporated. Q2 2010 Earnings Call Transcript</h1></div><div class="nW_a r_4 r_af s_eb aS_jo aS_jD aS_jS sQ_Ut r_4 r_6" data-test-id="post-page-meta"><div><span class="nW_ND nW_gY t_eC" data-test-id="post-date">Aug. 03, 2010 4:06 PM ET</span><span class="nW_gY t_eC" data-test-id="post-primary-tickers"><a class="wq_YW" href="/symbol/FRTX?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AFRTX">Fresh Tracks Therapeutics, Inc. (FRTX)</a></span><span class="nW_Nt t_eE"><a class="nW_G aS_jo aS_jD aS_jS" data-test-id="post-comments-count" href="#comments" id="commentsPianoElement">1 Comment</a></span></div></div></header><div class="uw_QM r_4 r_7 r_af s_eb" data-test-id="author-brief"><div class="uw_4 r_4"><a class="uw_Nq tm_Nq" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcSet="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"/></div></a><div class="uw_QN r_4 r_ab r_am s_cL"><a class="uw_Nq tm_Nq uw_Md aS_jp aS_jD aS_jT s_dX tm_Md" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="uw_rj r_4 r_ah"><div class="sx_T3 aS_jn aS_jC aS_jS uw_QL t_eC aS_jn aS_jC aS_jS">140.69K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="mC_LW" role="none"><button data-state-text="Following" class="I_0 r_5 r_6 r_ab I_fP I_fz aS_jo aS_jE aS_jT ky_IU s_ay s_bC s_aZ s_bm qO_I0 r_ar uw_Bf s_cy aQ_jg" data-test-id="follow-button" type="button"><span class=""><span class="ky_IW r_4 r_ab" data-state-placeholder="Following"><span class="ky_IX">Follow</span></span></span></button></div></div><div><div class="paywall-full-content jB_f r_4" data-test-id="article-content"><div class="jB_mC r_ap"><div class="jB_il" data-test-id="content-container"><p>Vical Incorporated. (VICL) Q2 2010 Earnings Call Transcript August 3, 2010 12:00 PM ET</p> <p><strong>Executives</strong></p> <p>Alan Engbring - Executive Director, IR</p> <p>Vijay Samant - President &amp; CEO</p> <p>Jill Broadfoot - SVP, CFO &amp; Secretary</p> <p><strong>Analysts</strong></p> <p>Alan Carr - Needham &amp; Co</p> <p>Eric Schmidt - Cowen &amp; Company</p> <p>Steven Willey - Stifel Nicolaus</p> <p>Reni Benjamin - Rodman &amp; Renshaw</p> <p><strong>Operator</strong></p> <p>Good day and welcome ladies and gentleman to the Vical Incorporated financial results conference call. At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for question-and-answers from invited participants after the presentation. </p> <p>I will now turn the conference over to Mr. Alan Engbring, Executive Director of Investor Relations. Please go ahead sir.</p> <p><strong>Alan Engbring</strong></p> <p>Hello everyone, welcome to our second quarter 2010 financial results conference call. Participating on the call today are Vical’s President and Chief Executive Officer, Mr. Vijay Samant and Vical’s Chief Financial Officer, Ms. Jill Broadfoot. I will begin with a brief notice concerning projections and forecast.</p> <p>This call includes forward-looking statements including financial expectations and projections of progress in our research and development programs that are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including the risks set forth in Vical’s annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission as well as the specific risks and uncertainties noted in Vical’s news release on second quarter 2010 financial results. These forward-looking statements represent the company’s judgment as of today. The company disclaims, however, any intent or obligation to update these forward-looking statements.</p> <p>Now, I would like to introduce Vical’s President and Chief Executive Officer, Mr. Vijay<span class="paywall-full-content"> Samant</span></p> <p class="paywall-full-content"><strong>Vijay Samant</strong></p> <p class="paywall-full-content">Thank you and welcome to all our listeners I’ll review the highlights of our recent developments in our call today, update our outlook for the remainder of the year and will then open the call to questions from invited participants, but before I do that let<span class="paywall-full-content no-summary-bullets"> me have our CFO Jill Broadfoot to give you financial update for this quarter.</span></p> <p class="paywall-full-content no-summary-bullets"><strong>Jill Broadfoot</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you, Vijay. Financial results for the second quarter and first half of 2010 were consistent with expectations. Revenue for the first half of 2010 was $3.5 million compared with $6.2 million for the first half of 2009 reflecting the reduction in revenue recognized from AnGes as we approach completion of our Phase 3 Allovectin-7 trial. </p> <p class="paywall-full-content no-summary-bullets">Last year’s revenues also included a $1.5 million milestone payment from Merck for its cancer vaccine program. Operating expenses were generally consistent year-over-year and net loss was $16.9 million in the first half of 2010 compared with $14.3 million in the first half of 2009. We ended the first half of 2010 with cash and investments of approximately $40 million.</p> <p class="paywall-full-content no-summary-bullets">Our cash used during the first half was approximately $18 million which was partially offset by inflows of approximately $5 million from more exercise which was consistent with our projections for the full year.</p> <p class="paywall-full-content no-summary-bullets">As a reminder, our forecast range included anticipated cash receipts from new or expanded partnerships not currently contracted. We continue to make progress towards those potential partnerships. With that I will turn the call back to Vijay.</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Thank you Jill, I will cover the highlights in our development programs today beginning with an update on Allovectin-7 immunotherapy for patients with metastatic melanoma. The recent approval of [Provenge] coupled with BMS’s second line melanoma data [task] therapy has created additional visibility for immunotherapy. I won’t go in to details about those data, but want to make a few observations.</p> <p class="paywall-full-content no-summary-bullets">First on safety, in our Phase 2 trial, there were no drug-related Grade 3 or Grade 4 adverse events, there were no discontinuations due to tolerability. We believe that’s more impressive when you consider the average of patients enrolled in that Phase 3 was 60 and we treated several patients in the 90s.</p> <p class="paywall-full-content no-summary-bullets">In our ongoing Phase 3 trial and Independent Safety Monitoring Board recently completed fourth scheduled safety analysis and recommended continuation of the trial for protocol. We believe safety profile of A-7 if it receives marketing approval would make it a compelling choice especially for patients who are not able tolerate toxic chemotherapy or biotherapy agents. </p> <p class="paywall-full-content no-summary-bullets">Second on efficacy, our Phase 3 trial was designed under an SPA to support approval as the first line therapy. We are comparing A-7 head-to-head against the chemotherapy standard of care. We believe our primary endpoint of response rate at 24 weeks or more would represent the meaningful benefits to patients. We will also evaluate survival of the historical chemotherapy controls have been typically demonstrated median survival of nine to 12 months. A-7 achieved a median survival of almost 19 months in our Phase 2 trial. If we reach our accepted goals in Phase 3, we believe A-7 would be an attractive treatment option for metastatic melanoma.</p> <p class="paywall-full-content no-summary-bullets">So on approach, while both EP and A-7 of immunotherapies that rely on different and potentially complementary mechanism of action, A7 is designed to make tumor cells more visible target for destruction by T-Cells, EP is designed to reactivate T-Cells that have been down regulated by cancer, both products because of their unique mechanisms would have the opportunity to address significant unmet need for patients with metastatic melanoma.</p> <p class="paywall-full-content no-summary-bullets">As a reminder we completed an enrollment on our Phase 3 in February with a total of 390 subjects. We expect to log the clinical trial database in the second half of 2011, as we gain further clarity by monitoring a trial progress. Over the coming months, we will provide you periodic updates and timelines.</p> <p class="paywall-full-content no-summary-bullets">Next I'll review the status of our Phase 2 trial for our TransVax CMV Vaccine. As we have noted previously these are primarily leukemia and lymphoma patients receiving transplants. We enrolled CMV-seropositive patients who are at high risk for CMV reactivation during the recovery period, our TransVax Vaccine is intended to reduce the need for toxic and expensive anti-viral drug therapy used to control CMV while the patients’ immune system is being restored.</p> <p class="paywall-full-content no-summary-bullets">There are three important datasets to consider in our Phase 2 trial and pay attention to this very carefully. The first as in most trials is safety. We had a clean safety review early in the study. There were no serious safety issues that prevented us from completing the trial per protocol. As part of our final data analysis, we'll be comparing the full safety profile of the TransVax vaccine versus placebo.</p> <p class="paywall-full-content no-summary-bullets">In our last quarterly call, we received the second dataset which is immunogenicity for our TransVax Vaccine versus placebo through the final 12 month follow up. These data have been presented on our conference in the April and are available in the CMV section of our website. We are pleased that our vaccine was able to elicit sustained T-Cell and anti-body responses to the encoded CMV antigens.</p> <p class="paywall-full-content no-summary-bullets">We believe this is the first time a vaccine has demonstrated success in immunocompromised patients. We also noted a boost in both T-Cell and antibody responses after the fourth injection which is relevant for the late onset of CMV reactivation.</p> <p class="paywall-full-content no-summary-bullets">The third dataset involves efficacy. We are evaluating a broad range of possibilities in this endpoint defining study, our four-month interim analysis last summer which is available on our website started to help us focus on the most important virological endpoints such as time to initial viremia duration of viremia, the number of viremic episodes and peak viral load.</p> <p class="paywall-full-content no-summary-bullets">Our goal for the 12-month analysis in the crux of this study is to complete that process and identify the most relevant efficacy endpoints for a Phase 3 trial. We look forward to presenting the final Phase 2 data and we’ll announce the presentation details when they are confirmed. We’ve been working with the leading CMV experts and transplantation experts throughout the Phase 2 trial and we have enlisted their help in designing an appropriate Phase 3 trial.</p> <p class="paywall-full-content no-summary-bullets">We expect to review our proposed trial design with the FDA as soon as possible in order to secure the necessary approvals to allow us to begin a Phase 3 trial next year. I will shift now to our Pandemic Influenza program, our ongoing Phase 1 trial of our H1 vaccine has been supported by funding from the US Navy and the Department of Defense’s Transformational Medical Technologies Program or TMT.</p> <p class="paywall-full-content no-summary-bullets">This trial expands on the success of our H5N1 vaccine. Enrollment in this trial took longer than expected primarily because of higher than percentage of our volunteers tested positive to the H1N1 influenza virus. Remember we just started the trial in the late second quarter and by that time the H1N1 flu season had swept through the US. </p> <p class="paywall-full-content no-summary-bullets">So it was hard to find patients.</p> <p class="paywall-full-content no-summary-bullets">However we were able to find enough healthy volunteers to complete enrollment and are now back on track with the trial progress. I am going to provide an update today on one of our most exciting pre-clinical programs, our vaccine for Herpes Simplex 2 or HSV-2. The last week at our Herpes conference, we presented pre-clinical data we believe were quite impressive.</p> <p class="paywall-full-content no-summary-bullets">First a little background of the disease, HSV-2 is a Herpes virus which means by the way same family of CMV. It means once that you are infected, you are infected for life. After the initial sexually transferred infection, the virus resides in a latent state in the ganglia. Periodic outbreaks and general lesions lead to additional virus shedding a disease transmission.</p> <p class="paywall-full-content no-summary-bullets">At least 40 million people in the United States are infected with the HSV-2 and about 1.6 million additional people are infected each year. About one out of six individuals of the US and one out of four worldwide is infected with HSV-2 by age 50, so it’s a really pandemic in the true sense. HSV-2 infection has also significantly increases the risk of acquiring HIV.</p> <p class="paywall-full-content no-summary-bullets">There is no proved vaccine for HSV-2, patients are typically treated with antiviral drugs, but they are inconvenient, expensive and prone to drug resistance. Cost of treating HSV-2 in the United States are in billion of dollars primarily related to drugs and outpatient medical care.</p> <p class="paywall-full-content no-summary-bullets">Better approaches are clearly needed to reduce the HSV-2 lesion’s shedding and transmission. A prophylactic vaccine encoding HSV-2 glycoprotein D antigen, by the way, it’s a DNA vaccine was formulated with our Vaxfectin adjuvant. It produced encouraging results in our pre-clinical studies.</p> <p class="paywall-full-content no-summary-bullets">Let me summarize those for you. The vaccine elicited antibody responses in 100% of mice against encoded antigen. It protected 100% of mice against subsequent challenge of the lethal dose of live virus. </p> <p class="paywall-full-content no-summary-bullets">It reduced viral shedding in mice both at primary and latent infection sites. It elicited sterilizing immunity in 80% of the mice as evidenced by no detectable virus after challenge, either the primary or latent infection sites.</p> <p class="paywall-full-content no-summary-bullets">The therapeutic vaccine encoded glycoprotein D as well as HSV-2 tegument proteins and was tested in the guinea pig model. Compared with placebo, our vaccine significantly reduced the recurrence of HSV-2 lesion in animals with latent infection with a P value of less than 0.05.</p> <p class="paywall-full-content no-summary-bullets">We are excited by the progress so far and pleased that the grant has been extended for another year. We intend to continue to develop this vaccine to address the significant and medical need. We will keep you posted on our progress.</p> <p class="paywall-full-content no-summary-bullets">Angiogenesis programs, Sanofi-aventis has now passed the final 12-month follow up point in this multi-national pivotal Phase 3 of Temusi, the clinical trial is known as TAMARIS. It is a gene therapy for advanced PAD. This double-blind placebo-controlled trial enrolled more than 500 patients and was designed to expand the safety and efficacy database from the successful Phase 2 trials.</p> <p class="paywall-full-content no-summary-bullets">Sanofi expects to present the data in the fourth quarter of this year and if all goes well, this could put this product in the market as early as next year. In conclusion we are advancing well on our independent and partnered programs and are looking forward to two important milestones before the year end.</p> <p class="paywall-full-content no-summary-bullets">We expect to present final data from our Phase 2 double-blind TransVax CMV vaccine study in September. Sanofi, our partner for a long period of time expects to present the final results for the Phase 3 Temusi PAD trial in the fourth quarter. We’ll be presenting at multiple investor conferences throughout the fall and look forward to seeing some of you personally there in the future. That’s concludes our prepared comments. Operator, we are now ready to open call to questions from our invited participants. Thank you </p> <p id="question-answer-session" class="paywall-full-content no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">(Operator Instructions). And our first question comes from Alan Carr, Needham &amp; Co.</p> <p class="paywall-full-content no-summary-bullets"><strong>Alan Carr - Needham &amp; Co</strong></p> <p class="paywall-full-content no-summary-bullets">You mentioned earlier that when you were talking about burn, Jill that you all were factoring in potential partnership revenue. Can you give us a sense of where things stand with and the various programs that you are seeking to partner in and the extent of revenue that you are expecting from these partnerships this year?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Well, it’s a excellent question Alan, obviously we had an active discussion, but we don’t have a partnership in hand, because if we had one we would have told you. The revenue projections that we have included in our burn rate are not so huge that it is going to blow our burn rate out of line if we don’t accomplish this particular partnership goal.</p> <p class="paywall-full-content no-summary-bullets">I think the issue is not whether we are going to accomplish the partnership goal Jill, but the timing of when that’s going to occur. Good probability, it may occur before the end of the year and it doesn’t occur, it may shift one quarter, but independent of that we have sufficient cash.</p> <p class="paywall-full-content no-summary-bullets"><strong>Alan Carr - Needham &amp; Co</strong></p> <p class="paywall-full-content no-summary-bullets">Okay and then thanks for going over the HSV-2 program, when do you think this one might move into the clinic?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Well as I said in my formal presentation that the grant has been extended for one year. That means we want to do some additional work. We want to put the program through some additional stringent challenges, fine tune the make up of the vaccine to make sure even further improve on the data that we have gotten.</p> <p class="paywall-full-content no-summary-bullets">So I think sometime in the second half of the year, we should be in a position based on the data to decide how where we want to take this program, but the data so far is very encouraging and HSV as you know as.</p> <p class="paywall-full-content no-summary-bullets">The data that I kind of mentioned and I hope you guys captured it, one out of four individuals in the world is infected with HSV-2 and those numbers may understated, so this is the pretty nasty part.</p> <p class="paywall-full-content no-summary-bullets"><strong>Alan Carr - Needham &amp; Co</strong></p> <p class="paywall-full-content no-summary-bullets">Anything new on Collategene approval in Japan?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">I didn’t mention anything specifically, not that we haven’t heard nothing new, and the outcome of that is certainly in hands of the Japanese regulatory authorities. Our partner has told they are going to hear it sometime in the second half of this year, so we wait patiently for the outcome.</p> <p class="paywall-full-content no-summary-bullets"><strong>Alan Carr - Needham &amp; Co</strong></p> <p class="paywall-full-content no-summary-bullets">And just sticking to the guidance of the second half this year?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Yes, it better be because it’s been going for sometime, there are not that many patients for the agency to go through now and I think both they and the agency is under pressure to make a call on this.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Our next question comes from Eric Schmidt with Cowen &amp; Company.</p> <p class="paywall-full-content no-summary-bullets"><strong>Eric Schmidt - Cowen &amp; Company</strong></p> <p class="paywall-full-content no-summary-bullets">Just on the AnGes front, since we were discussing the approval with Japan. Is there any update on the Japanese study starting up?</p> <p class="paywall-full-content no-summary-bullets"><strong>Unidentified Company Representative</strong></p> <p class="paywall-full-content no-summary-bullets">The PAD study you mean?</p> <p class="paywall-full-content no-summary-bullets"><strong>Eric Schmidt - Cowen &amp; Company</strong></p> <p class="paywall-full-content no-summary-bullets">Yes.</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">No, as we have said previously that they are waiting the outcome of the approval in Japan before embarking in that study because obviously that will be a pivotal point for them to even raise some more money for funding that study.</p> <p class="paywall-full-content no-summary-bullets">They have sufficient cash to start the study, but they want to raise more money to get the study to its completion. So, I think those events are both tied from a science perspective as well as from a financial perspective.</p> <p class="paywall-full-content no-summary-bullets"><strong>Eric Schmidt - Cowen &amp; Company</strong></p> <p class="paywall-full-content no-summary-bullets">Turning to your own pipeline and a couple of milestones, do you expect immunogenicity data from the H1N1 study this year?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Yes. I would say hopefully by second half of this year. Alain, what do we say?</p> <p class="paywall-full-content no-summary-bullets"><strong>Alain Roland</strong></p> <p class="paywall-full-content no-summary-bullets">Our original guidance was delayed because of the longer time to enroll patients, but we should have something out by the end of the year.</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Fourth quarter we should have the data.</p> <p class="paywall-full-content no-summary-bullets"><strong>Eric Schmidt - Cowen &amp; Company</strong></p> <p class="paywall-full-content no-summary-bullets">Okay, and then I know would you can't say exactly when the Allovectin results might be out, but is mid next year still a decent estimate there.</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">We should have some good idea going into first quarter, remember there are two issues in Allovectin-7? We have a minimum of 12 months follow up and that 12 months follow up ends in Feb? At that point in time if all the patients are off treatment, then it’s a matter of closing the database, but there are still a lot of patients on the study, then we are not going to close the database and continue to treat the patients because we want to make sure we get responders out, the study is blinded to us.</p> <p class="paywall-full-content no-summary-bullets">So, I think by Feb of next year, we should have an idea of where we going to be and the second important point is survival, we want to make sure that when we close the data base, we also lock in the survival. So, I think at this point in time, middle of the year or second half should be a reasonable time but we will give you a better understanding in the first quarter of next year.</p> <p class="paywall-full-content no-summary-bullets"><strong>Eric Schmidt - Cowen &amp; Company</strong></p> <p class="paywall-full-content no-summary-bullets">In terms of TransVax’s progression to Phase 3, is that a study that you could start on your own or would that be partner dependent?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">We would love to partner the European component of it because the study that we have done so far is in United States and unlike Provenge where there are differences in terms of treatment modalities between US and Europe. The transplant modalities or the treatment modalities between US and Europe are pretty identical, so doing a study in Europe would allow us to recruit the study faster, would also allow us to get after the European market and that’s what our focus is right now, is to see who we can rope in to help on the European segment of the study.</p> <p class="paywall-full-content no-summary-bullets">Can we do the study on our own. Right now, yes we can start the study, but obviously we need to raise more money to continue to study, but I think our efforts right now are focused on getting that CMV data out, particularly on TransVax to make sure the Is are dotted and the Ts are crossed for our September hopefully at a important meeting release and then the Allovectin-7 data collection which is really a top priority, but don’t forget and TransVax right, now we are in the process of developing our Phase 3 trial design.</p> <p class="paywall-full-content no-summary-bullets">We are looking at approaches how to engage the FDA in terms of the end points for the study which we’ve not publicly disclosed, which we have been working with a whole bunch of experts and proceed with that and that itself is a task right now.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Next we will go to Steven Willey of Stifel Nicolaus.</p> <p class="paywall-full-content no-summary-bullets"><strong>Steven Willey - Stifel Nicolaus</strong></p> <p class="paywall-full-content no-summary-bullets">You talked about some of the endpoints in the TransVax trial are going to be a little bit complex with respect to some of the virological endpoints. Can you maybe talk about whether or not you feel a partner in the US, given the complexity of that trial design would want to be involved in these current discussions around trial design and anything you might go to the FDA with?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">I think the first thing partner will want to see the data from the Phase 2 12 month follow up, and if that virological data is exciting, then all bets are off right because the devil is in the detail, it is all in the data. I can stand here and tell you virological endpoints are good enough, but if we can show immunocompromised patient that those virological endpoints indeed can be achieved, then you can get a partner excited.</p> <p class="paywall-full-content no-summary-bullets">Secondly everybody knows that this is a slam dunk. Normally if you get a Phase 2 study done and if you can complete a Phase 3 study done with an agreed upon endpoint with the FDA and the vaccine is efficacious as we have seen so far. This is a locked up market, we’ve [awful] drug status. The people are getting as a matter of point cell transplants or CMV positive, they will take this vaccine okay.</p> <p class="paywall-full-content no-summary-bullets">So there is not issue of market penetrability or unknowns about how to achieve the commercial goal. So those are two very clear, the third thing everybody knows that, CMV disease is not a valid endpoint because the entire treatment paradigm is based on virological endpoints and if the FDA is going to insist on doing CMV disease, it will require a huge trial and this will make the full program removed. </p> <p class="paywall-full-content no-summary-bullets">And so everybody knows including the clinical experts who are working with us. Remember how they treat people, they used PCR or whatever local assays and they look at the number of [copies] in the blood every week.</p> <p class="paywall-full-content no-summary-bullets">And then they put on an antiviral such as Ganciclovir. CMV disease occurs in less than 2% or 3% of the patient. So that’s not a relevant endpoint and that’s the goal and that’s the pieces and that’s the expert opinion that we are taking to the agency.</p> <p class="paywall-full-content no-summary-bullets">I think the European agency on the other hand already understands the importance of our virological endpoints. We have to do some convincing to do with the FDA.</p> <p class="paywall-full-content no-summary-bullets"><strong>Steven Willey - Stifel Nicolaus</strong></p> <p class="paywall-full-content no-summary-bullets">So the ultimate goal then I guess pre-Phase 3 be locking down in SPA and with that make it easier for a potential partner to come on board kind of halfway through the process?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">I think we would love to have the partner come on board after they see the Phase 2 12-month data. So they are part of the discussions with us, with the agency particularly in the trial design.</p> <p class="paywall-full-content no-summary-bullets"><strong>Steven Willey - Stifel Nicolaus</strong></p> <p class="paywall-full-content no-summary-bullets">Just with respect to AnGes, have you got any color on whether or not Collategene would be a bit of a restricted launch if and when it’s approved in Japan because the trial was our stopped so early and I know, we’ve seen this before in some of the previous Japanese Phase 3 trials that were stopped early. They typically have a pretty tapered, immediate launch following that?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">The answer to that question is I don’t know, the Japanese are being quite mum on this issue. So we are awaiting, all we know is we are going to hear something in the second half of this year definitely.</p> <p class="paywall-full-content no-summary-bullets"><strong>Steven Willey - Stifel Nicolaus</strong></p> <p class="paywall-full-content no-summary-bullets">On A-7 spending, I believe you worked through all of the reimburseful expenses under the AnGes agreement correct?</p> <p class="paywall-full-content no-summary-bullets"><strong>Jill Boardfoot</strong></p> <p class="paywall-full-content no-summary-bullets">We are still recognizing revenue from that and we’re recognizing that ratably over the end of the period of the trial, but there is still some that we are burning through.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">(Operator Instructions). We’ll go next to Reni Benjamin with Rodman &amp; Renshaw.</p> <p class="paywall-full-content no-summary-bullets"><strong>Reni Benjamin - Rodman &amp; Renshaw</strong></p> <p class="paywall-full-content no-summary-bullets">Regarding the Allovectin-7 program, Vijay can you remind me how many more SMB meetings there will be and about how often are they going to be occurring.</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">I think every six month is when we have a meeting, so I would guess another two meetings at most.</p> <p class="paywall-full-content no-summary-bullets"><strong>Reni Benjamin - Rodman &amp; Renshaw</strong></p> <p class="paywall-full-content no-summary-bullets">And just regarding the data set that will be presented in September. I am assuming that it will be around or at the [ICEC] conference and we’ve already seeing some of those data. So wanted to see if you can get to some specifics as to what new and additional data we would be looking, is it extended follow up and will P values will be associated with all the data that we are looking as coming up?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Let me remind the audience, first of all the data that we’ve presented so far is as follows, we presented safety data which was early safety look on the study. So we are going to show you all complete safety data in the entire 12-month follow up after the last injection. We showed virological endpoints with no P values only up to 4 months of our two injection, average is about two injection. Here we are going to show you all the virological endpoints by the way which are on our website.</p> <p class="paywall-full-content no-summary-bullets">After 12-month follow-up with all P values. We are not going to hold anything back and we already presented the 12-month immunogenecity data. So that’s already behind us, so the real efficacy data 12-months follow up after all sets of injections will be covered such as all the virological endpoints that we covered at 4 months with P value.</p> <p class="paywall-full-content no-summary-bullets"><strong>Reni Benjamin - Rodman &amp; Renshaw</strong></p> <p class="paywall-full-content no-summary-bullets">Can you just give us an update if there is one regarding the HIV vaccine and when we might expect completion of enrollment?</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">I think it’s a long program, the program is continuing as you know it’s the old VRC vaccine which kind of got slowed down because of the adverse data that came out of the Merck HIV trial. There are lot of plus points in the studies, so I would say the enrolment will continue through the end of 2011, middle of 2011 at least before meaningful data comes out sometime in 2012, 2013. So, it’s a long trial.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">There are no further questions, so I'll now turn the call back over to Mr. Samant.</p> <p class="paywall-full-content no-summary-bullets"><strong>Vijay Samant</strong></p> <p class="paywall-full-content no-summary-bullets">Well, thank you very much. We look forward to seeing some of you at the upcoming investor conferences come this fall.</p> <p class="paywall-full-content no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content no-summary-bullets">Ladies and gentlemen this concludes our conference for today, you may now disconnect.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="jB_Gz" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->FRTX<!-- --> <a class="I_0 r_5 r_6 r_ab L_G L_gv" href="/symbol/FRTX"><span class="">analysis and news</span></a></li><li class="jB_Gz" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="I_0 r_5 r_6 r_ab L_G L_gv" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nO_S r_4 r_af aQ_jg paywall-full-content" data-test-id="post-footer"><span class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd"><button class="vt_p9 sA_T6 r_4 r_6 vt_hT" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="vt_fd"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="vt_hV vt_gn">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="dV_ry dV_rw r_ar r_4 r_6 r_ab dV_fy aS_jp aS_jD aS_jS dV_o4" data-test-id="custom-share-button" type="button"><span class="dV_h bh_l4"><span class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="nP_fd"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="nP_hV s_cL nP_gn">Share</span></span></span></button><a class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd nO_Ns" data-test-id="comment-button" href="/article/218361-vical-incorporated-q2-2010-earnings-call-transcript#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="nP_fd nO_Nw"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="nP_hV s_cL nO_gn">Comment<!-- --> (1)</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="post-skeleton"><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:1"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.8333333333333334"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.6666666666666667"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.5"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.33333333333333337"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.16666666666666674"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div></div></div></div></div></section><!--/$--></div></div><div class="lg:basis-auto lg:w-auto lg:flex lg:flex-col grow-0 sm:basis-full sm:flex sm:flex-col grow-0 empty:hidden relative min-h-1 min-w-0 w-full max-w-full grow sa-col" data-test-id="grid-col"><div class="ja_qj aQ_jg r_4 r_am s_bH" data-test-id="right-rail"><!--$--><div></div><!--/$--></div></div></div></div></article></div><!--/$--></main><div class="l_L"><div></div><div></div></div><!--$--><!--/$--><div data-test-id="after-layout-content-slot"></div></div></div><div class="e_a s_eA s_cy s_dd s_dS r_4 r_ac s_aU s_bh" id="google-one-tap-popup-container"></div><div class="g_p t_eB" id="px-captcha-wrapper"><div class="g_g s_eA s_cy s_dd s_dS s_aE s_bH"><div class="g_f"><div id="px-captcha"></div><div><div class="g_q s_d9">To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.</div><div class="g_q s_d9">Is this happening to you frequently? Please<!-- --> <a href="https://seekingalpha.userecho.com/?source=captcha">report it on our feedback forum.</a></div><div class="g_q s_d9">If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.</div></div><div class="px-reference-id"></div></div></div></div></div></div><noscript><iframe height="0" src="https://www.googletagmanager.com/ns.html?id=GTM-MSK9R8B" style="display:none;visibility:hidden" title="google-tag-manager" width="0"></iframe></noscript><script async="" src="/samw/static/js/app.982fa237.js"></script></body></html>